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Abstract 
Background: Globally cervical cancer is the fourth most common cancer in women, and is 
considered a highly preventable disease if precancerous lesions are detected and diagnosed 
before they progress to malignancy. 
 
Palestine lack accurate or rare epidemiological statistical data on cervical lesion but it is 
estimated that the annual incidence of cervical cancer is 2.4 per 100,000.(Feraly et al,2014) 
Cervical lesion researches in Palestine have been neglected and the Palestinian health 
system has not been committed to the cervical screening program, despite the fact that it is 
a highly preventable disease and multiple modifiable risk factors play a role in increasing 
its incidence, but unfortunately, few studies about cervical lesion factors were done  before 
in Palestine  
  This study could be a baseline for decisions makers to develop a national strategy that can 
help in preventing precancerous and cancerous cervical lesions  
 
Aim & Objectives: This study aims to determine the role of Pap smear screening in the 
detection of various cervical lesions among Palestinian women. The objective of the study 
is to determine the associations between the various  socio-demographic,  reproductive 
health , participant  health status, family history of malignancy, and life style behavior 
factors  as smoking,  with the risk of  developing different  cervical lesions seen  as 
different positive  findings in Pap smear test, and by that determine the  effectiveness of 
Pap  smear test in detecting cervical lesion.  
 
Study methodology: A cross sectional study design was used. And by using a non-
probability convenience sampling method, a 100 female participants from Ramallah 
governorate were interviewed by the researcher  and cervical  Pap smears were  collected  
by a Gynecologist  and then was tested  by specialized pathologist, so three data collection 
tools were constructed; a face to face questionnaire , a medical form for the use of the 
physician and laboratory form.  
 
Statistical Analysis: IBM SPSS 23.0 was used for data entry and analysis. Frequencies 
were calculated for all study variables . Cross tabulation and the significance of Pearson 
chi-square test or fisher‘s exact test was used to examine the binary association between 
dependent and independent variables. Forward logistic regression models comparing odds 
ratio with confidence interval of 95%. P-value < 0.05 was used in the multivariate analysis. 
 
Results: Analysis of the data revealed that Pap smear test was able to detect 82% cervical 
lesions; 76% were infection, 66% were inflammation, 43% were Candida, 7% were 
precancerous, 3% were Atypical Sqaumous cell and 2% were Atypical glandular cells.  
IV 
In multivariate analysis, age at marriage , age at first baby , high parity, oral contraceptives  
having vaginal  infection, cigarette smoking  and water-pipe smoking  were the risk factors 
for cervical lesions  with an adjusted odds ratio, 7.6 (CI 95%: 2.5-23), 1.9 (CI 95%: 1.1-
3.4), 0.28 (CI 95%: 0.11-0.7) , 4.3(CI 95% 1.3-14.2), 30(CI 95% 9.2-50.7), 1.9(CI 95% 
1.8-4.1) and 5.6( CI 95% 1.2-26.2) respectively. 
 
 
 
Conclusion: The study revealed that Pap smear test is effective in screening and detecting 
multiple cervical lesions and factors such as age at marriage, age at first baby, high parity,  
using oral contraceptives use,  having vaginal  infection and smoking  are all associated 
with increased risk of cervical lesions. Therefore, the study recommendation for policy 
makers is to adapt a national strategy and screening program for cervical lesion in 
Palestine.  
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من آفات او   إصابات عنق الرحممختمف في الكشف عن   عنق الرحمتقييم دور اختبار مسحة 
 وعوامل الخطورة المسببة لهبين إناث الضفة الغربية  سرطان، 
 
 فلبح  فوزي عبد الله نانسي: داداع
 غسان بعموشة د.  :اشراف
 
  ممخص
، ويعتبر مرضًا سرطان عنق الرحم عالميًا ىو السرطان الأكثر شيوعًا لدى النساء :خمفية الدراسة
المرض  بقوعلبج  اللآفات الحميدة التي تسيمكن الوقاية منو بشكل كبير إذا تم اكتشاف وتشخيص 
 .الخبيث
، لكن فمسطين إلى بيانات إحصائية دقيقة أو حتى لا توجد بيانات إحصائية عن آفة عنق الرحم تفتقر
 ylareFشخص. ( 111،110لكل  2.4يقدر أن معدل الإصابة بسرطان عنق الرحم السنوي ىو 
 )4102 ,.te
فحص  ، ولا يمتزم نظام الصحة الفمسطيني ببرنامجنادرة ىي  أبحاث سرطان عنق الرحم في فمسطين
، كما أن عوامل الخطورة المتعددة عنق الرحم ، عمى الرغم من أنو مرض يمكن الوقاية منو بشكل كبير
يوجد القميل من الدراسات عن عوامل لؤسف ، ولكن للو  القابمة لمتحويل تؤدي دوًرا في زيادة حدوثو
 الخطورة المؤدية لأمراض عنق الرحم في فمسطين. 
خطة استراتيجية وطنية   وضع لبق الأولى  لصانعي القرارات لنقطة الإنطمثابة بلذلك تعد ىذه الدراسة  
 يمكن أن تساعد في الوقاية من آفات عنق الرحم المسببة لسرطان عنق الرحم 
تيدف ىذه الدراسة إلى تحديد دور فحص مسحة عنق الرحم في الكشف عن آفات  :أهداف الدراسة
تحديد الارتباط بين مختمف العوامل الاجتماعية  وكذلكالفمسطينيات. عنق الرحم المختمفة بين النساء 
، ، والتاريخ العائمي للؤورام الخبيثة، والحالة الصحية لممشاركين، والصحة الإنجابيةالديموغرافية -
 تظير عمى شكل ، مع خطر الإصابة بآفات عنق الرحم المختمفة التي وعوامل السموك مثل التدخين
، والتي تحدد فعالية اختبار مسحة عنق الرحم في الكشف جابية في اختبار مسحة عنق الرحمنتائج إي
 عن آفة عنق الرحم.
تصميم دراسة مقطعية. وباستخدام الطريقة الغير احتمالية لأخذ  اعتمدت الدراسة : منهجية الدراسة
ة مسحة عنق الرحم ليم  من امرأة من محافظة رام الله وتم جمع عين 110العينات ، حيث تمت مقابمة 
، حيث تم بناء ثلبث نسجةن قبل أخصائي عمم الأقبل أطباء متخصصين،  وتمت قراءة النتائج م
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والثانية كانت  ،استبيان يعبئ من قبل الباحثعبارة عن  تأدوات لجمع البيانات. الأداة الأولى كان
  خصائي الأنسجة. ر مخبري يعبئ من قبل اتقريعبارة عن  بيب، والثالثوتقرير طبي يعبئ من قبل الط
 
تم .  32 MBI-SSPS: تم إدخال جميع البيانات وتحميميا باستخدام برنامج الإحصائيالتحميل 
 erauqs-ihc nosraePلجميع المتغيرات في  الدراسة. من تم تم استخدام اختبار  نسب احتساب ال
لغير مستقمة. ومن ثم تم استخدام نماذج الانحدار لفحص الارتباط الثنائي بين المتغيرات المستقمة وا
 في التحميل متعدد المتغيرات. 01.1< pاستخدمت قيمة الأرجحية  حيث الموجستي لمقارنة نسبة 
 
٪ من 42كشف تحميل البيانات أن اختبار مسحة عنق الرحم تمكن من الكشف عن : النتائج الرئيسية
٪ منيم كانوا مصابين 77لإلتيابات المعدية ، ٪ منيم مصابين با76آفات عنق الرحم. كان 
 % خلبيا ما قبل السرطانية 6، ٪ كانوا مصابين بنوع من الفطريات (المبيضة)42، وبالإحتقان
، ، وتعدد الولادات، والعمر عند الطفل الأول، كان العمر عند الزواجفي التحميل متعدد المتغيرات
لآفات عنق   ةالأرجيمة  عوامل خطور وتدخين السجائر وتدخين ، يبميةالم  ألإلتيابات، وموانع الحمل
،   9.1 )4.3-1.1 :٪59 IC(،  )32-5.2 :٪59 IC(( 7.6، الرحم مع نسبة الأرجحية المعدلة
 ،   82.0 )7.0-11.0 :٪59 IC(
 ) و 1.4-88.1 :%59 IC(1.0) ، )7.05-2.9 %59 IC 14،  3.4 )2.41-3.1:٪59 IC( 
 .) عمى التوالي2.62-2.1 ٪59 IC( 7.0
 كشفت الدراسة أن اختبار مسحة عنق الرحم فعال في فحص وكشف آفات عنق الرحم: الخاتمة
، وتعدد الولادات ، واستخدام موانع الحمل، المتعددة وأن العمر عند الزواج ، والعمر عند الطفل الأول
، فإن ىذه الدراسة توصي صانعي لرحم لذاكميا مرتبطة بزيادة خطر آفات عنق ا الميبمية الإلتيابات 
 استراتيجية وطنية وبرنامج ممنيج للئستصقاءعن  آفات  عنق الرحمالقرار بالعمل عمى ايجاد 
 في فمسطين. باستخدام مسحة عنق الرحم 
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Thesis chapters 
This thesis is presented in 6 chapters as follows: 
Chapter one: Contains the background of the study, cervical anatomy and metaplesia. 
Pap smear, Bethesda system, problem statement and study justification, and study aim and 
objectives. 
Chapter two: Includes related data (literature review) of a conducted international, 
regional and in country studies and researches  
Chapter three: Includes the study conceptual framework. 
Chapter four: Includes the study area, study methods, population, sampling, and sample 
size, ethical consideration will also include data collection, processing and analyzing. 
Chapter five: Presents the results. 
Chapter six: Includes discussion and recommendations. 
 
0 
Chapter One: Introduction 
 
1-1  Background 
 
Globally Cervical malignancy  is considered the 4
th
  most common cancer in women, the 
2
nd
  most common cancer in female between the age 15-44 years old , and the seventh 
overall (Burni et al., 2014), it contributes nearly to 8% of all cancers and 12% of all 
women cancers. However, in developing countries after breast cancer, cervical cancer in 
women is considered to be the second most prevalent where 85% of the global burden 
occurs. (Ferlay et al., 2014). However, in 2012 WHO has had estimated the cervical cancer 
deaths to be 266,000, which was 7.5% of all women cancer deaths (WHO, 2012). In 
developed countries, cancer in general is considered the leading cause of death  among 
males and females , while in developing countries, is considered the second leading cause 
of death(WHO, 2008; WHO, 2013; WHO,2018). 
 
While cervical cancer is one of the cancers that can be treated if diagnosed early, it has 
been noted that in most of the developing countries, cervical cancer presents at its late 
stages thus making its management difficult(Akinlaja et al., 2014). 
 As a result, cancer of the cervix in developing countries, has been associated with high 
mortality and morbidity in women.(Sasco,2000), and according to WHO,  in 2015,   low 
and middle income regions have had  almost  90% of  all 270,000 deaths occurred  from 
cervical cancer (WHO,2015); WHO,2018). 
 
However, developed countries have had decreased the cervical cancer incidence by 70-
90% and this decline has been attributed to well established cancer cervix screening 
programs (Akama et al., 2008). On the other hand, due to limited  access to screening 
services or because these services don‘t exist at all, developing countries  suffer from 
higher incidence of cervical cancer morbidity and mortality  compared to developed 
countries (Juneja et al.,2007). 
 
Fortunately, Cervical cancer has a 10-20 year lag between cervical  precancerous phase 
and cancerous phase and by that and  it is considered to be a highly  preventable disease in 
women and is  easily identified  by its clinical features in an easily accessible organ (Utoo 
et al., 2016), therefore, adapting a comprehensive approach of prevention, screening  
diagnosis, and effective management may reduce  the high morbidity and  mortality rate of  
cervical cancer globally (WHO,2014). 
  
 Several risk factors determine the occurrence of precancerous and cancerous cervical 
cancer, but the most common cause is chronic infection with Sexually transmitted 
infections , especially with one  of the oncogenic high risk types of  the most common 
sexually acquired infection , human papillomavirus (HPV) that are acquired early in life 
for those sexually active (Makuza et al., 2015). However, other contributory factors 
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include early age at marriage or first sexual intercourse, high parity, multiple sexual 
partners, contraceptives and tobacco use (Das CR et al., 2014).  
 
 
1-2 Cervix 
1-2-1 Cervix anatomy :(Figure 1-1) 
One part of women reproductive system is the female cervix, which is almost 2.5-3 
centimeter long and 2-2.5 centimeter in diameter (Kurman, 1999). It is considered to be the 
continuous lower narrower (1/2 to 1/3 the uterus length) of the uterus (Gray et al., 1995). It 
is cylindrical in shape and it connects corpus uteri which is the uterus body, to the vagina 
through endocervical canal with no junction between the epithelium lining junction the 
body of the uterus and endocervical canal.  The cervix is composed from ectocervix which 
is the component of bulging of cervix through the anterior vaginal wall and has two lips; 
one anteriorly and the other posteriorly, it is completely encircled by the vaginal fornix and 
from cervix supravaginal part that is situated above the cervix (Gray et al., 1995). 
However, the vaginal lumen is connected to the uterus body by a central cervical canal, 
which has two orifices; the internal os and external os (Gray et al., 1995)( Gray et al., 
1995).  The canal is lined by a 7 to 8 mm fusiform mucosa 3 mm in thick ,  called 
endocervix with Pilca palmatae longitudinal ridge anteriarly and arbor vitae oblique ridge 
posteriorly (Drake at al., 2005), while the ectocervix is covered by the  exocervix mucosa 
(Ovall et al., 2013). The inner mucosal cervical layer consists of; smooth thick muscular 
layer and at the posterior supravaginal part consist of serosal layer of connective tissue and 
peritoneum (Gray et al., 1995). 
Figure 1.1: Cervix anatomy of a woman of reproductive age 
               
 1-2-2 Cervix histology: (Figure 1-2) 
 However, huge portion of the cervix consist of fibromuscular canal garmented by either 
columnar epithelium cells or squamous epithelial cells. The mucosa of the endocervical 
portion is garmented with one layer of columnar epithelial mucosal cells, and the 
underlying lamina propria has many mucosal tubular glands that are responsible for the 
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shedding alkaline viscous mucus into the cervical lumen. However, in a cross sectional 
view, the epithelium has multiple ring like shapes that look like clefts or glands and the 
mucosa is leaned on an ill defined layers of cells (Gray et al., 1995). 
 In contrast, nonkeratinized sqaumous stratified epithelium cells covers the ectocervix, that 
could be indigenous or metaplasti (Gray et al., 1995), and resembles the squamous 
epithelium lining the vagina (Beckman et al., 2013). 
Moreover, the SC junction is the area were columnar epithelial cells and sqaumous 
epithelial cells assembled and is lined by cytokeratin 7 + non-stratified cuboidal cells that 
due to the increase effect of the hormone estrogen and the bacterial vaginal flora growth 
can cause metaplastic replacement of columnar epithelial cells to sqaumous epithelial cells, 
producing new squamo-columnar junction. Moreover, multiple studies concluded that this 
site of SC junction is the origin of the population of the embryonic cells that are 
responsible for cervical changes (microglandular hyperplasia and metaplasia), and are the 
cell origin for precancerous and cancerous cervical lesions (Beckman et al., 2013)(Herfs et 
al.,2013). (Figure 1-3). Underlying both types of epithelium is a connective tissue lamina 
propria with tough layer of collagen (Deakin et al., 2006). During menstrual cycle, the 
endocervix mucosa is not poured out (Gray et al., 1995).  The cervix contains huge number 
of collagen and elastin fibrous tissue more than the other parts of the uterus (Gray et al., 
1995). 
Ectropion or the transformation zone is the production of metaplastic regenerative changes 
between the native and new SC junction, where more than 90% of dysplasia and squamous 
cell carcinomas occurs. 
The cellularity of the cervix includes, reserved basal cuboidal to low columnar  cells 
obtained  from SC junction cells with few oval nuclei and  cytoplasm, mature eisonophilic 
cytoplasm, low weight molecular keratin and estrogen hormone  receptors, no high weight  
molecular keratin (Herfs et al.,2013). 
Furthermore, the cervix has different quantities of glycogen in its supra-basal cells that can 
be detected by iodine in Lugol-Schiller‘s exam or by PAS stain (Herfs et al., 2013). 
Estrogen is produced by the ovaries during menarche this causes vaginal and cervical 
mucosa to regenerate  glycogen, which promotes endogenous  microorganism growth  in 
the  vagina , causing lowering in vaginal pH by increasing the production of acids;  causing 
the proliferation of reserved Basel cells, leading to  metaplasial changes  and overgrowth 
of squamous epithelial cells in relation to columnar cells and by that forbidding the 
opening of crypt causing Nabothian cysts. 
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Figure 1.2: Cervix histology 
                 
 
Figure 1.3: The squamocolumnar junction (SCJ) cervical epithelial cells  
 
1.3 Cervical metaplasia (Figure 1-4) 
A non-neoplastic change of one kind of mature cell to a completely another kind of mature 
cell that is not present at that site in normal situation is called metaplasia. The most 
common metaplastic changes of endocervical epithelium are squamous metaplasia.  .  
Cervical metaplasia is considered a physiological change; however, it could be 
pathological as non-malignant transformation of respiratory epithelium into squamous one 
due to dust or smoke severe exposure. 
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Figure 1.4: Cervical transformation zone of a female at her reproductive age 
 
1.3.1Site  
Sites of metaplasia mostly at the squamocolumnar junction, as well as, prolapsed decubitus 
ulcer, etc. 
1.3.2 Patho-physiology 
 The endocervical reserve sub-columnar epithelial cells differentiate, proliferate and 
change into squamous epithelial cells, and at the squamo-columnar junction they become 
the progeny of embryonic cells, that has "top-down" pattern of differentiation and become 
more susceptible to sexually transmitted infections, mainly with high-risk HPV that may 
cause neoplastic changes on the future  
 
1.3.3 Etiology 
 Cervical infection with STIs, cervical trauma or explored to chronic irritation can 
stimulate metaplastic changes or it could be the effect of the iatrogenic cause, for example; 
cryosurgery.  
 
1.4 Papanicolaou (Pap) smear test: 
The Papanicolaou smear test (Pap or cervical smear test) is a histological multichromatic 
staining technique established by  George Papanikolaou,  a Greek medical doctor , it is a 
screening procedure to detect precancerous and cancerous lesions of cervix. Followed by 
more specific and sensitive diagnostic tools and procedures for those with abnormal 
findings, so as to start early interventions to precancerous lesions to stop progression to 
cervical cancer (Pathology, 2011). 
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However, in Pap smear test, a fixed alcohol preparation is used, rather than air fixed 
preparation, because it has the ability to provide more effective nuclear information. Its 
classical form involves; five dyes in three solutions that cause blue to green staining to the 
ribosomes, especially mesothelial, para-basal and squamous metaplastic cells, as well as, 
staining inactive metabolic cells, for example; superficial cells, also it cause orange 
staining to thick keratinized cells either benign or malignant.  But in order  to prepare a 
successful staining,  the technicians must perform a quick staining because of the 
inadequacy of  dried air smears ( Pathology,2011). 
Furthermore, to collect the Pap smear sample from the cervix, a device called speculum 
must be inserted into the vagina, so as to open it, then cells from the transformation zone, 
at the outer cervical opening, where the inner endocervical glandular cells fuse with the 
outer cervical squamous cells are collected. Then these sample cells are placed and 
examined, for any abnormalities, using an electronic microscope.  
 The Pap smear staining test goal is to find any precancerous and cancerous  cervical cell 
changes,  for example; cervical dysplasia or CIN (cervical intraepithelial neoplasia) and 
SIL(sqaumous intraepithelial lesions), caused by HPV sexually transmitted DNA virus 
infection .Furthermore, the test is considered a widely used, effective procedure for 
precancerous and cancerous cervical cancer early detection, as well as, good method to 
detect any inflammation, infection, endometruim and endocervical abnormalities 
(Pathology,2011). 
In the USA, cervical Pap smear screening protocols recommends that sexually active and 
non-sexually active females around the age of 21 years must start screening until 65 years 
of age , where as non-sexually active female is not recommended to perform Pap smear 
test in many other countries (Moyer, 2012).  Frequency guidelines for performing cervical 
Pap smear test vary from 3-5 years (Moyer, 2012) (Saslow et al., 2012) (ACS, 2010). 
Abnormal results must be repeated in 6-12 months according to the type of abnormality 
(ACOG, 2009). However, the female patient must be referred to do more detailed 
colposcopy investigation for the cervix, if the abnormality require more investigations, or 
referred to do HPV DNA testing which can be routinely done as an adjunct to cervical Pap 
smear testing, or other evolving biomarker tests available for cervical cancer detection 
(Shidam et al., 2011). 
 
1.4.1 Pap screening: 
 Guidelines for cervical Pap smear screening differ from country to country. In general, 
cervical Pap smear screening must begin at the age 20-25 years old and may be  repeated 
in a frequency of 3-5 years interval, as long as there is no abnormal findings in the test, 
until the age 50-60 years old (Arbyn  et al., 2010, Strander  2009). 
The Pap smear screening test should be performed a few years after the female has had her 
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first sexual intercourse and shouldn‘t start screening for those less than 20 years old ( some 
countries don‘t perform Pap smear screening test till the age of 25 or later)    
HPV positive women mostly acquire the viral infection after becoming sexually active. 
And it requires an average of one to four years to overcome the infection by the women 
immune system ( ACS, 2010). Moreover, during this period,  a cervical Pap smear test   
may detect  the repair done by the  immune reaction as a mild abnormality , which is  
normally  not associated with precancerous or cancerous cervical lesions , but may increase 
women  stress and  drive them to do  further tests and try different kind of treatments. 
Cervical cancer usually takes time to develop, so delaying the start of screening a few 
years causes little risk of missing a potentially precancerous lesion (Sasiani et al., 2009). 
On the other side, minor benefits would occur from screening females who have never had 
sexual contact. For instant, the USPSTF guidelines recommendation is not to start Pap 
cervical smear screening until at least 3 years after first sexual intercourse.  
Frequency of cervical Pap smear screening vary; from 3-5 years for females with no 
abnormal Pap smear results (Arbyn et al., 2010). Previous recommendations suggested 
every 1-2 years but there has been no evidence base benefits from such frequent Pap 
cervical smear screening. Instead of that, frequent screening procedures, had been reported 
to be costly and are followed by multiple, unwanted procedures and managements (Saslow 
et al., 2012). Therefore, it has been concluded that decrease frequency of screening has 
been a better choice for public health (Smith et al., 2002). Other guidelines depend on 
female age to determine frequency of cervical Pap smear frequency. For example; in Great 
Britain, screening for those less than 50 years of age is performed every 3 years, while 
those 50 years old and above every 5 years.  
Guidelines recommended that Pap cervical smear screening procedures must stop around 
the age of  65 years, unless  there have been an abnormal findings or diseases in previous 
screening tests. Also that,   there is no benefits from screening females at 60 years of age or 
above, with no documented previous  positive Pap smear test.(Sasiani et al 2003). 
According to the guidelines from USPSTF, ACOG, ACS and ASCP  any female with 
negative three Pap smear test should stop screening at the age of 65 years old (Saslow et 
al., 2012). Moreover, after total hysterectomy for benign lesions or diseases, there is no 
benefits from continue cervical Pap smear screening. 
Furthermore , for those that have been vaccinated for HPV infection,  cervical Pap smear 
screening is still a recommendation ( Arbyn et al., 2010), since not all cervical cancer 
causing  strains of HPV  are been covered by the vaccination, and previously exposed 
females to HPV are not covered by the vaccination.  
Endometrial cancer female patients should stop routine cervical Pap smear screening tests 
(ACOG, 2009). Recurrence of cancer are unlikely to be detected by screening but may 
cause increase risk of false positive results ,that urge people to seek more unnecessary 
investigations (Salani et al., 2011). 
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However, if Pap cervical smears screening results showed abnormal findings, or after 
positive biopsy results or after cancer treatments, more frequent cervical Pap smear 
screening tests must be performed. (see table 1.1) 
Table 1.1:  Indication for Pap smear screening 
Evidences for screening indications  
Futures and   
characteristic 
Recommendation  Reasons  
 Female who has 
never had   sexual 
intercourse  
No need to do Pap 
smear screening  test 
HPV  infection is transmitted by sexual 
intercourse (Strander, 2009) 
Female age <20, no  
irrespective to her  
sexual history 
No need to do Pap 
smear screening  test 
Pap smear testing causes harm effects 
more than benefits (Apgar et al., 2003) 
Female from  20–25 
years of age till  50–
60 years of age  
If Pap smear test 
results are normal 
repeat test  every 3–
5years  
General  recommendation(Arbyn et al., 
2010) 
Female above 65 
years of age and with 
no abnormal previous 
findings  
No need to do 
further  Pap smear 
screening  test 
 USPSTF, ACOG, ACS and ASCP 
recommendations (Strander  2009) 
Female who have had 
had 
total hysterectomy 
with cervical 
removing  for disease 
other than cancer  
No need to do 
further  Pap smear 
screening  test 
Post hysterectomy screening have more 
harms than  benefits
 
(Arbyn et al., 2010) 
Female who have had 
partial 
hysterectomy with no 
cervical removing  
Testing should be 
continued as normal 
females  
 
 Female has been  
vaccinated with  HPV 
vaccine 
Testing should be 
continued as normal 
females 
Not all strains of HPV are covered by 
vaccination  (Arbyn et al., 2010) 
Female with positive 
history for 
 endometrial cancer 
Stop  routine testing Ineffective screening test with more chance 
of false positive(Salani  et al., 20011) 
 
9 
1.4.2 Effectiveness 
An effective combined program of cervical Pap smear testing, referral and follow up can 
reduce 80% of deaths from cervical cancer (Arbyn et al., 2010). 
However, many reasons can cause the failure in preventing cervical cancer by Pap smear 
screening test, for example; irregular screening, no follow-up for abnormal findings,  and 
errors in sampling and analysis (Deny 2007). More than 50% of invasive cervical cancer in 
the USA occurs in women whom in their life have never performed a cervical Pap smear 
screening test, and those whom never have had a cervical Pap smear screening in previous 
five years accounts for 10 to 20% of invasive cervical cancer cases. Approximately, 25% 
of invasive cervical cancers in the USA occurred in females who were not appropriately 
followed up (no referral, no return for follow up or the right care and management were 
given to them).    
Pap cervical smear screening test was not reported to stop cervical adenocarcinoma 
occurring. For example, cervical adenocarcinoma accounts for 15% of all cases of cervical 
cancer in the UK, despite the effective cervical Pap screening program (Deny 2007). 
However, the effective screening program in the UK can prevent approximately 700 deaths 
from invasive cervical cancer deaths. One death from cervical cancer can be prevented 
each 38 years from 200 cervical screening test done by medical physician and despite the 
effective screening, one female during the 38 years at least might die from invasive 
cervical cancer (Raffle et al., 2003). Furthermore, around 15-20 million of the 61 million 
UK  population might receive Pap smear screening, allowing the saving of one female out 
of  approximately 20,000 tested, if  yearly 15,000,000 women have been investigated,  but 
if  yearly 10,000,000 women have had a cervical Pap smear screening test one life would 
be saved if  about 15,000 women investigated.  
1.4.3 Results 
Generally, Pap cervical smear screenings are negative in populations with low risk of 
cervical cancer.  For example, 2-3 million abnormal results of cervical Pap smear are found 
in the USA annually. (Salani R et al., 2011), most of these abnormal Pap smear results (2-
5%) have mild abnormality; ASC-US or (2% of results) low-grade squamous 
intraepithelial lesion (LSIL). 
Although, spontaneously resolved HPV infection  is the cause of almost all cervical low 
grade dysplasia; dysplasia must be  considered a warning sign that has to be additionally  
investigated and followed up . 
Approximately , 0.5% of  positive cervical Pap smear screening  results are high-grade SIL 
(HSIL),  about < 0.5% of them  are  cancerous lesions , and almost 0.2 -0.8% of Pap smear 
screening positive results are AGC-NOS (Eversole et al 2010). 
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1.5 Bethesda classification system: 
Bethesda system has been used to report abnormal cytological cervical or vaginal diseases 
in Pap cervical smear screening tests (Nayer et al., 2009, Apgar et al., 2003) . Bethesda 
system was initiates in 1988, where it contained the following:  
SIL (Squamous Cell Lesions)  
ASC-US (Atypical Squamous Cells of Undetermined Significance)  
ASC-H (Atypical Squamous Cells – cannot exclude HSIL) 
LGSIL OR LSIL (Low-Grade Squamous Iintraepithelial Lesion) 
HGSIL or HSIL (High-Grade Squamous Intraepithelial Lesion)  
Squamous Cell Carcinoma 
Glandular Epithelial Cell Abnormalities 
AGC or AGC-NOS (Atypical Glandular Cells not otherwise specified) ((Apgar et al., 
2003) 
Number of other abnormalities such as Yeast, Trichomoniasis, Herpes and other Sexually 
transmitted infections, endocervical and endometrial lesions can also be detected, and 
classified according to the Bethesda system. However, this system is not so sensitive for 
detecting multiple infectious lesions, so negative results for infection in Pap smear does not 
exclude infection (Nayer et al., 2009). 
 
1.6 Study problem  
Cancer is becoming a main public health problem because of its high incidence, and 
mortality, and has a high burden on the health system especially in developing countries 
such as Palestine. Cervical cancer etiology is complex, and multi-factorial, with 
precancerous phase of 10 to 20 year apart between precancerous and cancerous cervical 
cancer.  Unfortunately, few local studies ( at least four studies between the years 1990-
2000) have been concerned with studying the effect of Pap smear screening in decreasing 
mortality and morbidity from cervical lesions; especially cancer as well as studying the 
determinants of cervical lesions, which makes it a rich area for research in Palestine. 
Therefore, studying Pap cervical smear screening benefits is very important in improving 
Palestinian women health, which may be used in developing, polices and determining 
priorities in public health programs in the future. 
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1.7 Justification of the study: 
 Globally, invasive cervical carcinoma is considered to be the fourth most common cancer 
in female; it contributes nearly to 8% of all cancers. However,  developing countries 
cervical cancer rates accounts for   approximately  85% of all worldwide  cervical cancer, 
with a  15.7 Age-Standardized Rate per 100,000. The Caribbean, Latin America and Africa   
have the highest cervical cancer incidence in the world. Due the expanded use of the  Pap 
cervical smear  screening programs  in developed countries, cervical cancer rates have 
been  extremely reduced  , 9.9 Age-Standardized Rate per 100,000, by that Northern 
America and Oceania has had the lowest cervical cancer incidence (Ferlay et al., 2014).  
In Palestine, the annual mortality rate per 100,000 people from cervical cancer has 
decreased by 28.3% since 1990, an average of 1.2% a year (Global Health Data Exchange, 
2016). 
More than 500,000 new cases are diagnosed annually (Utoo et al., 2016).More than 93% of 
all cervical cancers cases are preventable. Fortunately, precancerous cervical lesions that 
are detected by the inexpensive cervical Pap smear screening test, which has been used for 
a long time, can be treated as early as possible to stop progression to cancer. The 
continuous efforts of Pap cervical pap smear screening caused the significant decrease in 
death incidence caused by cervical cancer in USA between the year 2008-2010 (National 
Institutes of Health, 2015). 
In 2017,  the Palestinian  female population were 2.3 million , 28.3% were between 15-64 
years of age (PCBS,2017) where as  the total number of Pap smear obtained from primary 
health clinics in Palestinian MOH that covers 58.5% of the Palestinian population,  were 
484 sample , 7 were positive for Cervical cancer (MOH,2017). 
Precancerous and cancerous cervical cancer is believed not to run in families (not 
hereditary). However, persistent infection with high risk HPV, which is commonly 
transmitted from person to another through genital skin contact, has been responsible for 
approximately 99.7% of cases. Approximately 80% (4 out of 5) of adults, who are sexually 
active,   will acquire at least one strain of   HPV once in their lives. But fortunately, most 
of HPV infected females   will not progress to precancerous or cancerous cervical cancer, 
because precancerous and cancerous cervical lesions are rare despite the fact that HPV 
infection is common (Dilman, 2009). 
Early age of marriage or having sexual intercourse, early age at first childbirth, multi-para, 
weak immune system, consuming oral contraceptive, smoking habits and having multiple 
sexual partners are considered much less important risk factors for cervical cancer than 
HPV infection. Typically, it takes 10-20 years for a cervical lesion to progress to cervical 
cancer, where Sqaumous cell carcinoma accounts for 90% of them, Adenocarcinomas 
accounts for 10 % of them (National Institutes of Health, 2015). 
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Cervical cancer usually develop slowly because it  is one of the rare cancers that have a 
precancerous phase, which lasts 10-20 years before progressing to invasive cervical cancer, 
giving a wide opportunity for early diagnosis and managements.  Unfortunately, even it is  
preventable, most of the cervical cancer cases are diagnosed late; leading to poor outcomes 
because they do not have a well-established screening system , prevention and 
management programs , as well as the widespread of gender and cultural barriers 
(CDC,2014). The understanding of the risk factors for cancerous and pre-malignant lesions 
of cervical cancer can help establishing an organized screening program for controlling and 
prevention of cervical cancer among women (Makuza et al., 2015). 
Treatment of non-cancerous cervical lesions after early diagnosis of cervical lesion 
changes using cervical smear screening,  can prevent the development of invasive cervical 
cancer. Cervical cancer screening has been part of a woman's health checkup in many 
countries worldwide including Palestine. 
Since, to date, there have been no published study to exactly identify cervical Pap smear 
effectiveness in early detection of precancerous cervical diseases in Palestinian female, nor 
the determinates of precancerous and cancerous cervical cancer. Data on precancerous and 
cancerous cervical cancer  prevalence and associated risk  factors between healthy females 
are extremely helpful to convince policy makers on how to distribute their priorities and to 
urge them to establish an organized cervical cancer screening  programs strategies  that 
aims at female health improvements . However, in Palestine, no study has had  
documented, the associated risk factors and prevalence, for  precancerous and cancerous  
cervical lesion among healthy  females cervical. So, this study will be the baseline for 
future researches in this field and may help in developing polices and determining 
priorities in public health programs in future specially in primary level of prevention and 
control to prevent cervical cancer mortality and morbidity. 
1.8 Aim of the study : 
To study the role of Pap smear screening in the detection of various precancerous and 
cancerous cervical lesions among Palestinian women and to asses the risk factors 
associated with cervical abnormalities.   
 
1.9   Study Objectives: 
1. To determine the Pap cervical smear screening test effectiveness in the early detection 
of pre-cancerous cervical lesions in Palestinian female. 
2. To determine the role of  cervical Pap smear screening test  in detecting clinically 
significant precancerous lesions and cancer 
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3.  To determine the association between various factors and the risk for developing 
different cervical lesions . 
4. To evaluate the cervical cytological non cancerous lesions that are supposed to be found  
 
1.10 Expected outcomes 
Our study is expected to show the efficiency of early cervical lesions detecting  screening 
policies in decreasing incidence of invasive cervical cancer and how this will help in 
saving many lives with low costs. In addition, it will identify the most common cervical 
lesions among Palestinian woman. 
Also, it will help determine the most important risk factors for cervical lesions among 
Palestinian females. 
Moreover, we hope that these results will be of great values for health policy and decision 
makers, and could be used in Palestinian health planning and national strategies for 
controlling cervical cancer.  
 
1.11 Study limitations 
 
Every study, no matter how well it is conducted, has some limitations. Various limitations 
and obstacles may affect the study. In our study the main limitation was the small number 
of the studied population and this was caused mainly by the fact that Pap smear screening 
has not been a part of primary prevention and control strategies in MOH, UNRWA and 
even NGOs and also caused by the limited awareness of Palestinian females about the 
importance of early detection of cervical lesions. However, more samples would have been 
better for the study. 
 As any cross sectional studies, it was considered inadequate to assess cause and effect 
relationship, besides that we were not able to measure the risk, instead we studied the 
outcomes and looked backward to find out the risk or protective factors. Moreover, there 
may have been some biases which might have affected the results like information 
bias, recall bias, selection bias, and reporting bias because of the stigma that surrounds 
some of the risk factors for Cervical lesions. Female compliance was also an important 
limitation due the stigma associated with this subject 
 
  Also we were limited for recourses and time, and since the study included personal 
experience in detecting physical signs, taking the specimen, doing slide fixation and 
reading the results, human errors and experience was an important issue. 
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Chapter Two: Literature review 
 
2-1 Introduction 
In this chapter, literature related to the epidemiology of cervical lesion worldwide, in the 
Arab world and in Palestine will be presented, in addition to literature related to risk factor 
associated with cervical lesions.  
 
Cervical lesions, including cancer, trends  have been depending  on the availability of 
effective screening programs and in the of risk factor profile time changes (Freedman et 
al., 2007, Vaccarella  et al.,2013).  Cervical lesion incidence including invasive 
cervical cancer has decreased in a steady manner over the last few decades in 
developed countries. 
However, the cause of geographic differences  in precancerous and cancerous 
cervical rates among countries ,  are due to the variation  in the availability of  
cervical  lesions screening, which can prevent the development of precancerous and 
cancerous  cervical cancer  through early diagnosis and managements  of 
precancerous lesions, and to  the variation in  the prevalence of human 
papillomavirus (HPV) infection (Sherris  et al., 2001, Formana  et al.,2012). 
2.2 Cervical cancer epidemiology worldwide: 
 
Cervical carcinoma is considered worldwide as the 4
th
  most common female cancer, and 
the 7
th
  cancer from all types of cancer, despite the improvements  made by using cervical 
Pap  smear screening, in preventing precancerous and cancerous cervical lesions,  cervical 
cancer  globally is still considered  a critical cause of women death  and is a major problem 
for  public health. Worldwide, in 45 countries , cervical cancer is considered the most 
common female cancer and in 55 countries, it has been causing death more than any other 
type of cancers among females. This include 22.5% of all female cancers in sub-Saharan 
Africa, also  many cases  in Asia (including India), and some countries in South and 
Central  American ( Ferlay  et al., 2014). 
 
Precancerous and cancerous cervical cancer mortality and incidence rates have declined in 
many countries in the last 35 years, especially in  developed countries (Aryn et al., 
2011) including USA (Adegoke  et al., 2012) and Canada.(Dickinson  et al.,2012, 
Mosavi et al.,2013) in which  they have experienced a huge improvement in  
socioeconomic  status. This is attributed to the adaptation of effective primary and 
secondary prevention programs , with  effective cervical smear screening tools, early 
detection  and early and effective managements  for precancerous lesions (WHO,2012). 
On the other hand, the precancerous and cancerous  cervical lesion  incidence  has 
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had  minor  changes  in developing countries, except those  that  have had  
demographic and epidemiologic transition (WHO, 2009), as 85% of the global 
burden( 9 out of ten)  occurs in the low socioeconomic  developing  regions, where 12% of 
female cancers is the results of cervical cancer (Tebeu et al., 2013). High-risk regions in 
the world, with an ASRs estimation of more than  30 cases per 100,000 of the population 
,including 42.7% in  Eastern Africa, which has been considered the most heavily affected 
areas , 30.6% in middle and 31.5% in southern Africa and 33.3% in Melanesia. On the 
other hand, rates have been 5.5% in Australia and New Zealand , where it is considered the 
lowest and 4.4% in Western Asia and North Africa, Middle East and North Africa (GBD, 
2015) . Precancerous and cancerous cervical lesions are still  the most common female 
cancer in Middle and Eastern Africa (WHO,2012).(figure 1-5) 
 
However, mortality rates  varies between world regions by 18-fold , ranging from 2 case 
per 100,00 population of  Australia, Western Europe  and Western Asia to > 20 cases per 
100,000  population of Eastern (27.6) and Middle (22.2) Africa and  Melanesia (20.6) 
(WHO,2012) . (figure 1-6)  
 
However, 485,000 female  with precancerous and cancerous cervical lesions were 
diagnosed worldwide in 2013, causing the death of  236,000 female ( approximately  7.5% 
of all women deaths worldwide)  compared to  about 528,000 diagnosed in 2012 and 
266,000 died, from them, developing countries have 87% of cases and  developed 
countries have 13% of cases. However, 6.9 million DALYs have been caused by invasive 
cervical carcinoma, 15% of them in developing countries and  85% in developed countries. 
One female from 70 develops cancerous cervical lesions between birth and 79 years of age 
and in year 2012 the cumulative risk factor for female  <75 years of age was 1.42% 
worldwide ( GBD, 2013, Feraly, 2014). 
 
Furthermore, in 2013, at the following countries; Central African Republic, Zimbabwe, 
Uganda, Cameroon, Guatemala, Liberia, Nigeria, Somalia Afghanistan, Benin, , Eritrea, 
Ghana, Sierra Leone, Guinea,  Gambia, Guinea-Bissau, Lesotho, Mali, Mauritania, 
Malawi, Niger, Nicaragua, Senegal, , El Salvador,  Chad, Togo and  Zambia,   cancerous 
cervical lesions was the most commonly diagnosed  female cancer. Also in the same year, 
at Democratic Republic of the Congo, Senegal, Equatorial Guinea, Togo, Nigeria,  Angola, 
Burundi, Benin, Burkina Faso, Central African Republic, Côte d‘Ivoire, Cameroon, El 
Salvador , Congo, Comoros, Djibouti, Eritrea, Ethiopia, Ghana, Guinea, Guinea-Bissau, , 
Indonesia, Kenya, Liberia, Lesotho, , Mali, Mozambique, Mauritania, Malawi, Niger, 
Nicaragua, Papua New Guinea, Paraguay, Rwanda, Sierra Leone, El Salvador, Somalia, 
South Sudan, Sao Tome and Principe, Swaziland, Madagascar, Chad, Tanzania, Uganda, 
Zambia, and Zimbabwe cervical cancer  was the most common cause of female deaths 
from cancer (GBD,2013). 
 
The main reason for the difference between countries, is the lack of active, effective 
organized programs for cervical screening,  prevention, early diagnosis, management and 
program inequity access, within  the same  population. However, precancerous and 
cancerous lesions are diagnosed at late stages -where mortality rate is high-  if there were 
no effective screening intervention programs and the treatment is introduced late in the 
process. However, these results reflect the obvious neglect of this issue by policy makers  
in low, middle socioeconomic   countries, where  policy makers are advised to revise their 
priorities ( Ferlay et al., 2014). 
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Figure 2.1: Year 2012:  estimated incidence of  cervical carcinoma worldwide. 
 
 
 
 
Figure 2.2: Year 2012, estimated mortality rate of cervical cancer worldwide. 
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2.3 Cervical cancer epidemiology in the Arab world.  
 
Despite the well known cervical cancer epidemiology in many countries in the world, there 
are few available data in the Middle east including the Arab world.( Mosavi A et al., 2013). 
Moreover, the incidence of cancerous cervical lesions in the Middle East, is lower than that 
in developed countries with most cases detected at a late stage (Sancho et al., 2013). 
However,  the Arab world , stretching from Lebanon and Syria in the north, through to 
Morocco in the west, Yemen in the south and Iraq in the east, is the home of more than 300 
million people, and is  considered to be part of developing countries, with a well ongoing 
effort to develop effective screening and control program for all types of cancer;-including 
cervical cancer- which  in general  is considered a major problem with increasing burden 
on public health due to multiple factors including aging, population growth and changing 
life style (Salem et al., 2011). 
Furthermore, in general, cancerous cervical lesions rates are low in Arab words and do not 
seem to incline but in frequency is still in second position in Algeria, Tunisia and Oman 
(Elsayed et al., 2007). Underreporting is a huge issue in the Arab world, for example in 
Saudi Arabia the reported abnormal cervical Pap smear was 1.6%, which is lower than the 
results reported in one  prospective cohort  study that reported a percentage of  4.7% 
abnormal cervical Pap smears ( Altaf, 2006).  Adencarcinomas account for about  10% of 
the lesions ( Curdo et al., 2007).  
The highest age standardized rates ( ASR) among Arab females for cervical cancer was  in 
Algeria with incidence of 11.6 per 100,000 followed by UAE with incidence of  9.8 per 
100,000 Tunisia with incidence of 7.1 per 100,000, Bahrain 5.9 per 100,000,  Oman 5.3 
per 100,000, Qatar 5.1 per 100,000, Lebanon 4.6 per 100,000, Kuwait 4 per 100,000, 
Yemen 3.1 cases  per 100,000 population , while the lowest rate  incidence were in Iraq, 
Saudi Arabia, Jordan, Syria  and Egypt ,  which equal to 2.8, 2.7,  2.6, 2.6,  2.1 per 
100,000, respectively ( Bazarbashi et al., 2001, Curado et al., 2007,Freedman et al., 2007, 
Bener et al., 2008) ( Feraly  et al., 2014). (Figure 2-1) 
 
Unfortunately, Arab health systems have not been committed to precancerous and 
cancerous cervical  Pap smear screening programs, mostly due to  the attitudes of the 
health workers and the stigma that surrounds the risk factors. In a study that was performed 
in the UAE, of the 98 participants, who were all physicians, only 40% had referred a 
woman to do pap smear ( Badrinath et al., 2004).Moreover,  in a survey that was done in 
Jordan, approximately three-quarters of women didn‘t know the causes of cervical cancer 
and  25%  of them were unaware of the important effect  of  positive cervical Pap smear  
(Maaita and Barakat,2002). 
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Figure 2-3: Cervical cancer incidence/100,000 in the Arab world 
 
 
2.4 Cervical cancer epidemiology in Palestine  
 
Accurate or even no epidemiological data on cervical cancer in Palestine is available since 
the national population-based cancer registry is lacking detailed and important data. 
However, there is no official statistics from the Palestinian Ministry Of Health concerning 
cervical cancer, but the Journal of Asian Pacific of prevention and cancer  reported in 2009 
that the age standardized rates (ASR) in Palestine (including West bank, Gaza Strip and 
Israeli-Palestinian women) was 2.4 per 100,000, which is considered among the low 
incidence  in Arab world and worldwide, while in 2012  was 2 per 100,000 ( Feraly et al., 
20014).( table 2-1) 
 
 
Table 2-1: ASR Cervical cancer incidence\100,000 over time in Palestine  
 
Year  1982 1987 1992 1997 2002 2007 2009 2012 
Incidence  2.1 3 2.6 3 2.5 4.5 2.4 2 
 Muir et al., 1987; Feraly et al., 2014; Parkin et al., 1992; 1997;2002; Waterhouse 
et al., 1982; Curado et al., 2007, Asian Pacific Journal, 2009,  
 
 
 
In Palestine, the annual mortality rate per 100,000 people from cervical cancer has 
decreased by 28.3% since 1990, an average of 1.2% a year  (Global Health Data Exchange, 
2016).  
 
The Palestinian health system is not committed to the cervical screening program neither 
on MOH who covers 58.5% of the population, nor in UNRWA clinics that covers about 
41.2% of the population and considers pap smear test an invasive procedures and 
according to the International UNRWA regulation, invasive procedures are not part of 
screening programs. Unfortunately, in Palestine there is no established national screening 
program for cervical cancer. Nevertheless there are scattered efforts of screening in 
Ministry of Health, and private sector. In 2017,  the total No of Pap smear performed in 
primary health clinics in Palestinian MOH, were 484 sample ,7 were positive for Cervical 
cancer (MOH,2017). 
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2.5 Risk Factors for cervical lesions  
 
Most women are unaware of cervical lesions including cancer, its risk factor and the 
importance of precancerous screening. Multiple associated risk factors for precancerous 
cervical  lesions including cancer  have been  investigated and some of them have greater 
importance than others, some factors have had been concluded to be either as cause for or 
associated with precancerous and cancerous cervical lesion. Such as, socio-demographic, 
ethnic , age at marriage or age at  first sexual contact , number of sexual partners,  age at 
first child birth , contraception, and sexually transmitted  infectious agents such as 
persistent  HPV infection , Chlamydia trachomatis and type II herpes simplex , and others ( 
Shields et al., 2004) 
 
HPV infection is known as the most common precancerous and cancerous cervical lesion  
risk factor and in general the trends of cervical precancerous lesions including cancer 
follow the trends of HPV infection. Unfortunately, almost all cancerous and precancerous  
cervical lesions are the effect of  high risk HPV infection  (CDC,2018). 
 
 Exogenous or endogenous factors had been identified to, in conjunction with HPV 
infection, influence the risk for  precancerous and cancerous cervical lesions,  HPV 
infection cofactors may be classified into two categories : (1) exogenous or environmental 
cofactors, such as  lifestyle factor ( tobacco smoking habits including waterpipe, 
consuming of OCPs, dietary factors , multiple sexual partners, high parity)  cervical 
trauma, socioeconomic status and sexually transmitted infections ;  for example, infection 
with HIV,  (2)  endogenous factors or host cofactors –demographic factors; including 
endogenous hormones, age, family history , human leukocyte antigen  genetic factors, and 
other host immune factors ( Castellsague et al., 2003). 
 
 
2.5.1 Exogenous factors  
2.5.1.1 Sexually Transmitted Infections and risk of cervical lesions 
Precancerous and cancerous lesions are not by themselves sexually transmitted disease, but 
are the consequence of damage from a sexually transmitted diseases. Worldwide,  
epidemiological  and molecular studies have unequivocally shown that the vast majority- 
almost 99.7% -of precancerous and cancerous cervical lesion cases are caused by persistent 
infections with some high-risk types of  the most common viral STIs of the reproductive 
tract  HPV infection (Dilman, 2009).Most of  sexually active adults  will acquire HPV 
infection  at least once in  their lives- the lifetime risk of contracting the virus is estimated 
to be 75%-90% (Like et al., 2003) – and many sexual active adults  will be infected 
multiple times  and the estimated time of acquiring HPV  infection is  a short time after 
first sexual contact.  However, most  of HPV infections automatically will be cured 
without causing any symptoms or persistent disease. However, precancerous and cancerous 
cervical lesions occur from persistent infection with certain strains of HPV agents; mostly  
with  16 and 18 strains  of HPV,  and if those lesion were not treated , they may become 
cancer (WHO,2013). 
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Moreover, women with sexually transmitted infections other than HPV, such as 
Chlamydia, gonorrhea, Syphyllis, or herpes, also have high risk of acquiring precancerous 
and cancerous  cervical cancer. 
Various studies have had pointed out the significance of sexually transmitted disease in 
increasing risk for cervical lesions. A retrospective institutional based cohort case control 
study, that was made in Ethiopia in 2017, showed an  association between risk of 
precancerous and cancerous cervical lesions and  STIs  (AOR  =  2.5; P < 0.015; COR =  
2.2; 95% CI 1.18,-4.4) ( Kassa,2018). 
 Another cross-sectional institution based study ,made  in  Ethiopia in 2016, assessed the 
association between risk factors  and  prevalence of   precancerous and cancerous  cervical 
lesion between Ethiopian female ,  concluded that females  who have  acquired STIs  were 
more exposed  to precancerous and cancerous cervical lesion than those free of STIs 
infection. Moreover, in this cervical lesion screening study campaign, females who were 
infected with STIs have had fifty folds more likely to acquire precancerous and cancerous 
cervical lesion than those with no STIs .(AOR=49.9 ; 95% CI: 16.6- 149.9) ( Misgina et 
al., 2017). 
Another study done in Southern Ethiopia gave similar results (Gedefaw et al., 2013), in 
this study,  female infected with STIs  had higher risk to have precancerous and cancerous 
cervical lesions as well. Occupation, income level, level of education, age at first sexual 
contact or age at marriage , multi-parity, lifetime pelvic infection, STI, and multiple  of 
sexual partners were in bivariate  logistic regression analysis  statistically significant  at 
this study  with a  P- value =0.2. However, in multivariate analysis,  only multiple sexual 
partners and persistent STIs  have had significant statistical  association with cancerous  
and precancerous cervical  lesion with  P-value<0.05. Additionally, STIs infected females 
have 2.3 fold increase in risk of having precancerous and cancerous cervical lesions than 
females with negative history of STIs  (AOR=2.3, 95%; CI: 1.2- 4.3) ( Gedefaw  et 
al.,2013).  
Another  unmatched hospital case control based were done study in  Addis Ababa in 2018, 
found  significant statistical association between female with STIs and risk of  
precancerous cervical lesion, with 3 folds increase in risk  compared to those with no 
history of STIs  (Adjusted Odds Ratio = 3.20, 95% CI: 1.26–8.10) (Team  et al., 2018). 
 A positive association between genital STIs and precancerous and cancerous cervical 
lesions was found in a hospital-based control study that made on Turkish women in 2011. 
This study concluded that women with history of  STIs such as Chlamidia, Trachomatis, 
gonorrhoeae …etc, have had more risk to develop cervical lesion with an OR=5.2 (95% 
CI: 3.5-7.6) compared with females with no STIs (Nesrin et al.,2011). 
However, globally, the  most common sexually transmitted infection is HPV  , affecting 
millions of women each year, but only a small subgroup of them progress  to precancerous 
or cancerous cervical lesions (WHO, 2013). However, persistent HPV cervical infection is 
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necessary for the occurrence of precancerous and cancerous cervical lesion. The reason 
why some females acquire cervical cancers and many do not, even though they share the 
status of being infected by HPV, is related to multiple co-factors . However, many co 
factors for HPV may play a role in getting cervical cancer  through two or more possible 
pathways. The first pathway is through causing cervical  intraepithelial injury promoting  
HPV infection ,  such as high parity, early age of marriage or early age at first sexual 
contact   and early age at first child birth , and number of sexual partners  (Louie et al., 
2009, Matos et al., 2005, Kahn et al., 2002). The second pathway is through promoting 
HPV persistent cervical tissue  infection ,for example; prolonged OCPs use (Delvenne et 
al., 2007), which can  increase the  risk of acquiring  precancerous and cancerous cervical 
lesions in long use OCP females . On the other hand, multiple sexual activities may force 
the females to use OCPs for a long time  and by that increase the risk of being infected 
with many types of STIs especially HPV.  
Increase risk of HPV infection for cervical lesions was noted in multiple studies 
worldwide, for  example in a case control study, made by Sitakan  et al.,  in Thailand 2012, 
found that  the case group HPV prevalence with cervical cancer was 85.9% and was 14.1% 
in control group. And the increase risk for cervical cancer was the same for HPV infected 
females and active smoking habits even after adjusting with multiple logistic regression, 
with AOR = 38.1 (P-value =0.001).  This study, highly confirm that being infected with 
HPV infection stays  an important cervical lesion risk and cause  (AOR = 38.07 (P-value < 
0.001), and that other co- factors such as  active and passive smoking, sexual habits , active 
or passive smoking habits as well as  genetic predisposition  play a role alongside  HPV in 
increasing risk of acquiring  precancerous and cancerous cervical lesions   ( Settheetham-
Ishida et al., 2005, Settheetham-Ishida et al., 2004,  Almonte et al., 2008, Au et al., 2007).  
However STIs mainly persistent HPV infection, sexual behavior and smoking behavior 
were found to be major risk factors for precancerous and cancerous  cervical lesions  
among women ( Sitakana et al.,2012). 
 In 2013, another case control study made in Thailand found that the high risk HPV 
prevalence was  10.1% (21)  in the control sample  and 152 (76.8%) in the cases with 
precancerous and cancerous cervical lesions. Moreover, a significant increase in risk for 
precancerous and cancerous cervical lesions was found with those infected with HPV  (OR 
= 42.4; 95%CI: 22.4-81.4, p<0.001, AOR =40.7; 95%CI: 21.5-76.8; p <0.001). Also this 
study showed that the most prevalent HPV strain was HPV16. And by that concluded that 
HPV infection is  still a dangerous  risk factor for cervical precancerous and cancerous 
lesions.(Natphopsuk et al., 2013) 
A meta analysis study conducted in India, 2008 and used multiple studies that used 
HPV detecting  polymerase chain reaction for stains 6, 11,16,18   and other types of 
HPV. HPV infection prevalence was 94.6% for abnormal cytological findings of 
precancerous and cancerous cervical lesions and 12.0% in females with normal 
cytology/histology, respectively. However,  in precancerous and cancerous cervical 
lesions the most common HPV strain was HPV 16 with about 64.8% .  An 
estimation of 78.9%  16;18 HPV positive strain  fraction was found in those with 
precancerous and cancerous  cervical lesions, in South India it was about 77.2% 
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and in North of India it was 87.7% and  these with normal cytological finding were 
approximately 3.9% ( Bhatala et al, 2008). 
A case control study in china 2016, studied multiple HPV strains effects on number of 
cervical lesions revealed strong association between different HPV strains and cancerous 
and precancerous cervical lesions. However, the most frequently detected genotypes were 
HPV16, and 18. A triple combined HVP infection from HPV 16,31,58 strains was the most 
common (accounts for about 4.2%) and those females at the ages < 24 years are the most 
affected from all kinds of precancerous and cancerous cervical (Meizhu et al.,2016). 
Moreover, a cross sectional study done in 2018, at Zimbabwe  was done to specify 
different HPV strains distribution and prevalence in females suffering from precancerous 
and cancerous cervical lesions and were  referred to perform cytology smear testing  at 4 
urban hospitals.  The rates  for the most prevalent strains were as follow for  HPV strains 
16,18,33, 35, 45 and 56; 81.5%, 24%,13%, 11%, 7.4% and 9% respectively. HPV strains 
16 and 18 accounted for about 83% of all cases ( Washington et al., 2018). 
A cross section study on women   having stage II invasive cervical cancer or higher in 
South Africa ,where 50 sample from invasive cervical positive females were taken  for  a 
DNA molecular HPV testing .  HPV test was positive in 47 cases(94%), indicating a 
powerful association between  cervical invasive cancer and HPV infection (Nomonde al., 
2016) . 
Moreover, a population based survey  in China was conducted  to determine the 
distribution and prevalence of HPV strains among female with positive cervical cancer and 
showed  14.71% of  tested females have been infected with HPV, 85% were having high 
risk HPV strains while  14.8% were having low risk HPV strains. While stains HPV 16,18, 
58 and 66 were the most prevalent ( Xiujie  et al., 2015). 
Furthermore, a cohort population based study to evaluate the cumulative incidence of 
precancerous and cancerous cervical lesions  after short term persistent of HPV infection, 
done on Costa Rica in 2009; showed  a 17 %  precancerous and cancerous cervical lesion 
cumulative incidence for 3 years with 95% CI=12-22; P=0.002) concluding that  persistent 
infection with HPV can predict future  precancerous and cancerous cervical lesions, due to 
the strong association between them (Castle et al., 2009). 
2.5.1.2 Tobacco smoking and risk for cervical lesions 
It is well known that HPV infection is the main cause of precancerous and cancerous 
cervical lesions ( Bosch et al., 2002) However, a small number of case infected with HPV 
progress to precancerous and cancerous cervical lesions, while most  infections resolves 
spontaneously in 2 years time ( Jensen et al., 2012). Smoking habits (either active or 
passive) have also been reported in many epidemiological studies to increase risk of 
cancerous and precancerous  transformation from positively  HPV infected   lesions. 
Additionally, IARC has categorized tobacco smoking habits as causative agent for 
precancerous and cancerous cervical lesions from reviewing existing evidence 
(IARC,2004) . However, the causal association  evidence between the occurrence of  
precancerous and cancerous cervical lesions and smoking different types of tobacco, 
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without the present of HPV infection, is yet not clear, and there is no prove on the cofactor 
effect of smoking or  whether  it causes increasing in the risk of  persistent effect of HPV 
or the risk of  acquiring HPV (Appleby et al., 2006). 
An association between acquiring cervical lesions and the effect of tobacco smoking habits  
has been found in most of epidemiological published surveys and studies. For example, in 
Europe in 2014  a large prospective  multicentre cohort study confirmed the association 
between increasing risk of precancerous and cancerous cervical  lesions and female 
smoking habits, even after taking into consideration  history of  HPV infection, and found  
a strong positive associations duration of smoking , and inversely with stopping  smoking,  
even after adjustment for STIs and HPV strains ( Esther et al., 2014).  
Furthermore, in 2012 a published meta analysis study  by Zeng and collogues 2012 based 
on published case-control studies, showed a 20.8 fold increase in cervical lesion risk with 
female who were passive smoker  compared with non passive smoker, (OR = 2.8, 95% CI: 
1.97–4.25) ( Zeng et al., 2012). 
Another Norwegian  nested case control study in 2009 found a strong significant  statistical 
association between heavy  smokers infected with HPV virus and  the risk of developing 
cervical precancerous and cancerous lesions(OR= 2.71; 95%; CI:1.73-4.34), and after HPV 
infection  adjustment similar risk of cervical lesions risk was high in females with a habit 
history of heavy smoking  ( OR=3.25; 95%; CI: 2.62-4.22), by that confirming the 
independent association between  smoking habits and cervical lesions in those infected 
with HPV (Aline  et al., 2009).   
It has been difficult to justify smoking behavior independent role in  precancerous and 
cancerous cervical lesions due to the  strong correlation between smoking behavior  and 
being infected with HPV,in   nested case control study  found that cigarettes agents and  
chemicals, for example nicotine or  metabolite co-tinine that are consumed while smoking  
can lead to  squamous epithelial cells DNA damage , in mucosal tissues of smoker cervix, 
confirming the independent effect of smoking behavior in increasing risk  for precancerous 
and cancerous cervical lesions in HPV infected females (Kapeu  et al., 2009). 
In a case control population based  study  conducted in the US/ Sweden found  a 
significant increase risks of cervical precancerous and cancerous lesions  in positively HPV 
infected smoker  women,  compared with negative HPV  non smokers  (OR=5.23  - 7.22 
for precancerous cervical lesions  and 15.3 for cancerous cervical lesions ) (Gunnel et 
al.,2006, Kjelleberg , 2000). 
In a review of  literature done by Gadduci and collogues, it  concluded that the most 
significant exogenous, environmental risk agent  for cervical precancerous and cancerous 
cervical  lesions was  female  smoking behavior, and that the risk significantly increases 
with smoking duration and  intensity of smoking habit ( Gadduci  et al.,2011). 
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2.5.1.3 Socioeconomic factors and risk for cervical lesion  
 Socioeconomic Factors as income level, social class and level of education have had 
significant effect on individual‘s general health. However, socioeconomic status and level 
of education may play a significant role in causing precancerous cervical lesions including 
cancer. 
However,  in USA, precancerous and cancerous cervical lesion is one of many complicated  
abnormalities that are socioeconomically, ethnically/racially and geographically  strongly 
linked, as annual rates of precancerous and cancerous cervical lesion incidence and 
cervical cancer  mortality are similar to some low income countries rates and  much more  
higher  than the general population rates ( Freeman et al., 2005;Spenceet al., 2007). 
Various studies have pointed out the relationship between cervical lesions and 
socioeconomic factors.  Latha and colleagues conducted a cross section study to find out 
the prevalence of risk factors for  precancerous and cancerous cervical lesions  including 
socioeconomic status among women in the provincial  areas of Karanataka, India 2017, 
and found that the precancerous cervical lesions prevalence was 10% , concluding that it 
was  high due to multiple factors including  low  socioeconomic status, low level of 
education and  reproductive health factors . These study results were similar to the results 
concluded from the study conducted by Mhaske M et al at Pune, in  India 2011, where 
precancerous cervical lesion prevalence   was 12.7% and of cervical cancer lesion was  
4.4%, in addition to the study  that was made by Makuza JD et al in Rwanda 2015 where 
precancerous cervical  lesion prevalence was 5.9% and of cervical cancer was  1.7%. 
The association between precancerous and cancerous cervical lesions and low level of 
education and low level of income was reported in year  2017 through  a cohort 
retrospective  study that was made in Lithuania, targeting 2513 women ( Vincerzevskiene 
et al., 2017).  
 
  Multiple cross section studies that were made in India reveled the relationship between 
low socioeconomic factors such as low level of education and low income with increasing 
risk factor for cervical precancerous and cancerous lesions.( Aswathy et al., 2012, 
Chankapa et al., 2011) . Retrospective cross-sectional study done by Hailemarian and 
colleagues(2017) in Southern Ethiopia  revealed that the risk factors that showed 
significant  association with precancerous and cancerous  cervical lesions were place of 
residency , occupation, education level,  having multiple sexual partners, early age of 
marriage or early age of sexual intercourse  being HIV positive, and  exposure to  STI with 
a  prevalence of 16.5%.  
A hospital based cars control study that were made on Turkish women and showed a 
positive relationship between low educational  level and risk for cervical lesions ( Nesrin et 
al., 2011). Another prospective cohort study made  on women at  India in 2012,  gave a 
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very strong evidence that education in low socioeconomic countries is considered  an 
important risk factor for precancerous and cancerous cervical lesions among other  socio-
demographic and reproductive factors . There was a decrease in precancerous and 
cancerous cervical lesions risk in educated females (HR=0.5 ; 95% ; CI 0.243,-0.8) 
compared to illiterate females with  a dose response relationship significant increase with 
level of education  (P=0.018) (Jissa et al., 2012). 
In 2015,  a case control based study in Himachal Pradesh found that there was a significant 
association on multiple logistic regression between low level of education (OR=1.6; 95%; 
CI 1.1-2.2), low socio-economic status (OR= 1.4 ; 95% ; CI 1.3-2.6) and increase risk for 
precancerous and cancerous cervical lesions (Anita et al., 2015). 
Kalawole and colleagues reported a high amount of HPV –positive cases among married 
females (62.5%) compared with (5%) in divorced and widowed females ( Kalawole et al., 
2015). 
Vaccarella et al. reported that marital status played a significant role in increasing HPV  
risk, and by that increase the risk for cervical precancerous and cancerous lesions 
(Vaccrella et al., 2010). 
In an opposing results from a cross sectional study, 21.1% divorced females and 30.5% 
widowed females compared to 9.1% married females, have had a  higher risk acquiring 
cervical lesion. The researcher attributed the difference to the possibility of multiple sexual 
contact for widowed and divorced females  compared to married females ( Getinet et 
al.,2015). 
 
2.5.1.4 Reproductive health and risk for cervical lesions 
Risk factors studies  for precancerous and cancerous cervical lesions have found female 
sexual behavior to be highly associated with cervical lesion. For example, multiple sexual 
partner females who  have had  the first sexual contact at early age have higher risk for 
precancerous and cancerous  cervical lesions. Also, sexual acquired causes lead  to  the  
progression of precancerous and cancerous  cervical lesions from low to  high grade  
diseases.  Primary prevention of cervical lesions is mostly achieved by monogamy, not 
using OCPs, individual hygiene and  late commencement of sexual activity (Murthy et al., 
2000). 
A strong association between early age of sexual contact or early age  of marriage and 
increase risk  being infected with HPV, which in vulnerable  female  has been the cause of  
major  cases of precancerous and cancerous cervical lesion (Bosch et al., 2002). Moreover, 
early age of sexual contact or  marriage, multiple  sexual contacts, unprotected sexual 
behavior and polygamy  determine  the increase exposure to HPV. Also, readiness of the 
adult immature cervical tissue,  to changes done  by multiple biological agents  increase the  
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risk of acquiring persistent  HPV and therefore for higher risk  of  precancerous and 
cancerous cervical lesion development ( (Kjaer et al, 1998). 
 In  UK, where teenage pregnancies rates  are high, female  having sex at  early age   ⩽17 
years old  had a 2–3 times  higher  risk for  precancerous and cancerous cervical lesions  
compared with females  their  first sexual intercourse ⩾20 years (Green et al., 2003). 
 Multiple studies have had identified increased risk  for cervical precancerous and 
cancerous lesions in females having sex or married at early age (IARC,2007). 
 A large pooled case control study, from eight developing countries, with high rate of 
precancerous and cancerous cervical lesions incidence reported that  females married or 
have had sex at early age  have a 2.4 times higher risk for cervical cancer than those 
married or had sex at older age  ( OR =1.9 ; 95% CI; 1.5–2.4) and those who had their first 
born child at early age< 16 years  have a 2.3 fold higher risk  (OR= 2.31 95% CI: 1.85–
2.87; P<0.001) compared to those who had their first child at  age ⩾21 years. Moreover, 
the study showed that if pregnancy follows marring or having sex at early age  an  
additional increase in risk of precancerous and cancerous cervical lesions is yield (Louie et 
al.,2009). 
Two studies that were made in Ethiopia  in 2013 and 2017 concluded that marriage or 
having sex at early age  are independent predictors of precancerous  and cancerous cervical 
lesions. The first one was a cross section study made by Deksissa and colleagues , it 
showed that women who got married or  started intercourse at early age <16 years have 
more risk to develop  precancerous  and cancerous cervical lesion by 2.2 folds  (OR= 2.23, 
95% CI 1.1-4.3). The other one was case control study made by Kassar R, to assess the 
association between marriage or  having sex at early age and risk for  precancerous  and 
cancerous cervical lesions, showed that  females married or have had  sex at early age <15 
years has  increase   risk of 5.6 folds  to acquire  precancerous  and cancerous cervical 
lesion (Kassar, 2017).  
Another two cross sectional study showed the high prevalence of  precancerous and 
cancerous cervical lesions among female  who were  early at age of marriage or early at 
age of  first sexual intercourse; in Nigeria 2018, Utoo  and colleagues  reported that 77% of 
the tested positive female  for precancerous and cancerous cervical lesions were early at 
age of  marriage or early at age of first sexual intercourse.( Utoo BT et al., 2018). In 2013, 
in Pakistan, Chandra and colleagues reported 59.4% of patients with precancerous and 
cancerous cervical lesions have early age marriage < 15 years ( Chandra et al., 2013). 
An opposing conclusions by Latha K and collogue and Chankapa and collogues  were 
shown in tow cross sectional study that were  made in Karnataka in 2017 and India 2011,  
and found that there is no association between marriage or having sex at early age  and risk 
for precancerous  and cancerous cervical lesions(Latha et al., 2017; Chankapa et al., 2011). 
High parity has been reported in multiple studies, to be significantly associated with 
precancerous and cancerous cervical lesions risk , such as the cross sectional study that 
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was made by Andrew and collogues in Uganda in 2017 and found a significant association 
between high parity and  precancerous and cancerous cervical lesion, and the cross 
sectional study that was made by Kalawole and collogues in Nigeria in 2015 and found a 
strong association between high parity as a co-factor risk and  precancerous and cancerous 
cervical lesions ( Andrew et al.,2017; Kalawole et al.,2015). 
Another case control study that was done in Ethiopia, 2015 concluded that there is a strong 
independent association between high parity (female having >4 children ) and  
precancerous and cancerous cervical lesions .( OR =10.3, 95% CI= 3.6–29.0). However, 
those having > 4 children were 8 folds  more susceptible  to  precancerous and cancerous 
cervical lesions than females  having one or two children. However, parity (No of child 
birth)  is considered an excellent indicator for multiple traumas to the cervix  and  for 
circulating estrogen throughout female  fertile life  for females  with multi-parity ( Bezabih 
et al.,2015). 
Moreover, a cross sectional study by Getinet M and colleagues in 2015 concluded that  
high parity > 3 children has been a  significant predictor of  prevalence of  precancerous 
and cancerous cervical lesions , high parity women > 3 children were 11 folds  more 
susceptible to   precancerous and cancerous cervical lesions  than with<3 children  (OR= 
11;  95 % ; CI: 4.2 − 16.8, p < 0.001) (Getinet et al.,2015). 
Marriage at small age,  means engagement in sexual intercourse with high possibility of 
having first baby at small age . Also, having sex at early age , or having fist child at small 
age  can cause trauma to the cervical tissues and by that increase risk  for precancerous and 
cancerous cervical lesions (IARC, 2007). 
However, early age at first pregnancy, has been studied less than other possible risk factors 
for its contribution to  precancerous and cancerous cervical lesions. For example, in  case 
control pooled  study analysis taken from 8 developing countries in 2009, concluded that   
precancerous and cancerous cervical lesions risk increases by 2.4-fold in females who 
reported early age at fist baby birth  ≤16 years (with OR= 2.31,95% CI: 1.85 – 2.87) 
compared with those with early age at fist baby birth ≥ 21 years. So by that, confirming 
that early age at fist childbirth has been  risk factor for precancerous and cancerous 
cervical lesions in eight developing countries, but as a cofactor with no independent effect 
(Louis et al., 2009). 
In an opposing conclusion made by Bezabih and colleagues in 2016, they had reported   
having first child at small age  ≥25 years, a  significant risk factor that contributes to 
having cancerous and  precancerous cervical lesions as well as  the advancement of  
cervical carcinoma, so they considered it to be an independent  risk factors for acquiring 
precancerous cervical lesion and invasive cervical cancers in their study, and  suggested 
that intervals among deliveries also contribute to   the disposition of precancerous and 
cancerous cervical lesions, not only the small age at fist child birth ( Bezabih et al.,2016). 
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Also Chankapa and colleagues in their cross sectional study in India  2011 found no 
significant association between early age at first full term delivery and risk for  
precancerous and cancerous cervical lesions but found an increase incidence of 
precancerous and cancerous  cervical lesions with increasing age, prolonged sexual 
intercourse and high parity ( Chankapa et al., 2011) 
In a cross sectional study by Mhaske and colleagues in India 201, they  highlighted the 
significant associations between risk of cervical precancerous and cancerous lesions and 
early age of marriage<17 years of age (prevalence was 19.04% compared to 7.94% for 
those married >17 years of age 7.94%),  female  with first child birth before 20 years of 
age (26.31%) and those  with high parity (Mhaske et al., 2011). 
The risk of precancerous and cancerous cervical lesions is affected to a great extend by 
female‘s partner sexual habits, such as polygamy, multiple sexual partners and having 
intercourse with prostitutes  by the husband or partner, and by that increase the risk of 
acquiring HPV infection , which will increase the risk of precancerous and cancerous 
cervical lesions.. Polygamy is not a rare  practice,  especially  among Muslims and is 
considered  among positive HPV females  a cofactors that could lead to precancerous and 
cancerous  cervical lesions among HPV infected female .(  Bayo  et al., 2002). However, a 
cross sectional study in 2009 by Domfeh and colleagues found a high HPV  prevalence in 
polygamies Ghanaian females  were incidence of precancerous and cancerous cervical 
lesions has been high ( Domfeh et al., 2009). 
In  a case control study done  by Bezabih and colleagues in 2015 found that polygamist  
husbands was  significantly statistically  associated with high risk of  precancerous and 
cancerous cervical lesions, and that  husband sexual habits may play an important role in 
acquiring precancerous and cancerous cervical lesions ( Bezabih et al., 2015). 
Owki and colleagues in their cross sectional study in 2017 found a strong association 
between cancerous and precancerous  cervical lesions and  multiple endogenous and 
exogenous risk factors,  such as STIs, polygamy and  marriage or having sex at early age  
and that these factors were highly linked to one another ( Owki et al., 2017). 
2.5.1.5 Contraceptive hormones, devices and the risk of cervical lesions  
 
Many studies have had illustrated that OCPs consuming females  for ≥5 years have a 
higher risk of precancerous and cancerous cervical lesions than female who have had never 
used oral contraceptives, also the longer a female uses oral contraceptives, the greater the 
increase risk of  precancerous and cancerous cervical lesion ( National Cancer institute, 
2018). 
 
 Because,  hormone replacement therapy has no obvious correlation with precancerous and 
cancerous cervical lesions. So, by weighing risks and benefits,  no changes have been done  
in OCPs protocols and recommendation by the World Health Organization (WHO, 2011). 
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 In 2016, Roura E and collogues in their large cohort prospective study, that was done in 
10 European countries showed the relationship between certain exogenous and endogenous 
hormonal factors and  precancerous cervical lesions and cervical carcinogenesis, it 
highlighted the strong  positive associations between OCPs and risk of precancerous and 
cancerous cervical lesions(  (HR = 1.6 and HR = 1.8 respectively for ≥15 years versus 
never use); specifically,  the risk increased with  increase  number and duration of oral 
contraceptive use and decreased with cessation of use and increase years since last oral 
contraceptive have been used. However, the study  found a significant association between 
using menopausal hormone therapy and reduce risk of precancerous and cancerous  
cervical lesions  (HR = 0.5, 95%; confidential interval: 0.4–0.8), and  a non-significant 
reduce risk of cancerous and  precancerous cervical lesions  with the use of  intrauterine 
devices (IUD)  as a contraceptive method (OR = 0.6). However, oral contraceptive risk 
factor mostly induces precancerous and cancerous lesions not independently but as HPV 
cofactors ( Roura et al.,2016). 
 
Another case control study results has shown the increase risk for precancerous and 
cancerous cervical lesion for those using  OCPs and the increase  risk with OCPs  time  
duration consumption  (relative risk = 1.91 with 95% ; CI: 1.7-2, for those using ≥5  years 
compared with females who have  never use) . The cervical lesions risk have decrease after 
stopping OCPs consumption  and  have return to the same risk for those never used by 10 
or more years Moreover, estimated cumulative incidence increase by age 50 years  for 
precancerous and cancerous cervical lesions for those who have started  OCPs use between 
the age of 20-30 years  and kept on using it for 10 years by age 50 from 3.8 per 1000 to 4.5 
per 1000 in developed countries and from 7.3 per 1000  to 8.3 per 1000 in developing 
countries (Appleby et al.,2007). 
 
 
In a systematic review by Gadduci A and colleagues showed an increase in RR for 
precancerous and cancerous cervical lesions  with increasing  OCPs consumption duration 
compared  to those who had never used oral contraceptive pills. Similar results were seen 
for Adenocarcinoma and Sqaumous cell carcinoma, with RRs been declined after stopping 
OPCs (Gadduci et al. 2011). 
 
Another  case control study done in Ethiopia  by Kassa R,  in 2017 , showed that risk for 
precancerous and cancerous cervical lesions increase 2 times more  with OCPs  
consumption  (OR = 2.1; 95% ; CI 1.- 4.2; AOR = 2.3; P < 0.03) (Kassa, 2017). On the 
other hand Herrero and collogues in their large study in 2006,  showed that  injecting 
females for 5 years or more will  increase risk for precancerous and cancerous lesions  by 
430% ( Herrero et al., 2006).  
 
An opposing conclusion was made by Syrjanen K on a prospective cohort study that was 
made in Russia in 2006 found that the use of OC is not an independent risk factor for 
precancerous and cancerous cervical lesions .In their multivariate regression model, they  
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found that all mode of contraception  were of no  value for either cancerous and 
precancerous cervical lesions, and concluded that main  risk factor was  sexual behavior, 
which  was different among oral contraceptive users and  nonusers  and it was the main 
factor predisposing women to precancerous and cancerous cervical lesions, and it  
determined the outcome of their cervical lesion ( Syrjanen et al.,2006). 
 
A two case control pooled study analysis made by the Institute Català d‘Oncologia  and 
International Agency for Research on Cancer an concluded that there was  a strong(OR= 
0·6, 95%; CI: 0·4–0·71; P<0·0001) inverse association between using intrauterine 
contraceptive device (IUDs) and precancerous and cancerous cervical lesion and a 
protective association was noted for Adenosquamous carcinoma and  Adenocarcinoma 
(OR= 0·5, 95% CI:0·2–0·94; P=0·04) and Squamous cell carcinoma, (OR=0·6; 
95%;CI:0·4–0·7; P<0.0001)  but no association was found between HPV infected cervix 
with no lesions and using IUD. Furthermore, the triggered cellular immunity by the IUD 
device makes it a protective factor against cervical precancerous and cancerous lesions ( 
Castellsague et al.,2011) 
 
Moreover, a cross sectional study by Getinet M and colleagues in 2015 concluded  that the 
using OCPs for a long time was a significantly increase  the  prevalence of precancerous 
and cancerous cervical lesions  (OR= 11.9, 95 % CI: 2.1 − 16.7, p = 0.02) (Getinet et al., 
2015) 
 
2.5.2 Endogenous factors  
 
2.5.2.1 Demographic factors and risk of cervical lesions 
 Studies concluded that 47 years old was the peak age of developing precancerous and 
cancerous cervical lesion. Approximately 47% of women with precancerous and cancerous 
cervical lesions are diagnosed at the age <35 years old. However, those >65 years females 
are about 10% of patients with precancerous and cancerous cervical lesions. Although only 
10% of cases are presented at older age, they are more likely to die of cervical cancer, 
because diagnosis occurs at late stages (Gattoc et al., 2015). 
 
Furthermore, the age difference among females with precancerous and cancerous cervical 
lesions could be the result of the long time needed for precancerous cervical lesions to 
progress after persistent infection with HPV (Shiferaw et al., 2016) 
 
 In 2018,  Team H and colleagues in their case control study  reported that women  
between the age of 40 and 49 years, had 2.4 time  more  risk for   precancerous and 
cancerous cervical lesions compared to women between the  age 30–39 years old  (AOR = 
2, 95% CI: 1.3–4.5). A retrospective cohort study results done in Addis Ababa, and 
reported similar results; in which the age group between 40 and 49 years had the peak 
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incidence for precancerous and cancerous cervical lesion.(Abate,2016). Moreover, similar 
findings were reported in 2015 at Ethiopia, in a case control study, where greater risk for 
precancerous  and cancerous cervical lesion  in female with age group  between 40-59 
years old compared to female < 40 years (Bezabih et al.,2015). 
 
Getinet and colleagues reported in their cross sectional study in 2015 that female aged   ≥ 
30 years were at greater risk of acquiring precancerous and cancerous cervical lesions, so 
the older the women the greater the  risk (Getinet et al., 2015). 
Moreover, the prevalence of precancerous  and cancerous cervical  lesions was equally 
found to vary according to age, was the results obtained from cross sectional study by 
Okwi and colleagues in 2017, where they documented that the prevalence of  precancerous 
and cancerous cervical lesions (1 (0.6%)) seen among females  < 30 years, was lower than 
the prevalence  seen among women between 31-40 years(3 (2.5%)) , 6 (11.5%) between 
41-50 and 4 (26.7%) above 50 years. The lower prevalence among women <30 years old  
could be  attributed to  the  established and effective programs for  screening and early 
diagnosis for  precancerous and cancerous cervical lesions  among young reproductive 
women (Okwi et al.,2017). 
However, there are also some documented studies, which reported  contradicting findings. 
For example, Gessesse et al. in his case control study that took place in Northern Ethiopia 
in 2015 documented that there was no  significant statistically association  between 
precancerous and cancerous cervical  lesion and age of the females . Also, Makuza JD and 
colleagues in their cross sectional analytical study in 2015 documented older age (OR= 
0.52; 95% CI= (0.28, 0.97) as a protective factor ( Gessesse et al.,2015; Makuza et 
al.,2015). 
Another opposing results were seen in Embolo and colleagues cross sectional study in 
Cameroon and  found that around 20.52% of Cameroonian females have precancerous and 
cancerous cervical lesions at early stages of their life, extended from 20 to 30 years old ( 
Emblo et al., 2016) 
 
2.5.2.2 Genetic susceptibility and risk for cervical lesions 
Epidemiological studies supported the  genetic link for precancerous and cancerous  
cervical lesion  development. A hereditary component of cervical lesions was detected in 
twins comparisons and studying  mother-daughter family (Galloway , 2003).  By observing 
the biological first degree relatives of females who have developed a cervical lesions , the 
possibility of host genetic predisposition has been  strengthened because biological first 
degree relatives of females suffering from cervical lesions , experience a two-fold risk of 
developing precancerous and cancerous lesions  compared to non-biological relatives of 
females  with cervical lesions ( Magnusson  et al., 1999) The heritability of precancerous 
and cancerous cervical lesion  has been determined as 27% ( Hemminki et al., 1999). 
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 Being infected with persistent high risk HPV strains are considered to be  the most 
common cause of precancerous and cancerous cervical lesions, despite the fact that  huge  
numbers of  sexually active  young females  acquire different types of  HPV infection, only 
few of them develop precancerous and cancerous cervical lesions, this might be attributed 
to host genetic variation and body responses to different  HPV genotypes  and the ability to 
acquire precancerous and cancerous cervical lesions, Furthermore, the complex 
multifactorial cervical diseases outcomes are  highly affected by the  host genetic factors 
that   are also known to regulate precancerous and cancerous cervical lesion rate   
progression (Chattopadhyay , 2011) . 
 
Moreover, genome-wide and preclinical association studies  have had  reported the 
associations of genetic variations in several susceptible female  for acquiring precancerous 
and cancerous cervical lesions ( Bahrami et al.,2018). 
 
Furthermore,  the host immune system genetic variability has an extremely important role 
in the defense against  HPV infection  and therefore to the probability of developing 
precancerous and cancerous cervical lesion.  
 
Worldwide, several international studies have reported that some genetic variations in host 
immune system, are associated with susceptibility to precancerous and cancerous cervical 
lesions , but there have been no conclusive studies about how genetic susceptibility is 
mechanically related to precancerous and cancerous cervical lesions and  the HPV 
infection ( Mora et al., 2016). 
 
 
2.5.2.3 Family history and risk for cervical lesion 
 
Unfortunately, cervical cancer runs in some families. The familial tendency is suspected by  
many researchers to the cause of  an inherited factors making female more susceptible  to 
HPV infection than others, or that , females  may share other risk factors that are not 
genetic in origin. ( ACS,2017) 
 
The theory of familial aggregation of  precancerous and cancerous cervical lesions has 
been supported by many published studies, which have had suggested,   that the etiology of 
precancerous and cancerous cervical lesions might be affected by  genetic variation,  also  
suggesting a 2 time  risk  increase for  precancerous and cancerous cervical lesions  
associated with positive history of cervical lesions .Regardless of  the relationship or  the 
first degree affected female relative, a significant association was observed for both  
precancerous and cancerous cervical lesions ( Paltrik  et al., 2000). 
 
However , full-blooded relatives showed a  stronger risk  as compared to adapted  to half-
blooded relatives. The full siblings familial risk was 1.84, compared with 1.40 for half-
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siblings maternal and 1.27 for paternal.  Familial risk for  cancerous and precancerous and 
cervical lesions  in full siblings of the total risk accounts for 36%  for the environmental 
component  and 64% for the heritable component (Hemminki  et al.,2006). 
 
Also, strong familial aggregation was suggested by multiple studies for precancerous and 
cancerous  cervical lesions among dizigoteic -monozygotic twins when  evaluating 
precancerous and cancerous cervical lesions (Ahlbon et al.,1997). 
 
 
However, in order to determine if the familial aggregation of cervical lesions that was 
observed was the cause of  shared environmental exposures among family members or the 
cause of mutual genetic susceptibility. Patrik and collogues reported that shared genes 
(heritability) explain 27% of the total  precancerous and cancerous cervical lesion risk 
(95% ; CI:  0.26–0.29 ) are attributed to hereditary factors ( shared genes)   with no  
significant effect of shared environmental familial factors between mother and daughters 
but a significant effect of  shared environmental familial factors between sisters. However, 
specific sister shared environment was about 2% (95% CI 0.01–0.04). Their study results 
indicated that development of precancerous and cancerous cervical lesions depends on  
factors that were inherited, which affect  cervical tissue sensitivity to persistence HPV, as 
well as ,  precancerous and cancerous cervical lesions development rate (Patrik  et 
al.,2000). 
 
2.6 Pap smear screening test and role in detecting cervical lesions: 
 
Carcinoma of the cervix  is considered one of the most preventable cancers, where 
precancerous lesions can easily be detected through cytology screening before they 
become cancerous. When detecting precancerous lesions by screening , treatment can start 
as early as possible, so as to avoid cervical cancer development. Also, cancerous lesions 
can be detected by  cervical Pap smear screening  at early stages so as to be treated early 
leading to high potential of cure(WHO, 2015). 
 
Cervical cancer in developing countries is considered one of  the leading cause deaths 
related to cancer  among female. 75% of females are screened for precancerous and 
cancerous  cervical lesions in developed countries , mostly  by  cervical Pap smears 
screening test, which is a method for  cervical screening and has been  used to find 
precancerous and cancerous lesions in the cervix, on the other hand, in developing 
countries 55 of females are screened (Denny et al., 2006). The Pap smear  cytology based 
cervical screening has the ability to detect  the incidence of cancerous and precancerous 
cervical lesions  for decades despite the argument  that has had been surrounding the 
ability  of medical and public community to use Pap smear test  for screening (Gedefaw et 
al.,2013). 
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Preventing   cervical cancer morbidity and mortality is the goal for precancerous and 
cancerous cervical lesion screening. However, screening strategies  should be  maximizing 
the benefits of screening by identifying   those precancerous cervical lesions , which might 
to progress to carcinoma and  to decrease  the harmful effect  associated with screening, by 
avoiding undesired  treatment for  HPV infection and for  benign lesions that may not 
progress to cancer. In countries with good effective screening programs,  a decrease in 
mortality and incidence from precancerous and cancerous cervical lesion  was seen as the 
results of using cervical Pap smears screening test. Despite the fact that false positive 
abnormal cytology results are common and precancerous and cancerous lesions doesn‘t 
develop in  most cervical tissue with abnormal results on Pap smear, cervical cancer is of a 
concern (Castle et al., 2010). 
 
 WHO reported in 2013 that repeated Pap smear cytology screening test organized 
programs in developed countries has helped a lot in decreasing incidence and mortality 
rates from cervical cancer. In contrast, in developing countries and due to the absence of 
effective screening organized programs cervical lesions and cancer remain largely 
prevalent.  
 
 Sqaumous cell cancer of the cervix accounts for 80%-90% of all cervical carcinomas, and  
has been decreased globally due to the  effective screening with Pap smear cytology test ( 
Debbie et al., 2012). In the middle  of the 20
th
 century, USA introduced  Pap smear 
cytology screening test , which obviously lead to decrease in precancerous and cancerous 
cervical lesions  and instead of being the most common cause of cancer deaths in female to 
the 14
th
 rank as the  cause of  female cancer deaths ( Siegel et al., 2012).  Invasive cervical 
cancer early detection, by cervical Pap smear test , has reduced mortality, and made  the 
survival 5 years rate almost  92% , also by using the detection screening methods  
precancerous cervical lesions were caught treatment earlier, and by that decreasing cervical 
carcinoma incidence (Debbie et al., 2012).  In USA , almost about 50% , of  precancerous 
and cancerous  cervical lesions  were diagnosed in females who never had Cervical 
screening , and another  10%  were females who didn‘t had any cervical screening in the 
past 5 years ( Freeman et al., 2005;Spence et al., 2007). 
 
 
Various studies have pointed , cervical Pap smear screening test role in catching 
precancerous and cancerous cervical lesions including invasive cancer, Sachan and 
colleagues (2018) in their prospective  study, evaluated the effectiveness of the cervical 
Pap smear cytology  test  screening procedure  to  detect  precancerous and cancerous 
cervical lesions in  Indian female   , concluded that  Pap smear testing is a very 
economical, useful, simple, and safe tool for detecting cancerous  and precancerous  
cervical epithelial lesions. However, 48.84%  were  negative for malignancy and 43%  
were diagnosed with  infection and/or inflammation . High-grade squamous intraepithelial 
lesion (HSIL) atypical squamous cells of undetermined significance (ASCUS), and were 
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detected in 0.5%,  3% and 5.%, respectively. ECA was detected in 8.48% (Sachap et al., 
2018). 
 
 Two Indian retrospective studies have  recommended that cervical Pap smear test  should 
start at 30 years old age  for all females , because  Pap smear is inexpensive, simple, 
practical and safe  diagnostic procedure, for precancerous and cancerous cervical lesions 
early detection   in high risk population, and must be adapted as  an organized  routine 
screening procedure. The study also, concentrated on  Pap smear test role in  diagnosing 
inflammatory lesions and  causative agents, radiation therapy changes, rare tumors and  
atrophic changes. In the first study Patel et al., 2011  found that out of the   995 patients 
who were screened  95%  were inflammatory and  benign and 6% were precancerous  and 
cancerous lesion, out of the precancerous lesions 84% were ASCUS and AGUS. While in 
the second study  Veghela et al., 2014  found that from all the cases ; LSIL  was the most 
common (12.4%) of cases,  followed by HSIL (5%), then ASCUS( 2.8%), Squamous cell 
carcinoma (2.4%) and AGCUS (1.2%)  
In another retrospective study that were made in UAE to estimate abnormal epithelial cell   
frequency in female  undergoing Pap smear examinations; 0.4% was screening rate  with 
Pap smear was, 3%  were abnormal epithelial cells , with atypical ASCUS found in 2%, 
LSILs found in 1%, HSILs found in 0.3% and  there was no abnormal squamous cell 
carcinoma. And found an ECA detection rate, of 9.% ( Eyad et al.,2012). 
Another  cross sectional study made in 2012 by Sarma and colleagues to differentiate 
cervical  precancerous and cancerous lesion using  cervical  Pap smear test  and Bethesda 
system, found  that  cervical Pap smear test has an important  role precancerous and 
cancerous cervical lesions early detection , after obtaining the study results that showed the  
detection of precancerous and cancerous cervical lesions in 4 % of all cases, while 88% 
were negative for cancer and ECA with 12 % out of which 30  % smears were equally 
having invasive squamous cell carcinoma,  HSIL , LSIL  and ECA detection rates of 12%   
Verma and colleagues in their cross sectional study that were made in 2017,  to determine 
the specificity and  sensitivity of Pap smear test to detect precancerous and cancerous 
cervical lesions, concluded that cervical  Pap smear screening method  was specific and   
sensitive  in finding  precancerous and cancerous cervical lesions. In this study, NILM 
were  56% , 33%  were inflammatory, nonspecific findings  were 2% . ASCUS was in 1%, 
LSIL in 6% and HSIL in 3 % women. LSIL detecting  sensitivity and specificity were 
77%, 96% and  for  HSIL were 67%  and 98 %.  
In a retrospective cohort study Cervical Pap smear test  showed abnormal epithelial high 
prevalence  among the population at the  East part  of Saudi Arabia  . About 624 abnormal  
cases were found  (53%), 58 cases  had SIL ,  accounting for  5% of total smear samples, 
most of the SIL were ASCUS, representing 60%. The prevalence was 0.3% for  abnormal 
squamous cervical cells (Magdi et al.,2011). 
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 However the prevalence of cervical  Pap cytological smear  abnormalities done on Turkish 
population in 2012  was 2.8%,  epithelial abnormalities were ASCUS:  2% , Atypical 
squamous cell suspicious for high-grade squamous intraepithelial lesion, LSIL= 0.2%,  
HSIL= 0.5% ,  AGUS=0.1%,  and squamous cell carcinoma (SCC)=  0% (Atilgan  at., 
2012). 
 Furthermore, the was a strong significant and independent association between  abnormal 
results of Pap and  age, lack of awareness about cervical  Pap smear screening tests and 
HPV infection, in the cross sectional study that were made by Maleki A and colleagues in 
Iran in 2015, mild inflammatory changes were found (37%) , 4% abnormal epithelial  cells 
and ASCUS were  the highest abnormal percentage of  changes with 2% .  
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Chapter Three: Conceptual Framework 
 
 
In this chapter major definitions, dependent and independent variables, variables 
operational definitions and the study conceptual framework will be presented. 
  
3.1 Cervical lesions  definition 
  
A precancerous cervical lesion, or intraepithelial lesion, is considered changes or 
abnormalities in the cervical cells that if not early treated can progress into cervical cancer. 
Precancerous conditions are not cancer, but these abnormal changes have higher chance 
than normal cells to become cancerous if not  properly  treated. 
Moreover, if these precancerous changes or lesions are left untreated, it may take them 10 
years or more to be transformed into cancerous cervical lesions, but sometimes these 
cancerous lesions occur in less time. Squamous and glandular cells are the two main types 
of cervical cells that line the ecto and endo cervix respectively and where abnormalities 
can occur (Canadian Cancer Society, 2018) . 
 
 
3.2 Cervical cancer definition: 
 
 Abnormal cervical cell growth into the lining of cervix  is referred to as  cervical cancer, 
where the transformation zone is the first to be affected most of the time , and may spread 
to  nearby tissues, for example , the  vagina, or may cause metastases to other body organs 
, such as the liver as well as the lungs . The most frequent types of cervical cancerous 
lesions are: 1)Squamous cell carcinoma (SCC), accounts for 70% of case (7 of every 10 
cases ), and is considered the most common type. 2)  adenocarcinoma that starts in the 
glandular cells , accounts for 25% of cases and is considered   less common type of 
cervical cancerous lesions . However, the abnormal glandular cells are harder to recognize 
and occurs higher up in the cervix that is why adenocarcinoma is more difficult to diagnose 
than SCC. 
Moreover, cervical cancer may contain tow types of cell growth called adenosqaumous or 
mixed carcinoma that consists of squamous cells and glandular cells. Cervical sarcoma and  
small cell carcinoma are rare types of cervical cancer (Hammond , 2017). 
 
3.3  Cervical  lesions determinants risk factors model: 
 
Figure 3.1 Presents the conceptual framework model for the exogenous and endogenous 
risk factors for precancerous and cancerous cervical lesions used in this study  
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Figure 3.1: The Study conceptual framework  
 
Endogenous factors such as family history, genetic predisposition and age may play a 
major role in developing precancerous cervical lesion that at the long term may evolve to 
cervical cancer.(Medscape,2014) 
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Exogenous factors that are found to be associated with cervical lesions; such as lifestyle 
factors, including smoking, multiple sex partners, polygamy, high parity. In addition to 
environmental risk factor, such as cervical trauma and STIs. 
  
Cervical lesion determinants and risk factors causing positive Pap smear results: 
 
1. Lifestyle factors: Smoking different types of tobacco 
2. Reproductive health factors:  polygamy, multi-para  and using OCPs   
3. Environmental and exogenous factors: cervical trauma  if  sexual contact starts  at 
small age or having children at small age and STIs especially the most common 
cause of cervical lesions  HPV infection  
4. Socio-demographic factors; age , income level, education level and employment 
status   
5. Family history and genetic predisposition that make females more susceptible to 
persistent HPV infection  
  
3.4 Independent variables  
 
3.4.1 Socio-demographic variables (annex 1) 
 
1. Age: represented in intervals in the  constructed questionnaire  
2. Marital status: Cervical lesions incidence is much more higher in married women 
and formerly married women due to multiple sexual partners (Leck et al,1978). 
a. This variable was categorized into three groups, constructed as follow: 
married, divorced, widowed, no single group was used because culturally 
no Pap smear test can be performed on single female. 
3. Income level: Low socioeconomic status increase females vulnerability to acquire 
cervical lesions, for example, most of those living in low social-economic 
circumstances are unable to provide enough income to seek medical care and 
treatment for STI‘s including HPV infection (Tadesse,2015). 
This variable was categorized into five categories, constructed as follow: low 
income , middle income, high income, no income and do not know  
4. Level of education: Females with low level of education tend to suffer more from 
STIs including HPV and the don‘t seek medical treatment as these with high level 
of education ( Nejo et al,2018). Level of education for the participants was 
categorized into four groups constructed as follow: primary school or less, high 
school, Bachelor degree and postgraduate 
5. Employment status: categorized in five groups constructed as follow: house wife, 
self employee,  wage worker, field officer and office employee 
 
 
3.4.2 Environmental variables (annex 1) 
 
a- Cervical trauma which is measured by assessing the following:  
1- Early Age at first intercourse, which was categorized in six age  intervals: <15, 
15-24. 25-34, 35-44 and  ≥45 years old and I don‘t know  
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2- Early Age at first baby which was categorized in 9  age intervals : ≤15 year , 
16-20 year , 21-25 year , 26-30year , 31-35year , 36-40year ,41-45year , >45 
years old and I don‘t know  
 
 In developing countries, starting sexual contact or marriage and getting pregnant at early 
age  are considered important risk factors for precancerous and cancerous cervical lesions 
(Louie  et al, 2009) 
 
The hormonal effect on HPV and  host immune response to it  during  the period of pre-
adolescence and adolescence can explain how early marriage or sexual contact and early 
pregnancy play a role in increasing  the risk of precancerous and cancerous cervical lesion. 
The cervical epithelium site, which is mostly liable to cancerous lesions by HPV infection, 
is the transformation zone area, in which high susceptibility might be related to stratified 
epithelium excoriation , and by that facilitates basal layer exposure to   HPV infection with 
scant trauma. Another additional susceptibility factor is biological immaturity during 
adolescence ( Singer et al., 2000, Elson et al., 2000, Moscicki et al., 1989; ).  
Moreover, during adolescence and pregnancy , changes  to the cervical tissue are  induced 
by high level of  hormones .(Singer et al., 2000), where the acidification of vaginal activity 
is stimulated by estrogen, causing  squamous cell  meta-plasia when the endo-cervical 
epithelial changes (Elson et al., 2000).  
Furthermore, he presence of HPV  infection during the  metaplastic transformation induced 
by estrogen increases the probability of transforming the  cervical cells into  neoplastic 
cells (Shai et al.,  2008; Elson et al., 2000; Hwang et al., 2009). The neoplastic 
transformation changes are primarily the effect of multi-parity, especially during the first 
pregnancy (Singer et al., 2000). Although metastatic changes is suspected to be affected  
by  the mechanism of trauma and repair during deliveries, but there has been no clear 
evidence that those trauma can increase risk for precancerous and cancerous cervical. 
(Munoz et al., 2002). 
Moreover,  another postulated explanation could  the effect of estrogens on the host  
immune response (Arbei et al.,1996; Mitrani et al., 1989), specially  during pregnancy and 
during the ovarian follicular phase cycle, when there is a 3-8 fold increase in the normal 
level of the estrogens hormone (Marzi et al., 1996; Duncan et al., 1994; Jabbour et al., 
2008). The effect of HPV oncoproteins  in addition to the presence of high level of 
estrogen and high density of estrogen receptors in the transformation zone, decrease the 
level of cytotoxic cytokines and the mediated immune response  by the cervical cells - that 
usually cause the clearance of infection- casing the persistent of HPV infection. ( Giannini 
et al., 2002; Marzi et al., 1996; Jacobs et al., 2003).  
 
b- Sexually transmitted infections including HPV: Cervical cancer risk increases 
in women havening persistent STIs, almost all precancerous and cancerous 
cervical lesions are caused by certain high risk types of HPV, which are 
extremely common. For example, in USA 20 million of the population is 
already infected with certain types of HPV, six million acquire it each year, and 
more than half of all sexually active adults will acquire the HPV infection once 
in their life (CDC,2014). 
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This variable was assessed in the questionnaire by asking directly about being 
diagnosed or infected with STIs previously and whether have ever had abnormal 
discharge or still having any STIs symptoms  
 
 
3.4.3 Life style factors: (Annex 1) 
 
- Smoking:  HPV infection prevalence and incidence  that is associated with cervical 
lesions is highly affected by smoking behavior, the carcinogenic effect of tobacco 
is related to multiple factors including local immune-suppression effect or direct 
local carcinogenic effect (Moutinho,2011).  
Participants were asked if they are currently smokers or whether previously had 
been smoking (Cigarettes or waterpipes) and the amount smoked per day  
 
3.4.4  Reproductive health factors: (Annex 1) 
1- Polygamy: Polygamies marriages or random sex done by husbands make their 
female partner more prone to precancerous and cancerous cervical lesion , 
especially with low personal hygiene husbands, polygamy has been a main co-
factor for precancerous and cancerous cervical lesions in populations were HPV 
infection is common ( Bayo et al., 2002).  
Participants were asked whether they were married more than one time or 
whether their partners have multiple wives  
2- High parity:  is considered a main cofactor for precancerous and cancerous 
cervical lesions among females suffering from persistent infection with 
HPV(Jensen et al.,2013). 
Participants were asked about No of deliveries, which was categorized into four 
groups as follow: No deliveries, 1-4 times, 5-10 times and > 10 times  
3- Use of contraceptives: Risk of precancerous and cancerous cervical lesion 
increases in women who have had used or still using oral contraceptive pills for 
≥ 5 years. The longer the use of oral contraceptive the higher the risk of 
acquiring cervical lesions, and after stopping the use of them the risk decreases 
over time ( NIH,2018).  
Participants were asked about current or past  using of oral contraceptives. 
 
 
3.4.5 Family history and genetic factors: (annex 1)  
 
 Persistent HPV infection is considered the most common etiological cause of most 
precancerous and cancerous cervical lesions, rather than genetic susceptibility or 
family history, so little information and knowledge is available about the role of 
family history and genetic predisposition for cervical lesion, but still they are 
considered as co-factor with persistent HPV infection to cause precancerous and 
cancerous cervical lesions. (Bellingeret al., 2013). 
Participants were asked whether they have family history of cervical, ovarian and 
uterine cancer or not. 
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3.5 Dependent Variable  
 
3.5.1 Precancerous and cancerous lesions with positive Pap smear findings 
1- Cervical lesions were assessed clinically so as to compare the clinical findings 
with the test results  (annex 2)  
The most common symptoms for cervical lesions are vaginal bleeding which is 
usually postcoital bleeding, abnormal vaginal discharge especially with bad odor, 
dysuria, vaginal discomfort or pelvic pain. 
These symptoms were assessed by asking the participant whether they have any 
vaginal bleeding or discharge, menorrhagia, postcoital or contact bleeding, spotting 
between periods, postmenopausal bleeding , dysuria, lower abdominal or pelvic 
pain and vaginal mass 
   
-However, in early stages of precancerous and cancerous cervical lesions, physical 
examination done by Gynecologist could be normal but with the progression of the 
disease abnormal appearance of the cervix become obvious for the physician, 
including gross erosion, ulcer and even mass. 
These signs were assessed by the Gynecologist, who reported whether he/she could 
see vaginal bleeding or discharge, erosions, ulcers, external polyps, ecto-cervical 
polyps, masses, warts, pelvic or parametrial metaplasia, leukoplakia and ectopy.                      
  
 
2- Pap smear results (annex 3)  
 
Pap smear test can detect precancerous cervical cell lesions that may progress to 
cancerous cells if not treated properly and it can detect cancerous cells ,as well, in 
early stages giving the chance for early treatment and good prognosis. It also can 
detect noncancerous condition such as inflammation as well as infection. 
However, for every female, cervical lesion screening must be part of her routine health 
care. Routine precancerous cervical lesion screening has shown a great reduction in 
both invasive cervical cancer incidence and death from cervical cancer, it is rare for 
Pap smear test to miss cervical abnormalities in females ≥ 30years old if the 
procedures of obtaining the biopsy and reading the biopsy were with no fouls.  
Unfortunately, Pap smear test alone is not effective in detecting adenocarcinoma and 
glandular cell abnormalities which are less common than sqaumous cell abnormalities 
and sqaumous cell carcinoma that are more likely to be detected by Pap smear test, so 
it would more beneficial to add the HPV contesting screening to Pap smear screening 
in almost all cases (NIH,2014). 
 
The cervical lesions were assessed by Pap smear test screening and this procedure was 
performed by Gynecologists using the same kits for all the participants and using the 
same procedure for obtaining the smear by following the written instructions on the 
kits, also it has been fixed and read by  the same professional histo-pathologist  with 
the same universal routine procedure for performing Pap smear test. 
Moreover,  the test assessed the presence of inflammation and degree of inflammation( 
mild, moderate and severe), fresh or old blood , atypical glandular cells, atypical 
sqaumaous cells, CIN 1,2,3 cervical cancer, Candida and inadequate sample  
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Chapter four: Methodology 
 
 
4.1 Introduction 
 
In this chapter, study setting, study designs, sampling method and sample size, selection of 
the study population with its inclusion and exclusion criteria, study tools (questionnaire, 
medical form and Lab results form ), field work and data collection are presented. In 
addition, study statistical analysis methods, as well as study ethical considerations are 
presented. 
  
4.2 Study settings 
 
The study was done in Ministry of Health -primary health care Obstetrics and Gynecology 
clinic- and in Al-Zakat committees Gynecology clinics in addition to private clinics all in 
Ramallah district. 
  
Primary Health Care (PHC)  directorate is one important division of Palestinian Ministry 
of Health . It‘s considered the main first line of defence because it provides screening and 
preventive measurements in addition to primary care services. 
PHC through its 466 centres in West Bank provides Palestinian citizens with primary 
health services, these services differ from one center to another according to the level of 
the primary health care center. These centers are divided into: comprehensive health 
centers, second, third, and fourth, depending on the size of the medical staff in each health 
center, and the level of medical services provided. PHC centres provide services to 
approximately 2,881,687 inhabitants in West Bank including; women and maternal health, 
child health, mental health, dental health , non-communicable , preventive medicine, 
environmental, educational and school health services through general, family medicine 
and specialized clinics. PHC centres in MOH offer a range of health services to Palestinian 
females through its 313 Gynaecological centres, and this specialized clinic  is considered 
one of the main clinics in PHC that provides STIs treatments, Pap smear screening, family 
planning  and other gynaecological counselling and treatments.  
 
Ramallah and Al-Bireh directorate is one of the 14 directorates of PHC centres in West 
Bank that provides services to approximately 328,861 inhabitants with its 56 centres, 
including gynaecological health services, Pap smear screening and follow up . All female 
medical records are computerized under the DHIS2 system. In these centres with the help 
of nurses and gynaecologist the Pap smear biopsies were taken and send to a specialized 
histopathology centre in Ramallah for the fixation and microscopic reading of the results  
 
  
Al-Zaka Committees is a nongovernmental nonprofit organization that provides health 
services in addition to welfare activities in West Bank and Gaza Strip. Zakat committees 
have two major best rank hospitals and 14 medical service clinics and centers in West 
Bank. 
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 Basic health services with small drug costs are provided by the Zakat clinics and centers 
so as to decrease health care financial burden on patients. These clinics cover the main 
cities with limited services in rural areas  
Zakat committee in Ramallah, is situated  in the  city center  where it is available for all 
types of people, offering many health services including general health practices and 
specialized health practices such as gynecological health services including Pap smear 
screening in addition to a pharmacy services , dental services,   basic cardiological 
orthopedic and lab test services . In addition, private doctors attend the clinics on a regular 
base to offer free checkups on fixed schedules during the month, and by that providing an 
additional option of healthcare system for poor and marginalized people beside 
governmental public health services. From this centre Pap smear biopsies were taken by a 
gynaecologist and send to a specialized histopathology centre in Ramallah for the fixation 
and microscopic reading of the results 
 
 
Private sector Obstetric and Gynecologic clinics are clinics managed by gynecologist, and 
offers many specialized services for females attending the clinics especially Pap smear 
screening service, which are then send to special labs for the final results. From these 
clinics multiple Pap smear biopsies were taken by the specialists and then send to a 
specialized histopathology centre in Ramallah for the fixation and microscopic reading of 
the results 
 
 
Pathocare histopathology lab is a private laboratory that was established on 2015. It is a 
specialized Tissue Center for all Tissue Biopsy and Early Diagnosis of Cancer, situated in 
Ramallah district in Israel Street in the center of Ramallah city. It receives biopsies from 
all districts of West Bank and it is managed by professional certified pathologist Dr 
Ghassan Balosha who diagnoses the cases. All technical work including fixation and 
staining is accomplished by lab technicians. The researcher had performed the technical 
process of her cases under the supervision of the technicians and followed up the process 
of diagnosis on the microscope screen with her supervisor. 
 
4.3 Study Design 
 
A cross-sectional quantitative design was employed to achieve study objectives and had   
aimed to recruit Palestinian females, in their productive age.   
 
4.4 Study population 
 
All Palestinian female, in their productive age attending Gynecological clinics (MOH, 
NGOs and private clinics) in Ramallah, West Bank. A sample of 100 female were 
interviewed and tested, after giving their approval to be part of the research, during the 
time of the study data collection period, i.e. December 2017 to July 2018.  
From the 100 sample, 60 were from PHC centers in MOH, 20 from Al-Zaka Committee 
clinics and 20 from private clinics.  
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4.4.1 Inclusion criteria: 
 
 Palestinian female at her productive age( 55-91  years old) 
 Those with no history of uterine or cervical lesions, diseases or cancer  
 Those who were in the past or are still sexually active. 
 All Palestinian females visiting the gynecology clinics and seeking 
counseling or treatment for gynecological problem other than cervical 
disease.  
 Participants‘ consent to participate in the study was required. 
 
4.4.2 Exclusion criteria 
 
 Female with positive cervical cancer or disease history. 
 Those not in their productive age. 
 Those how have never been married(never had sex before)   
 Those not Palestinian  
 Those not living in West Bank. 
 
 
4.5 Study period 
 
The study collection data was carried out in the period December 2017 until July 2018. 
The questionnaire, the medical form, the lab form, the consent form, Ministry of Health 
Al-Zaka committee and private sector approval and permission, and the logistic 
preparation were ready by the end of November 2017. Data collection and study 
population interviews started in December 2017. After eight months, the number of 
eligible participants that were included in the study was 100 female participants and Pap 
smear sample were collected. 
 Laboratory microscopic testing started in December 2017 and finished in September 2018. 
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4.6 Sampling and sample size 
 
4.6.1 Sampling method  
 
A non-probability convenience sampling methods was used, including the accessible 
female population by the researcher. From Ramallah district; a random selection from 
MOH, NGOs and private sector gynecological clinics, so one clinic from each will be 
selected. The sample was convenient and the sample size was dependent on the number of 
patients attending the gynecological clinic (500 female ; 300 attended MOH clinics , 100 
attended Al-Zakat and 100 attended  private clinic ) evenly- proportion to size,  all female 
patients attending the gynecological clinic during the study period have been invited to 
participate , after they have signed  the concept form, they were asked to perform the Pap 
smear test and were interviewed  to fill a questionnaire designed by the researcher, and the 
medical forms for the participants were filled by the gynecologist.  
 
4.6.2 Sampling size 
Using the sample size calculation software available online on EpiTools epidemiological 
calculators (epitools ,2016), the sample size was estimated to be about 100, according to a 
specific formula: 
p) -* p (1 ²tN=  
  d² 
N= appointed  sample size. 
t= CI  95% (1.96) 
P= estimated prevalence  
D= margin error at 5% (.05) 
 
The estimated prevalence in Palestine was 2.4% (Asian Pacific journal, 2009)  
  
 
 
 
4.7. Data source and study tools  
   
4.7.1 Structured interview questionnaire 
 
A face-to-face structural interview questionnaire was developed by the researcher after 
reviewing similar studies  and  previously validated questionnaires. The questionnaire was 
divided into sections to cover the study objectives. The full questionnaire, in Arabic is 
presented in Annex 1 . The following sections cover the questionnaire and source of 
questionnaire parts. 
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 Section one: The socio-demographic and economic characteristic, it included 
questions about participant‘s age, marital status, physical characteristics , 
profession, education, residence type, residence area, history of polygamy and level 
of income.   
 Section Two: Reproductive health, it included questions about participant‘s age at 
menarche, history of menstrual cycle and menopause , age of marriage, hormonal 
history and oral contraceptive use, history of parity and gravidity , abortions,  age at 
first child birth, history of ectopic pregnancy and history of Pap smear screening 
test. 
 Section three: Present and past medical history, it included questions about health 
status of the participants  vaginal discharge and bleeding, pelvic and low abdominal 
pain, history of STIs, history of hormonal dysfunction,  past medical and surgical 
history ,history of malignancies, inherited disease and chronic diseases. 
 Section four: Family history: it contained questions regarding family history of 
malignancy, chronic diseases and STIs 
 Section five:  The lifestyle section included questions about smoking habits, 
alcohol drinking and physical activity.  
 
4.7.2 Medical form  
 
A structural medical form was constructed after reviewing gynecological medical files 
form gynecological departments in hospitals and outpatient clinics and previously valid 
medical forms used by professionals, Annex 2. The form was divided into two sections:  
 First section : covers the  participants symptoms and complains that are connected 
to STIs and cervical lesions  , it included questions about vaginal bleeding and 
discharge, menorrhagia, contact and postcoital bleeding, spotting , menopausal 
bleeding , pelvic and lower abdominal pain and vaginal masses. 
 Second section: covers the physical findings by the Gynecologist. It included the 
observation of vaginal bleeding and discharge, the presence of erosions, ulcers, 
polyps, masses warts leukoplakia, parametrial or pelvic metastases and ectopy.    
 
 
 
 
 
4.7.3 Laboratory  Form  
 
A structural laboratory result form was constructed by the expert pathologist 
containing the required information to cover the study objectives, Annex 3. It 
contained the observed results from reading the fixed Pap smear , whether the 
results showed inflammation , infection , precancerous lesions, cancerous lesions or 
inadequate cell.  
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4.7.4 Validation for the instruments 
The questionnaire and the medical form were structurally built by the researcher, 
based on literature review of previous studies (Elamurugan et al., 2016; Sabrina et 
al., 2010; Harsha et al.,2014), and the two instruments as a whole were reviewed by 
experts in the research field, Gynecologist and Pathologist. The Lab result form was 
structurally built by a Pathologist who is an expert in his field.  
 
4.8 Field work 
 
The field work has been done in three steps; step one was the interview by the researcher, 
step two was obtaining the Pap smear biopsy and filling the medical form( Annex 2)   by 
the gynaecologist at the gynaecology clinics  and step three was reading the results by the 
pathologist at the histopathology lab  
4.8.1 Interviews  
 
 The researcher face to face interviewed the study participants during their waiting time for 
clinic visit in Primary health care clinics in MOH, Al-Zaka and private Gynecological 
clinics 
Before filling the study questionnaire, study aim and objectives were clarified for the 
participants. After the participant accepts to participate, she signed the consent form 
(Annex 8). 
  
 
4.8.2 Pap smear  
 
To obtain the Pap smear biopsy a uniform tool was distributed by the researcher to all the 
clinics that were part of the study, with the same instructions on how to take the biopsy and 
from where and how to use the fixing stain gel 
A PAP-PAK kit was used containing one microscope slide, one cervical-vaginal scraper, 
one CytoSoft cytology brush one cytology fixative pouch, and instruction how to use the 
kit. 
Before starting the procedures the researcher explained to the physicians how to use the kit 
and from where to obtain the sample and how to apply the fixation solution 
All procedures were observed by the researcher who is a medical physician.  
After visual inspection of the cervix and looking for any abnormalities or specific signs, a 
Pap smear biopsy was taken by the physician.  
The Pap smear biopsy has involved collecting cell sample from the cervical tissue of 
participants, then placing the cell tissue on a slide made up of glass, then using 
Papanicolau stain substance to stain the tissues.   
 
So, as to complete the procedure the gynecologist use the following instruments light for 
examination, foot support table examination , examination light, metal speculum, sterile  
gloves, cyto-brush, cervical spatula and cytology base liquid glass slide and fixative.  
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Procedure took about 15 min: while the woman positioned on her back, the gynecologist 
examined the outside area of female rectal and genital areas as well as, the urethra to make 
sure that they have no abnormalities then  
1. A metal speculum  was inserted by the gynecologist  into the vagina   
2. A small brush or swab (cervical spatula and cytobrush) was inserted into the cervix 
opening and turned around to collect enough cell samples. 
3.  As part of Pap smear sampling, a second sample has been  collected from cervical 
tissue  surface  
4. The samples were  in a glass slide and a fixating  solution was added to it to isolate 
cells in the slides for laboratory evaluation 
 
4.8.3 Laboratory test 
 
After obtaining the Pap smear biopsy the sample was send to Pathocare 
histopathology lab were the sample was placed in a Coplin jar with 99% ethyl or 
reagent alcohol for 15 minutes. Then it was placed in Alcohol 70% for 2 min, then 
in H2O for 2 min, then in Hematoxylene for 4 min, then in HCL 0.05% for another 
1.5 min, then in H2O for 5 min, then in Orange G for 3 min, then in alcohol 95% 
for 2min then EA for 4 min then another 2 min in alcohol 95% then at last for 2 
min in alcohol 100%, then it was ready to be examine by the pathologist under 
microscope. Annex 3      
 
  
4.9 Statistical analysis 
Data collected was entered, cleaned and analyzed by using Statistical Package for Social 
Sciences (SPSS® version 23.0)  
 
For descriptive analysis, frequencies were calculated for all study variables and were 
presented in tables and figures  
To examine the binary associations, univariate analysis was done using the cross tabulation 
and the significance of Pearson and Fisher exact chi square-as needed- at P-value 0.05 was 
calculated, to study the association between dependent and independent variables.  
 
Multivariate analysis was done after the univariate analysis, all the variables that showed 
significant association were introduced in the multivariate analysis. Logistic regression 
model was used. The logistic regression was used to compare odds ratio with confidence 
interval of 95%. P-value < 0.05 was used. 
 
  
4.10 Ethical approval 
 
Before starting the study, we got the approval from Al Quds University-Local Helsinki of 
research committee. In addition, we obtained the approval to conduct the study at 
Ramallah and Al-Bireh primary health directorate from PHC directorate in MOH (Annex 
4.7), from Al-Zakat Committee in Ramallah and Al-Bireh Governorate (Annex 5) and 
from the Private sector (Annex 6). Also all female participants were informed about the 
study aim,  objectives and signed a consent form before participating (Annex 8). 
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Chapter Five: The Results 
 
 
5.1 Introduction 
 
In this chapter, study results will be presented in three parts. In part one; descriptive 
analysis will be presented for all the data from the three questionnaires, the participant 
interview questionnaire, the medical form data and the laboratory result data. In part two, 
univariate statistical analysis for the association between dependent and independent 
variables will be presented. In part three, the multivariate statistical analysis results will be 
presented. 
 
5.2 Part 1: Descriptive analysis  
 
5.2.1  Socio-demographic characteristics of the participants: 
  
The response rate of study was 100% ; 100 participants were included in study. 34% of 
them were between the ages of 35-44 years, while 86% of them were married, 68% of 
them were housewives , More than three quarter of them (84%) came from intermediate 
income families. More than half of them  lives in the city (55%), around (40%) the  of 
participants finished their high school education.( table 5.1) 
 
5.2.2  Reproductive health related characteristics 
 
More than three quarter of the participants (79%)  got married between the age of  15-24 
years old. 45% of them had 5-10 childbirth, 61% had their 1
st
 baby between the ages of 16-
20 years old . Around three quarter of the participants (70%) have had used oral 
contraceptives; of these 63% have had used oral contraceptive. Almost less than half of the 
participants (49%) have had a Pap smear test in their life. (Table 5.2).  
 
5.2.3 Past medical history  
Among the 100 participant, 67% reported having a history of vaginal infection after being 
previously examined and tested by physicians , 66% still having symptoms of infection , 3 
reported having cervical lesions before and 5% reported having other types of 
cancer.(Table 5.3)  
5.2.4 Family and genetic history : 
Among the 100 participants, 31 reported that their husband have had suffered from 
infection , 34% have a family history of different kind of malignancies including cervical 
cancer, breast , uterine and ovarian cancer, 14% of them reported having some form of  
genetic diseases in their families.(Table5.4) 
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Table (5.1): Socio-demographic distribution of participants 
 
Variable Frequency n=100 Percentage  
Age(in 
years) 
<15 2 2% 
15-24 7 7% 
25-34 18 18% 
35-44 34 34% 
45-54 23 23% 
≥55 16 16% 
Marital 
status  
Married  86 86% 
Divorced  8 8% 
Widow 6 6% 
Residency City 55 55% 
Village 38 38% 
Camp 7 7% 
Education 
level  
Elementary or no 
education 
21 21% 
High school 40 40% 
Bachelor degree 31 31% 
Post graduate  8 8% 
Income 
status  
Low 8 8% 
Intermediate  84 84% 
High 4 4% 
Don‘t know  4 4% 
Occupation  Housewife 68 68% 
 Field work 
Employee 
5 5% 
Hand paid 
workers 
2 2% 
Office clerk  23 23% 
Free business(self 
employee)  
2 2% 
59 
Table 5.2 Reproductive health characteristic distribution  
 
Variables Frequency(n=100) percentage 
Age at Marriage(in 
years) 
<15 3 3% 
15-24 79 79% 
25-34 17 17% 
35-44 1 1% 
≥45 0 0 
Parity(No of  childbirth) None 3 3% 
1-4 44 44% 
5-10 45 45% 
>10 8 8% 
Age at first baby(in 
years)  
≤15 5 5% 
16-20 61 61% 
21-25 23 23% 
26-30 9 9% 
31-35 1 1% 
41-45 1 1% 
Use of contraceptives; 
            
 
Yes  70 70% 
Oral 63 90% 
Metallic IUD 4 5.7% 
Plastic IUD 3 4.3% 
Others  0 0% 
Pap smear done before  Yes  49 49% 
Once 33 67.3% 
Twice 9 18.4% 
3 times 6 12.2% 
>3 1 2% 
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Table 5-3:  Medical history of the Participants  
Variables  Frequency n=100 Percentage % 
Past History of infection  67 67% 
Treated for past hx of 
infection 
67 100% 
Present symptoms of 
infection 
66 98.5% 
Cervical lesions  3 3% 
Other type of cancer * 5 5% 
*Breast cancer, ovarian and uterine  cancer   
Table 5-4: Family and genetic history among participants 
Variable  Frequency n=100 Percentage % 
Husband with infection 31 31% 
Family history of cancer* 34 34% 
Genetic diseases in family 14 14% 
Chronic diseases** 23 23% 
*Breast, ovarian, uterine and cervical cancer. ** DM, HTN, CVD and Respiratory 
diseases  
 
5.2.5 Smoking behavior among participants . 
Almost half of the participants (49%)  smoke cigarettes , 36% smoke water-pipe.(Table 
5.5) 
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Table5-5: Smoking behavior among Participants  
Risk factor  Count percentage 
Smoking cigarettes  Nonsmoker 42 42% 
Smoker 49 49% 
Ex-smoker 9 9% 
Cigarettes per day <10 8 16.3% 
10-20 41 83.7% 
>20 0 0% 
Period of cigarette 
smoking 
<one year  2 4.1% 
1-5 years  8 16.3% 
6-10years 23 46.9% 
>10years  16 32.7% 
Smoking water-pipe  Nonsmoker 64 64% 
Smoker 36 36% 
Water-pipe per frequency  Daily  9 25% 
4-6times/wk 7 19.4% 
2-3times/wk 16 44.4% 
1-3times/month 4 11.1% 
Period of water-pipe 
smoking  
<one year 6 16.7% 
1-5 years  24 66.7% 
6-10years  6 16.7% 
 
5.2.6  Medical symptoms and signs   
 Table 5.6 shows that the main complains for participants at presentation were vaginal 
discharge (74%) , vaginal bleeding(58%) and 22% presented with lower abdominal pain. 
While the main physical findings by the physician were ; vaginal discharge (68%) , 51% 
vaginal bleeding and 21% were presented with erosions.(Table 5.6) 
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Table 5-6: Symptoms and signs distribution among participants  
Variable Frequency  Percentage  
Symptoms  No symptoms  19 19% 
Vaginal bleeding 58 58% 
Vaginal discharge  74 74% 
Menorrahagia 6 6% 
Contact bleeding 8 8% 
Blood spots  13 13% 
Dysuria 9 9% 
Post menopausal 
bleeding  
3 3% 
Post coital 
bleeding 
16 16% 
Pelvic pain  10 10% 
Lower abdominal 
pain  
22 22% 
Pain during sexual 
intercourse  
17 17% 
Vaginal mass 2 2% 
Sings  No significant 
clinical 
observation  
18 18% 
Vaginal bleeding  51 51% 
Vaginal discharge  68 68% 
Erosion 21 21% 
Ulcers  12 12% 
External polyps 1 1% 
Ecto-cervical 
polyps  
2 2% 
Endo-cervical 
polyps  
3 3% 
Well defined mass 4 4% 
Warts  1 1% 
Vaginal bleeding 
after PV  
2 2% 
Ectopy  3 3% 
 
5.2.7 Histopathology findings  
Table 5.7, shows  that 82% of the participants have positive Pap smear; )presence of 
cervical lesions) . Infection was the most common histological findings among the 
participants with 76%, followed by non-infectious inflammation  that accounted for 66 % 
and 7% have precancerous lesions; from them 3% atypical sqaumous cells,  2% atypical 
Glandular cells. 1%  CIN I&II and 1% CIN III (Table 5.7)  
Table 5-7: Histopathological findings among participants  
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Variables * Frequency (n=100) Percentage  
Pap Smear positive  Yes  82(n=100) 82% 
Inflammation  Yes  66 66% 
Infection  Yes   76 76% 
Candida 43 43% 
Precancerous  Yes  7 7% 
Atypical sqaumous 
cells  
3 3% 
Atypical Glandular 
cells 
2 2% 
CIN I,II 1 1% 
CIN III 1 1% 
Cervical cancer  Yes  0 0% 
Inadequate  Yes  7 7% 
Within normal 
limits 
Yes  11 11% 
*some participants may have more than one histopathological finding 
 
5.3 Part 2 : Association between dependent and independent variables  
Chi-square test was applied to check associations between different independent 
variables and dependent variables, which is cervical lesions that are measured by 
Pap smear test. 
5.3.1 Risk factors association with positive Pap smear  
5.3.1.1 Association between socio-demographic (independent) variables and the 
dependent variable. 
Participants were classified according to their Pap smear results (positive and negative), 
which was used as an indication for the presence of cervical lesion. 
Results showed that there no significant association between socio-demographic variables, 
including age, level of income, level of education, occupation and marital status with the 
dependent variable which was Pap smear results. (Table 5-8) 
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Table 5.8: Associations between socio-demographic (independent) variables and 
dependent variable(positive Pap smear)  
 
5.3.1.2 Association between reproductive health (independent) variables and Pap 
smear results  
Results showed that age at marriage was significantly associated with Pap smear results 
(P<0.001) , Parity or Number of child birth indicated significant association with Pap 
smear results (P=0.03), in addition age at first baby was significantly associated with Pap 
smear results (P<0.001) and contraceptive use including oral contraceptive was 
significantly associated with Pap smear results (P<0.001 for contraceptive use and P=0.002 
for oral contraceptive use). (Table 5.9) 
Variable Positive Pap 
smear frequency 
N=82 
Negative 
Pap smear 
Frequency 
N=18  
P value  
N(%) N(%) 
Age(in 
years) 
<15 1(50%) 1(50%) 0.367 
15-24 5(71.4%) 2(28.6% 
25-34 14(77.8%) 4(22.2%) 
35-44 31(91.2%) 3(8.8%) 
45-54 17(73.9%) 6(26.1%) 
≥55 14(87.5%) 2(12.5%) 
Marital 
status  
Married  71(82.6%) 15(17.4%) 0.865 
Divorced  6(75%) 2(25%) 
Widow 5(83.3%) 1(16.7%) 
Residency City 44(80%) 11(20%) 0.104 
Village 34(89.5%) 4(10.5%) 
Camp 4(57.1%) 3(42.9%) 
Education 
level  
Elementary or no 
education 
18(85.7%) 3(14.3%) 0.766 
High school 34(85%) 6(15%) 
Bachelor degree 24(77.4%) 7(22.6%) 
Post graduate  6(75%) 2(25%) 
Income 
status  
Low 5(62.5%) 3(15.5%) 0.108 
Intermediate  71(85.5%) 13(15.5%) 
High 2(50%) 2(50%) 
Occupation  housewife 56(82.4%) 12(17.6%) 0.892 
 Field work 
Employee 
4(80%) 1(20%) 
Hand paid 
workers 
2(100%) 0(0%) 
Office clerk  18(78.3%) 5(21.7%) 
Free business(self 
employee)  
2(100%) 0(0%) 
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Table 5.9: Reproductive health variables and association with Pap smear results  
 
Variables Positive Pap 
smear frequency 
N=82 
Negative 
Pap smear 
Frequency 
N=18  
P value  
N(%) N(%) 
Age at Marriage(in 
years) 
<15 3(100%) 0(0%) 0.001 
15-24 71(89.4%) 8(10.1%) 
25-34 7(41.2%) 10(58.8%) 
35-44 1(100%) 0(0%) 
≥45 0 0 
Parity(No of  childbirth) none 2(66.7%) 1(33.3%) 0.03 
1-4 31(70.5%) 13(29.5%) 
5-10 41(91.1%) 4(8.9%) 
>10 8(100%) 0(0%) 
Age at first baby(in 
years)  
≤15 3(60%) 2(40%) 0.001 
16-20 58(95.1%) 3(4.9%) 
21-25 16(69.6%) 7(30.4%) 
26-30 3(33.3%) 6(66.6%) 
31-35 1(100%) 0(0%) 
41-45 1(100%) 0(0%) 
Use of contraceptives; 
            
 
Yes  64(91.4%) 6(8.6%) 0.001 
Oral 60(95.2%) 3(4.88%) 0.002 
 
5.3.1.3 Association between Participant medical history and Family 
history (independent variables) with Pap smear results  
 
Results showed that history of having vaginal infection  was significantly associated with 
Pap smear results (P<0.001) , family history of cancer indicated significant association 
with Pap smear results (P=0.03), in addition husband having infection   was significantly 
associated with Pap smear results (P=0.01) .While  history of cervical cancer, and other 
types of cancer was not significantly associated with Pap smear results. (Table 5.10) 
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Table 5-10: Association between Medical and family history and Pap smear results  
 
 *Breast, ovarian and uterine cancer   
 
 
 
5.3.1.4 Smoking  behavior and association with Pap smear results 
 
Results showed a significant association between smoking behavior whether it was  
cigarette smoking (P=0.01) and water-pipe smoking (P=0.01)  and Pap smear results. 
(Table 5.11).  
  
 
Table 5.11: Association between smoking behavior and Pap smear results 
 
  
 
Variables   Positive Pap 
smear frequency 
N=82 
Negative Pap 
smear 
Frequency 
N=18 
P value  
N(%) N(%)  
Smoking cigarettes  Smoker  45(91.8%) 4(8.2%) 0.01 
Nonsmoker 29(69%) 13(31%) 
Ex-smoker 8(88.9%) 1(11.1%) 
Smoking water-pipe  Nonsmoker 48(75%) 16(25%) 0.01 
Smoker 34(94.4%) 2(5.6%) 
 
 
Variable Positive Pap 
smear frequency 
N=82 
Negative 
Pap smear 
Frequency 
N=18  
P value  
N(%) N(%) 
History of  vaginal infection 
 
66(98.5%) 1(1.5%) 0.001 
Family history of cancer * 
  
24(70.6%) 10(29.4%) 0.03 
Husband with history of 
infection 
 
30(96.8%) 1(3.2%) 0.01 
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5.3.1.5 Association between Symptoms and physical findings and Pap smear results  
 
Table 5.12 shows  that the only significant association between symptoms and Pap smear 
results were with vaginal bleeding(p<0.001), vaginal discharge(P=0.003), while other 
symptoms were not significantly associated with Pap smear results. However, concerning 
the physical findings  there have been  significant association between vaginal 
bleeding(p<0.001), vaginal discharge(p=0.01) and erosion(p=0.05) with Pap smear results, 
while other findings have had no significant association.(Table 5.12)  
 
 
Table 5-12: Association between medical findings and Pap smear results   
Variable Positive Pap 
smear 
frequency 
N=82 
Negative Pap 
smear 
Frequency 
N=18 
P value  
N(%) N(%) 
Symptoms  Vaginal bleeding 56(96.6%) 2(3.4%) 0.001 
Vaginal discharge  66(89.2%) 8(10.8%) 0.003 
Menorrahagia 5(83.3%) 1(16.7%) 0.706 
Contact bleeding 7(87.5%) 1(12.5%) 0.559 
Blood spots  12(92.3%) 1(7.7%) 0.272 
Dysuria 7(77.8%) 2(22.2%) 0.509 
Post menopausal 
bleeding  
2(66.7%) 1(33.3%) 0.452 
Post coital bleeding 15(93.8%) 1(6.3%) 0.164 
Pelvic pain  9(90%) 1(10%) 0.428 
Lower abdominal 
pain  
20(90.9%) 2(9.1%) 0.181 
Pain during sexual 
intercourse  
14(82.4%) 3(17.6%) 0.636 
Sings  Vaginal bleeding  50(98%) 1(2%) 0.001 
Vaginal discharge  61(89.7%) 7(10.3%) 0.01 
Erosion 20(95.2%) 1(4.8%) 0.05 
Ulcers  11(91.7%) 1(8.3%) 0.319 
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5.3.2 Risk factor association with different Pap smear findings  
 
When comparing each finding from the Pap smear test with those variables that 
showed significant association with Pap smear results the results were as follow;  
 
5.3.2.1 Inflammation findings: 
 
a) Association with  Reproductive health effect  
 
There was a significant association between age at marriage (p=0.001), age at 
first baby (p<0.001) and use of oral contraceptives (p=0.01) with inflammation 
findings in Pap smear test. In the contrary there was no significant association 
between inflammation findings and Parity (No of child birth)(p=0.06) (Table 
5.13) 
 
Table 5.13  Association between Reproductive health effect  and inflammation  
  
 
Variables  Positive 
Inflammation 
frequency N=66 
Negative 
inflammation  
N=34  
P 
value  
N(%) N(%) 
Age at Marriage(in 
years) 
<15 3(100%) 0(0%) 0.001 
15-24 58(73.4%) 21(26.6%) 
25-34 4(23.5%) 13(76.5%) 
35-44 1(100%) 0(0%) 
≥45 0 0 
Parity(No of  childbirth) none 2(66.7%) 1(33.3%) 0.06 
1-4 23(52.3%) 21(29.5%) 
5-10 41(91.1%) 4(47.7%) 
>10 7(87.5%) 1(12.5%) 
Age at first baby(in 
years)  
≤15 3(60%) 2(40%) 0.001 
16-20 51(83.6%) 10(16.4%) 
21-25 9(39.1%) 14(60.9%) 
26-30 2(22.2%) 1(77.8%) 
31-35 0(0%) 1(100%) 
41-45 1(100%) 0(0%) 
Use of contraceptives; 
            
 
Yes  52(74.3%) 18(25.7%) 0.01 
Oral 50(79.4%) 13(20.6%) 0.01 
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b) Medical and family history 
 
The results showed a significant association between having vaginal  infection (p<0.001) 
and husband having infection (p=0.03) and inflammation findings on Pap smear test, but 
there was no significant association with positive family history of cancer 
(p=0.193)(Table 5.14)  
 
Table 5-14  Association between Medical and family history and inflammation   
 
 * Breast, cervical. Ovarian and uterine cancer  
c) Smoking behavior  
The results showed a significant association between smoking cigarettes (p=0.01) and 
water-pipe (p=0.01) with inflammation findings with Pap smear test. (Table 5.15)  
Table 5-15 Association between smoking behavior and inflammation findings  
 
   
 
Variables    Positive 
Inflammation 
frequency N=66 
Negative 
inflammation  
N=34  
P value  
N(%) N(%)  
Smoking cigarettes  Smoker  40(81.6%) 9(18.4%) 0.01 
Nonsmoker 20(47.6%) 22(52.4%) 
Ex-smoker 6(66.7%) 3(33.3%) 
Smoking water-pipe  Nonsmoker 36(56.3%) 28(43.8%) 0.01 
Smoker 30(83.3%) 6(16.7%) 
 
  
 
Variable  Positive 
Inflammation 
frequency N=66 
Negative 
inflammation  
N=34  
P value  
N(%) N(%) 
History of vaginal  infection 
 
55(82.1%) 12(17.9%) 0.001 
Family history of cancer * 
  
20(58.8%) 14(41.2%) 0.193 
Husband with history of 
infection    
 
25(80.6%) 6(19.4%) 0.03 
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d) Symptoms  and physical findings  
 
The results showed  symptoms of vaginal bleeding and discharge as well as physical 
findings of both were significantly associated with inflammation findings in Pap smear 
test (P value respectively; <0.001,0.01,<0.001 and 0.01). However, erosion physical 
findings was not associated with inflammation findings.(Table 5.16)   
 
Table 5-16: Association between medical findings and inflammation findings    
Variable  Positive 
Inflammation 
frequency 
N=66 
Negative 
inflammation  
N=34  
P value  
N(%) N(%) 
Symptoms  Vaginal bleeding 51(87.9%) 7(12.1%) 0.001 
Vaginal 
discharge  
55(74.3%) 19(25.7%) 0.01 
Sings  Vaginal bleeding  46(90.2%) 5(9.8%) 0.000 
Vaginal 
discharge  
51(75%) 17(25%) 0.01 
Erosion 16(76.2%) 5(23.8%) 0.199 
 
 
5.3.2.2 Infection findings: 
 
a) Association with  Reproductive health effect  
 
There was a significant association between age at marriage (p=0.003), parity 
(No of child birth) (p=0.01), age at first baby (p=0.002) and use of 
contraceptives (p=0.01) with infection findings in Pap smear test. In the 
contrary there was no significant association between infection findings with 
oral contraceptives(p=0.138)  (Table 5.17) 
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Table 5.17  Association between Reproductive health effect  and infection   
  
 
Variables  Positive 
Infection 
frequency N=76 
Negative 
infection  
N=24 
P 
value  
N(%) N(%) 
Age at Marriage(in 
years) 
<15 3(100%) 0(0%) 0.003 
15-24 65(82.2%) 14(17.7%) 
25-34 7(41.4%) 10(58.8%) 
35-44 1(100%) 0(0%) 
≥45 0 0 
Parity(No of  childbirth) none 2(66.7%) 1(33.3%) 0.01 
1-4 27(61.3%) 17(39.6%) 
5-10 39(86.7%) 6(13.3%) 
>10 8(100%) 0(0%) 
Age at first baby(in 
years)  
≤15 3(60%) 2(40%) 0.002 
16-20 54(88.5%) 7(11.4%) 
21-25 14(60.8%) 9(39.1%) 
26-30 3(33.3%) 6(66.6%) 
31-35 1(100%) 0(0%) 
41-45 1(100%) 0(0%) 
Use of contraceptives; 
            
 
Yes  58(82.8%) 12(17.1%) 0.01 
Oral 54(85.7%) 9(14.2%) 0.138 
 
 
 
b) Medical and family history 
 
The results showed a significant association between having history of vaginal  infection 
(p<0.001) and husband having infection (p=0.01) and infection findings on Pap smear 
test, but there was no significant association with positive family history of cancer 
(p=0.252)(Table 5.18)  
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Table 5-18  Association between Medical and family history and infection    
 
 * Breast, cervical. Ovarian and uterine cancer  
 
c) Smoking behavior  
The results showed a significant association between smoking cigarettes (p=0.04) and 
water-pipe (p=0.004) with infection findings with Pap smear test(Table 5.19)  
Table 5-19 Association between smoking behavior and infection findings  
 
   
 
Variables    Positive 
Infection 
frequency N=76 
Negative 
infection  
N=24 
P value  
N(%) N(%)  
Smoking cigarettes  Smoker  43(87.7%) 6(12.2%) 0.04 
Nonsmoker 26(61.9%) 16(38.1%) 
Ex-smoker 7(77.8%) 2(22.2%) 
Smoking water-pipe  Nonsmoker 43(67.2%) 21(32.8%) 0.004 
Smoker 33(91.7%) 3(8.3%) 
 
  
d) Symptoms  and physical findings  
 
The results showed  symptoms of vaginal bleeding and discharge as well as physical 
findings of both were significantly associated with infection findings in Pap smear test (p 
value respectively; <0.001,0.001,<0.001 and 0.002). However, erosion physical findings 
was not associated with infection findings.(Table 5.20)   
Variable  Positive 
Infection 
frequency N=76 
Negative 
infection  
N=24 
P value  
N(%) N(%) 
History of vaginal infection  
 
64(95.5%) 3(4.5%) 0.001 
Family history of cancer * 
  
24(70.6%) 10(29.4%) 0.252 
Husband with history of 
infection   
 
29(93.5%) 2(6.5%) 0.01 
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Table 5-20: Association between medical findings and infection findings    
Variable  Positive 
Infection 
frequency 
N=76 
Negative 
infection  
N=24 
P value  
N(%) N(%) 
Symptoms  Vaginal bleeding 53(91.4%) 5(8.6%) 0.001 
Vaginal 
discharge  
63(85.1%) 11(14.9%) 0.001 
Sings  Vaginal bleeding  47(92.2%) 4(7.8%) 0.001 
Vaginal 
discharge  
58(85.3%) 10(14.7%) 0.002 
Erosion 18(85.7%) 3(14.3%) 0.190 
 
5.3.2.3 Candida findings: 
 
a) Association with  Reproductive health effect  
 
There was a significant association between age at marriage (p=0.02), age at first baby 
(p=0.04) and use of contraceptives (p=0.002) with Candida  findings in Pap smear test. In 
the contrary there was no significant association between Candida findings and Parity (No 
of child birth)(p=0.0825) nor with oral contraceptives(p=0.062)  (Table 5.21) 
 
Table 5.21  Association between Reproductive health effect  and Candida    
  
 
Variables  Positive Candida 
frequency N=43 
Negative 
Candida   
N=57 
P 
value  
N(%) N(%) 
Age at Marriage(in 
years) 
<15 1(33.3%) 2(66.7%) 0.02 
15-24 39(49.4%) 40(50.6%) 
25-34 2(11.8%) 15(88.2%) 
35-44 1(100%) 0(0%) 
≥45 0 0 
Parity(No of  childbirth) none 0(0%) 3(100%) 0.101 
1-4 22(50%) 22(50%) 
5-10 20(44.4%) 25(55.6%) 
>10 1(12.5%) 7(87.5%) 
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Age at first baby(in 
years)  
≤15 0(0%) 5(100%) 0.04 
16-20 32(52.5%) 29(47.5%) 
21-25 9(39.1%) 14(60.9%) 
26-30 1(11.1%) 8(88.9%) 
31-35 0(0%) 1(100%) 
41-45 1(100%) 0(0%) 
Use of contraceptives; 
            
 
Yes  38(54.3%) 32(45.7%) 0.002 
Oral 35(55.6%) 28(44.4%) 0.825 
 
 
 
b) Medical and family history 
 
The results showed a significant association between having history of vaginal infection 
(p=0.002) and Candida  findings on Pap smear test, but there was no significant 
association with positive family history of cancer (p=0.091) and husband having infection 
(p=0.360) (Table 5.22)  
 
Table 5-22  Association between Medical and family history and Candida    
 
 * Breast, cervical. Ovarian and uterine cancer  
 
 
c) Smoking behavior  
The results showed no significant association between smoking cigarettes (p=0.910) and 
water-pipe (p=0.198) with Candida findings with Pap smear test(Table 5.23)  
Variable  Positive Candida 
frequency N=43 
Negative 
Candida   
N=57 
P value  
N(%) N(%) 
History of   vaginal infection 
 
36(53.7%) 31(46.3%) 0.002 
Family history of cancer * 
  
11(32.4%) 23(67.6%) 0.091 
Husband with infection   
 
12(38.7%) 19(61.3%) 0.360 
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Table 5-23 Association between smoking behavior and Candida findings  
 
   
Variables    Positive 
Candida 
frequency N=43 
Negative 
Candida   
N=57 
P value  
N(%) N(%)  
Smoking cigarettes  Smoker  20(40.8%) 29(59.2%) 0.910 
Nonsmoker 19(45.2%) 23(54.8%) 
Ex-smoker 4(44.4%) 5(55.6%) 
Smoking water-pipe  Nonsmoker 25(39.1%) 39(60.9%) 0.198 
Smoker 18(50%) 18(50%) 
 
  
d) Symptoms  and physical findings  
 
The results showed  symptoms of vaginal bleeding and discharge as well as physical 
findings of both  and erosion were not significantly associated with Candida findings in 
Pap smear test (P value respectively; 0.410,0.108, 0.268, 0.298 and 0.111).(Table 5.24)   
 
 
Table 5-24: Association between medical findings and Candida findings    
Variable  Positive 
Candida 
frequency 
N=43 
Negative 
Candida   
N=57 
P value  
N(%) N(%) 
Symptoms  Vaginal bleeding 26(44.8%) 32(55.2%) 0.410 
Vaginal 
discharge  
35(47.3%) 39(52.7%) 0.108 
Sings  Vaginal bleeding  24(47.1%) 27(52.9%) 0.268 
Vaginal 
discharge  
31(45.6%) 37(54.4%) 0.298 
Erosion 12(57.1%) 9(42.9%) 0.111 
 
69 
 
5.3.2.4 Precancerous cells findings: 
 
 
a) Association with  Reproductive health effect  
 
There has been   no significant association between age at marriage (p=0.945), parity (No 
of child birth) (p=0.770) , use of contraceptives (p=0.232 ), oral contraceptives(p=0.840)  
and age at first baby (p=0.783)  with Precancerous cells findings in Pap smear test. (Table 
5.25) 
 
Table 5.25  Association between Reproductive health effect  and Precancerous cells   
   
 
Variables  Positive 
Precancerous 
cells frequency 
N=7 
Negative 
Precancerous 
cells  N=93 
P 
value  
N(%) N(%) 
Age at Marriage(in 
years) 
<15 0(0%) 3(100%) 0.945 
15-24 6(7.6%) 73(92%) 
25-34 1(5.8%) 16(94.1%) 
35-44 0(0%) 1(100%) 
≥45 0 0 
Parity(No of  childbirth) none 0(0%) 3(100%) 0.770 
1-4 4(9%) 40(90.9%) 
5-10 3(6.7%) 42(93.3%) 
>10 0(0%) 8(100%) 
Age at first baby(in 
years)  
≤15 0(0%) 5(100%) 0.783 
16-20 3(4.9%) 58(95%) 
21-25 3(13%) 20(86.9%) 
26-30 1(11.1%) 8(88.9%) 
31-35 1(100%) 0(0%) 
41-45 0(0%) 1(100%) 
Use of contraceptives; 
            
 
Yes  3(4.2%) 67(95.7%) 0.232 
Oral 3(4.7%) 60(95.2%) 0.840 
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b) Medical and family history 
 
The results showed no significant association between having history of vaginal infection 
(p=0.595),  husband having infection (p=0.626) and positive family history of cancer 
(p=0.555) with Precancerous cells findings on Pap smear test (Table 5.26)  
 
Table 5-26  Association between Medical and family history and Precancerous cells   
 
 * Breast, cervical. Ovarian and uterine cancer  
 
c) Smoking behavior  
The results showed a significant association between smoking cigarettes (p=0.001) with 
Precancerous cells findings with Pap smear test, but there was no association and water-
pipe (p=0.493) (Table 5.27)  
 
Table 5-27 Association between smoking behavior and Precancerous cells findings  
   
 
Variables    Positive 
Precancerous 
cells frequency 
N=7 
Negative 
Precancerous 
cells  N=93 
P value  
N(%) N(%)  
Smoking cigarettes  Smoker  0(0%) 49(100%) 0.001 
Nonsmoker 4(9.5%) 38(90.5%) 
Ex-smoker 3(33.3%) 6(66.6%) 
Smoking water-pipe  Nonsmoker 3(8.3%) 33(91.7%) 0.493 
Smoker 4(6.2%) 60(93.7%) 
 
Variable  Positive 
Precancerous 
cells frequency 
N=7 
Negative 
Precancerous 
cells  N=93 
P value  
N(%) N(%) 
History of vaginal  infection  
 
5(7.4%) 62(92.5%) 0.595 
Family history of cancer * 
  
2(5.8%) 32(94.1%) 0.555 
Husband with infection   
 
2(6.4%) 29(93.5%) 0.626 
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d) Symptoms  and physical findings  
 
The results showed signs of vaginal bleeding were significantly associated with 
Precancerous cells findings in Pap smear test (p value=0.05) . However, vaginal  bleeding 
and discharge symptoms as well as physical findings of vaginal discharge and erosion  
were not associated with Precancerous cells findings. (P value respectively; 0.324, 0.587, 
0.145 and 0.159) (Table 5.28)   
 
 
Table 5-28: Association between medical findings and Precancerous cells findings    
Variable  Positive 
Precancerous 
cells 
frequency 
N=7 
Negative 
Precancerous 
cells  N=93 
P value  
N(%) N(%) 
Symptoms  Vaginal bleeding 3(5.1%) 55(94.8%) 0.324 
Vaginal 
discharge  
5(6.7%) 69(93.2%) 0.587 
Sings  Vaginal bleeding  1(1.9%) 50(98%) 0.05 
Vaginal 
discharge  
3(4.4%) 65(95.5%) 0.145 
Erosion 3(14%) 18(85.7%) 0.159 
 
 
 5.4 Multivariate analysis 
 
All variables that were significant (p<0.05) in univariate analysis were included in a 
multivariate model, adjusted Odds ratio was calculated using forward logistic regression 
model. 
 
5.4.1 Positive Pap smear  
 
 Table 5.29 shows that being married at young age increase risk (adjusted odds ratio) for 
cervical lesions (positive Pap smear test) by 7 folds, while increase No of child birth 
increase it by 0.2 folds, and the younger the age of having first baby increases the risk by 
1.9 fold.(Table 5.29)  
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Table 5-29 Multivariate logistic regression models for the association between 
independent variables and Positive Pap smear test  
 
Variable AOR* 95% CI* P-value 
Age at marriage  7.612 2.512-23.064 0.001 
Parity 0.283 0.113-0.710 0.01 
Age at 1
st
 baby  1.962 1.122-3.429 0.02 
Contraceptives  7.100 2.418-20.847 0.001 
Oral contraceptives  4.313 1.302-14.282 0.02 
History of vaginal 
infection  
30.800 9.222-50.725 0.001 
Husband with 
infection  
9.808 1.242-77.433 0.03 
Smoking  1.908 1.888-4.100 0.04 
Smoking water-pipe  5.667 1.222-26.280 0.03 
Vaginal bleeding 
(symptom) 
17.231 3.687-80.520 0.001 
Vaginal discharge 
(symptom) 
5.156 1.754-15.157 0.003 
Vaginal bleeding 
(sign) 
26.562 3.369-50.457 0.002 
Vaginal discharge 
(sign) 
4.565 1.566-13.301 0.01 
* AOR: Adjusted Odds Ratio, 95%CI: 95% confidence interval. Variables included in 
the model: age at marriage and 1
st
 baby, parity, contraceptive and oral contraceptive , 
history of  vaginal infection  and husband with infection , family history of malignancy, 
smoking cigarettes and water pipe, vaginal bleeding and discharge as a symptom and sign 
and erosions  
 
 
5.4.2 Inflammation in Pap smear  
 
Table 5.30 shows that being married at young age increase risk (adjusted odds ratio) for 
inflammation (positive Pap smear test) by 5 folds and the younger the age of having first 
baby increases the risk by 2.4 fold.(Table 5.30)  
 
Table 5-30 Multivariate logistic regression models for the association between 
independent variables and inflammation  
 
Variable AOR* 95% CI* P-value 
Age at marriage  5.384 1.902-15.238 0.002 
Age at 1
st
 baby  2.434 1.367-4.333 0.003 
Contraceptives  3.331 1.401-7.920 0.01 
Oral contraceptives  6.577 1.452-29.785 0.02 
History of vaginal  
infection  
10.083 3.807-26.707 0.001 
Husband with 
infection  
2.846 1.034-7.831 0.04 
Smoking water-pipe  3.889 1.422-10.636 0.01 
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Vaginal bleeding 
(symptom) 
13.114 4.771-36.049 0.001 
Vaginal discharge 
(symptom) 
3.947 1.547-10.072 0.004 
Vaginal bleeding 
(sign) 
13.340 4.509-39.463 0.001 
Vaginal discharge 
(sign) 
3.400 10.403-8.239 0.01 
* AOR: Adjusted Odds Ratio, 95%CI: 95% confidence interval. Variables included in 
the model: age at marriage and 1
st
 baby, contraceptive and oral contraceptive , history of 
vaginal infection  and husband with infection , smoking cigarettes and water pipe, vaginal 
bleeding and discharge as a symptom and sign  
 
 
5.4.3 Infection in Pap smear  
 
Table 5.31 shows that being married at young age increase risk (adjusted odds ratio) for 
infection (positive Pap smear test) by 4 folds and the younger the age of having first baby 
increases the risk by 1.7 fold.(Table 5.31)  
 
Table 5-31 Multivariate logistic regression models for the association between 
independent variables and infection  
 
Variable AOR* 95% CI* P-value 
Age at marriage  4.449 1.628-12.162 0.004 
Parity  0.295 0.130-.0673 0.004 
Age at 1
st
 baby  1.717 1.027-2.870 0.04 
Contraceptives  3.334 1.336-8.325 0.01 
History of vaginal  
infection  
13.071 4.389-38.930 0.001 
Husband with 
infection  
4.083 1.117-4.929 0.03 
Smoking water-pipe  5.372 1.476-19.554 0.01 
Vaginal bleeding 
(symptom) 
8.757 2.915-20.306 0.001 
Vaginal discharge 
(symptom) 
5.727 2.106-15.578 0.001 
Vaginal bleeding 
(sign) 
8.103 2.517-26.084 0.001 
Vaginal discharge 
(sign) 
4.511 1.712-11.883 0.002 
* AOR: Adjusted Odds Ratio, 95%CI: 95% confidence interval. Variables included in 
the model: age at marriage and 1
st
 baby, parity,  contraceptive , history of vaginal infection  
and husband with infection ,  smoking cigarettes and water pipe, Vaginal bleeding and 
discharge as a symptom and sign  
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5.4.4  Candida in Pap smear  
 
Table 5.32 shows that  using oral contraceptive increase risk  (adjusted odds ratio) by 5.8 
folds  for Candida  (positive Pap smear test) while having vaginal infection  increase the 
risk by 4 folds. (Table 5.32)  
 
Table 5-32 Multivariate logistic regression models for the association between 
independent variables and Candida  
 
Variable AOR* 95% CI* P-value 
 Oral Contraceptives  5.807 2.012-16.757 0.001 
History of vaginal  
infection  
4.147 1.579-10.897 0.004 
* AOR: Adjusted Odds Ratio, 95%CI: 95% confidence interval. Variables included in 
the model: age at marriage and 1
st
 baby, oral contraceptive , history of vaginal  infection  
 
  
 
5.4.5 Precancerous cell   
 
 Table 5.33 shows that smoking cigarettes increase risk (adjusted odds ratio) for 
Precancerous cell  (positive Pap smear test) by 0.12 folds. (Table 5.33) 
 
Table 5-33 Multivariate logistic regression models for the association between 
independent variables and Precancerous cell   
 
Variable AOR* 95% CI* P-value 
Smoking cigarettes   0125 0.032-0.483 0.003 
Vaginal bleeding 
(sign) 
0.143 0.017-1.238 0.07 
* AOR: Adjusted Odds Ratio, 95%CI: 95% confidence interval. Variables included in 
the model: smoking cigarettes and vaginal bleeding (sign)   
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Chapter 6: Discussion 
 
 
6.1 Introduction  
 
Multiple associations were revealed by the study between multiple risk factors and  
cervical lesions among the Palestinian female  population. The study  aim was to assess  
the role of Pap smear screening in  detection of  various  cervical lesions among  
Palestinian women and to study the risk factors for them  . This chapter will be discussing 
the major finding of the study and compare it to the present literature. 
 
6.2  Socio-demographic study factors: 
  
6.2.1  Age factor 
 
The risk of developing precancerous and cancerous cervical lesions is shown in this study  
to  have no change or association with age of the participants.. This result is almost similar 
to previously published case control study in 2015 by Gessesse and colleagues that showed 
no significant association between precancerous and cancerous cervical lesions and the age 
of the women.( Gessesse et al.,2015) 
 Other opposing studies results, like a case control study by Team and colleagues (2018)  
showed that women aged 40-49 years old have had  an  increase risk (AOR=2.4,CI:1.27-
4.54)  of developing precancerous and cancerous lesions by 2.4 folds than those in other 
age groups, as well as,  in another case control study done by Bezabih and colleagues in 
2015  found that the peak incidence for precancerous cervical  lesions was between the age 
of 40-59 years old (Bezabih et al., 2015) 
 Makuza and colleagues in a cross sectional study found that older age is a protective factor 
from cervical lesions (AOR=0.52; 95%CI=.028-0.97) (Makuza et al., 2015). 
However, Embolo in his cross sectional study in 2016, documented that 20.52% of 
Cameroonian women develop precancerous cervical lesion at early age of life (20-30years 
old) (Emblo al., 2016).   
  
6.2.2 Socioeconomic factors 
 
In this study 68% of participants were housewives, 84% have intermediate level of income, 
40% of them have had only high school education. 
  Despite that socio-economic factors such as education level and income level and social 
class have a significant effect on an individual‘s general health, in this study no significant 
association was found between education level, income level, occupation and positive Pap  
smear results for cervical lesions .These  results contradicts other studies which showed a 
relationship between the various socioeconomic indicators and precancerous and cancerous 
76 
cervical lesions, and found a significant inverse association between the indicators of 
socioeconomic status and cervical lesions ( Latha et al.,2017, Mhaske  et al., 2011, Makuza 
et al., 2015, Vincerzevskiene et al.,2017). Aswathy et al.,2012, Chankapa et al., 2011)  
 
These results may be explained by the small number of sample or due to small differences 
in educational level and income among the study participants. Moreover, Latha and 
colleagues ,2017 concluded that low socioeconomic status force  women to have multiple 
sex partners which make them more susceptible to STDs and starting sexual intercourse at 
early age, these kind of behavior is restricted in Palestinian society by our religion and 
culture.  
 Moreover, in this study 86% of the participants were married, but there was no significant 
association between marital status and risk of cervical lesion. These results contradicted 
other results, which documented that marital status plays a significant role in increasing the 
risk for acquiring HPV and by that increasing the risk of developing precancerous cervical 
lesions. For example, Vaccrella  and Kalawole  in their studies had showed that married 
females have higher risk of acquiring  cervical lesions ( Vaccrella et al.,2010, Kalawole et 
al.,2015),  but other opposing studies showed that being widow or divorced significantly 
increase the risk of developing precancerous and cancerous lesions compared to married 
women, attributing the results to having multiple sex partners (Getinet  et al.,2015). 
 
6.3 Reproductive health factors and cervical lesions:    
 
6.3.1 Age at marriage factor 
  
In this study, 79% of the participants were married between the ages 15-24 years old. 
The results in this study showed significant inverse association between the age of 
marriage and having cervical lesions ( AOR =7.612; 95%CI= 2.512-23.064; p<0.001). 
Women have 7.6-fold increase risk of developing cervical lesion if they have got married 
at age ≤24 years old . This is attributed to the fact that the earlier the sexual intercourse , 
the earlier the immature cervix is exposed trauma that make it more vulnerable to acquire 
persistent HPV, which is the main cause of almost all of the cervical lesions. 
 
Louie  and colleagues in 2009, in their case control study concluded that cervical lesion 
risk has increased by 2.4 folds among females that had married at early age ≤16 years old 
(AOR=1.8; 95%CI: 1.50-2.39) compared to those married at age  ≥21 years old, and that  
the risk  increased more when pregnancy occurred immediately after being married at early 
age (Louie et al.,2009). 
 
 Same results were concluded by Deksissa and colleagues in 2013, their study had 
documented a 2.2 fold risk  increase ( AOR 2.2; 95%CI; 1.1-4.3) for precancerous cervical 
lesion in those women married at age <16 years old (Deksissa et al.,2013). Another study 
made in 2017 by Kassar showed that women married at age <15 years old have 5.6 times 
more risk to develop precancerous and cancerous lesions (Kassar,2017). 
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An opposing conclusion was documented by Latha and Ranganath  in 2017 and Chankapa 
and collogues in 2011, and showed that there was no significant association between 
marriage at early age and risk for precancerous and cancerous cervical lesion ( Latha  and 
Ranganath ,2017: Chnkapa et al., 2011). 
 
 This study  showed a significant association between early age of marriage and acquiring 
cervical inflammatory lesions( AOR=5.3; 95%CI: 1.902-15.238; p<0.001) infection 
(AOR=4.449; 95%CI:1.628-12.162; p=0.004), so that those married at age ≤24 years old 
have 5.3 folds risk increase for having inflammatory cervical lesion,  4.4 folds risk increase 
for infection than those married at age >24 years old. 
 
6.3.2 Age at first childbirth factor 
 
If marriage occurs at early age this means engaging in early sexual intercourse, by that 
increasing  the probability of getting pregnant at early age( early childbirth)  and  increase 
risk of cervical trauma which may lead to cervical carcinogenesis.  
 
In this study, 61% of the participants had their first child between the ages 16-20 years old  
The results in this study showed significant inverse association between the age of having 
the first baby and cervical lesions ( AOR =1.962; 95%CI= 1.122-3.429; p=0.018). Women 
have 1.9 folds increase risk of developing cervical lesion if they have had their first child at 
an age ≤20 years old, because the early the age of having children the early the immature 
cervix is exposed to trauma, that makes it  more vulnerable to acquiring HPV infection that 
is considered the main reason for cervical lesions. 
 
 Other studies showed that the risk of cervical lesions tended to inversely increase with the 
age at first baby, for example in 2009 a large pooled case control study reported that 
females  who have their first child  at age ≤16 years old have an increase risk ( AOR =2.31; 
95%CI:1.85-2.87) of 2.3-folds to have precancerous and cancerous lesions more than those 
having their first baby at age ≥21 years old ( Louie et al.,2009). Mhaske and Jawadekar in 
2011 documented  a significant association between risk of precancerous and cancerous 
cervical lesion and having first baby at age <20 years old.( Mhaske and Jawadekar , 2011) 
 
In an opposing conclusion made by Bezabih and collogues in 2016, reported that having 
first baby at age >25 years is a significant risk factor for cervical lesions especially 
invasive cervical carcinoma, and suggested that intervals between deliveries play an 
important role for the  disposition to cervical carcinoma ( Bezabih et al.,2016). Also 
Chankapa and collogues in their study reported no significant association between early 
age at first baby and risk for precancerous and cancerous lesions, but found higher 
incidence with high parity, increasing age and prolonged sexual intercourse ( Chankapa et 
al.,2011).  
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This study showed a significant association between early age of having first baby and 
acquiring cervical inflammatory lesions(AOR=2.434; 95%CI:1.367-4.333; p=0.003) and  
infection (AOR=1.717; 95%CI:1.027-2.870; p=0.039), so that those having their first child 
at age ≤20 years old have 2.4 folds risk increase  for  having inflammatory cervical lesion 
and 1.7  folds risk increase  for infection  than those married at age >20 years old  
 
6.3.3 Parity ( Number of childbirth) factor  
 
Parity , throughout women fertile years of life, is considered a good probable marker of 
normal female hormone, which is estrogen, , as well as, a good marker among multiparas 
for repeated trauma to the female genitalia especially the cervix. More deliveries causes 
more trauma to the cervix, and by that make the cervix more susceptible to acquire HPV 
persistent infection - the most common cause of cervical lesions. In this present study, 45% 
of the participants have had 5-10 childbirth. 
 
High parity have been reported in many studies as a risk factor for cervical lesions, in this 
study as well parity was found to have a significant direct association with cervical lesions 
( AOR= 0.283; 95%CI; 0.113-0.710; P=0.007), compared to two  cross sectional studies 
that were made in 2017, 2015 and showed significant association between high parity as a 
co-factor and risk of precancerous and cancerous cervical lesion ( Andrew et 
al.,2017;Kalawole et al., 2015).  
 
Bezadih  and colleagues reported in 2015 a strong independent association between women 
with >4 children and precancerous and cancerous cervical lesions (AOR=10.3;95%CI; 3.6-
29.0), so they have 10 times higher risk to develop cervical lesions ( Bezadih  et al.,2015). 
Also, Getinet and colleagues concluded that women with high parity >3 were 10.9 folds 
more likely to acquire precancerous and cancerous cervical lesions than female  with <3 
children (AOR =11 ;95%CI;4-17 ; P<0.001) and that high parity is a significant predictor 
of precancerous and cancerous cervical lesion prevalence ( Getinet et al.,2015). 
 
  In this study , the results showed a significant association between high parity and  
cervical infectious lesions(AOR=0.295; 95%CI:0.130-0.673; p=0.004) so that those having 
>5 children have  0.29 folds increase in risk of having cervical infection compared to those 
with <5 children . In the contrary, this study showed no association between high parity 
and precancerous and cancerous lesions. However, these results may be explained by the 
small number of sample. 
 
 
   
6.3.4 Contraceptive factors  
 
In this cross sectional study, 70% of the participants have had used contraceptives, 90% of 
them used oral contraceptive pills. 
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Additionally, it was found in the study that there was a significant association between 
contraceptive consuming in general and risk for cervical lesions (AOR= 7.100; 95%CI; 
2.418-20.847; P<0.001), and oral contraceptive consuming in particular (AOR= 
4.313;95%CI;1.302-14.282; P=0.017).  
 
Many studies documented that women who used oral contraceptive drugs for more than 5 
years have  greater risk of having cervical lesions than those who have never consumed 
oral contraceptive pills  , and that the longer the use of OCPs  the higher the risk.( National 
Cancer Institute, 2018) 
 
Roura and colleagues showed a strong positive association between taking oral 
contraceptive drugs and risk of having cervical lesions ( HR= 1.6 for ≥ 15 years use and 
HR=1.8 for ≥15 year never use). However, they documented that increasing the number of 
oral contraceptives consumed and duration of using, increase cervical lesions risk , and 
decrease the risk with stopping the oral pills and increase years of since last pill was 
consumed. They also documented that oral contraceptives act as a cofactor that interact 
with HPV infection to cause the cervical lesions, and that they do not work independently 
as a risk factor ( Roura et al.,2016). 
 
In another case control study, association between using oral contraceptive and increasing  
risk of precancerous and cancerous lesions, and the association between increasing 
duration of using oral contraceptives and increasing  risk of precancerous and cancerous 
lesions was shown by Appleby and colleagues. ( RR =1.9;95%CI; 1.7 -2  for  >5 years use 
versus never use), they also showed the decline in risk after stopping the use of oral 
contraceptive pills and by ≥10 years passed with no use of the pills (Appleby et al.,2007). 
 
Another case control study done in 2017 by Kassa , showed an increase in risk for 
precancerous and cancerous cervical lesions by 2 folds(COR 2 ;95%CI;1-4.2; 
AOR=2.3;P<0.03) for those using oral contraceptives compared with those who do not use 
it ( Kassa  ,2017).  
 
An opposing conclusion that oral contraceptive pills are not an independent risk factor for 
precancerous and cancerous cervical lesion  was made by Syrjanen  and colleagues. They 
found in  the multivariate regression model study  that all types of contraceptives mode 
have no significant predictive value for precancerous nor cancerous cervical lesions, and 
concluded that the different  sexual behavior between those consuming oral contraceptives 
and those who not consuming is the main risk factor for precancerous and cancerous 
cervical lesions ( Syrjanen et al.,2006) 
 
 
In this study , the results showed a significant association between using contraceptives  
and acquiring cervical inflammatory lesions(AOR=3.331; 95%CI:1.401-7.920; p=0.006) 
and infection (AOR=3.334; 95%CI:1.336-8.325; p=0.01) so that those using contraceptives 
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have 3.3 folds increase in risk of having inflammatory cervical lesion, 3.3 folds increase in 
risk of infection  than those not using contraceptives. 
Also it showed that there is a significant association between using oral contraceptives  and 
acquiring cervical inflammatory lesions(AOR=6.577; 95%CI:1.452-29.785; p=0.015) 
Candida  (AOR=5.807; 95%CI:2.012-16.757; p=0.001) so that those using contraceptives 
have 6.5 folds increase in risk of having inflammatory cervical lesion, 5.8  folds increase in 
risk of Candida than those not using contraceptives 
 
 
6.4 Medical history    
 
Studies from all over the globe showed that persistent HPV infection causes 99.7% of 
precancerous and cancerous cervical lesions (Dilman,2009) 
 
In this study, 67% of the participants have had acquired infection in their life, 67% of them 
claimed that they have treated their infection , 98.5% of them have claimed that they still 
have infection  symptoms.  
The multivariate analysis in this study showed a significant association between having 
infection and having cervical lesions,(AOR=30.800;95%CI; 9.222-50.725;P<0.001), so 
that those having infection have 30 fold increase risk of having cervical lesions than those 
not having infection. 
 
Various previous studies pointed out the significant association between history of 
infection  and the increase risk of cervical  lesions. For example, a strong association 
between having infection and risk for cervical lesion was concluded by Kassa,( 
COR=2.187;95%CI; 1.078-4.440;AOR=2.485). (Kassa,2018) 
 
This finding was consistent with the results form a cross sectional study in 2016, that 
showed that infection  had been the only significant associated factor with the outcome 
variable, the study concluded that those with STDs have 50 fold  more risk to have cervical 
lesions  compared to those with no infection ( AOR=49.88; 95%CI;16.59-149.91) ( 
Misgina  et al.,2017). 
 
Another study in Southern  Ethiopia made by Gedefaw and colleagues, concluded that 
women with infection have 2.3 fold more likely to have precancerous and cancerous 
cervical lesions than those with no infection .(AOR=2.3; 95% CI; 1.23-4.29) (Gedefaw et 
al.,2013). 
 
Another positive significant association was found by Nesrin and colleagues in 
2011,(AOR=5.17; 95%CI; 3.51-7.6) and Team and colleagues  in 2018,( AOR= 3 
;95%CI;1.3-8 )  between women having infection  and increase risk of cervical lesion. 
 
Unfortunately, this study did not test the samples for the presence of HPV infection, which 
is considered the most common STIs globally and the most common cause of cervical 
lesion, Moreover, most of the risk factors for cervical lesions works as a cofactor for 
persistent HPV infection in causing cervical lesion ( Matos et al., 2005; Kahn et al., 2002;  
Louie et al.,2009).  
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Sitakana and colleagues in their study and after adjusting with multiple logistic regression, 
showed the persistent risk increase with HPV infection for precancerous and cancerous 
cervical lesions with AOR =38.07(P<0.001) (Sitakana et al.,2012). 
 
In another case control study in 2013, showed that HPV infection is significantly 
associated with   increased risk for precancerous and cancerous cervical lesions with 
AOR=42.4(95%CI;22.4-81.4;P<0.001) ( Natphopsuk et al., 2013).  
 
 Another  case control study with the  same results was conducted by Nomonde and 
collogues in 2016, and showed a strong association between Persistent HPV infection and 
precancerous and cancerous lesions especially stage II cervical cancer ( Nomonde et 
al.,2016). 
 
In this study , the results showed a significant association between STDs and acquiring 
cervical inflammatory lesions(AOR=10.083; 95%CI:3.807-26.707; p<0.001) infection 
(AOR=13.071 ; 95%CI:4.389-38.930; P<0.001) Candida (AOR=10.1; 95%CI:3.807-
26.707; P=0.004) so that those having infection  have 10 folds increase in risk of having 
inflammatory cervical lesion, 13  folds increase in risk  of infection and 10 folds increase 
in risk of Candida than those not suffering from infection . 
 Moreover, there was no association between having infection and acquiring Precancerous 
cervical lesion; including Atypical squamous cells, Atypical glandular cells, CIN I,II and  
III.  
 
 
6.5 Family history and genetic factors  
 
Precancerous and cancerous cervical lesions may run in families, due to inherited 
conditions that do not allow females to fight STIs especially persistent HPV infection. 
Alternatively, women may share non-genetic risk factors like STIs with their partner ( 
American Cancer Society,2017). 
 
In this study and after adjusting with multiple logistic regressions, there was no significant 
association between having family history with any type of cancer and risk of precancerous 
and cancerous cervical lesions. Our results may be explained by the small number of 
sample. 
 
In contrast to multiple published studies that supported the genetic familial aggregation of 
precancerous and cancerous cervical cancer, as Paltrik K and collogues concluded in 2000 
that there has been a 2-fold increase in risk for cervical lesions in those with positive 
family history of cervical lesions (Paltrik  et al.,2000). 
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Hemminik  and colleagues concluded that there is a strong association among full-blooded 
relatives (RR= 1.84)  with cervical lesion than those with half blooded ( RR=1.4 for 
maternal, 1.27 for paternal half siblings) ( Hemminiki  et al., 2006). 
  
Pattrik  and colleagues concluded in their study that precancerous and cancerous cervical 
lesions depend on inherited genetic factors that may influence the sensitivity of the cervix 
for HPV infection ( Patrik  et al., 2000). 
 
However, the sexual behavior of the husbands may have a great effect on their wives, 
making them more susceptible to cervical lesions. Therefore,  increasing  number of  
husband‘s sexual partners, for example,   in polygamy,  may increase their susceptibility to 
acquire STIs that will be  transmitted to the wives.  
 
In this study , the results showed a significant association between husband suffering from 
infection  and increase risk of cervical lesions ( AOR= 9.808m 95% CI; 1.242-77.433; 
P=0.03) , so females has 9.8 folds increase in risk of cervical lesions with husband having 
infection compared to those husbands with no infection.  
 
Bezabih and colleagues showed in their study that husbands with multiple wives or with 
multiple sexual partners has a significant association with increase risk of their wives 
having cervical lesions ( Bezabih et al.,2015). In addition, the same significant association 
was reported by  Owki and colleagues in 2017 (Owki et al., 2017). 
 
 In this study, the results showed a significant association between husband having STDs  
and acquiring cervical inflammatory lesions( AOR=2.846; 95%CI: 1.034-7.831; p=0.04) 
infection (AOR=4.083; 95%CI:1.117-14.929; p=0.03), so that those married to a husband 
with infection  have 2.8 folds increase in risk of having inflammatory cervical lesion and  4 
folds increase in risk  of infection than those married to husband with no infection. 
 
6.6  Smoking Life style factor.  
 
Multiple evidence based studies showed that exposure to tobacco products may have an 
influence in  turning HPV infection from precancerous state to malignancy, but the direct 
causal association apart from being co-factor for HPV infection has not been clear yet 
(Appleby et al.,2006). Also, biological evidence showed that cigarette components is a 
well known carcinogenic chemicals that causes changes in cellular bases   and may cause  
the growth of  different kind of tumors (IACR,2004) 
 
 Cigarette and water pipe smoking were investigated in this study, which results reported 
cigarette smoking and  water-pipe smoking as a significant risk factors for developing 
cervical lesions among Palestinian women. Women who smoke cigarettes have 1.9 folds 
higher risk( AOR=1.908;95% CI; 10888-4.100; P=0.04) to develop cervical lesion 
compared to those who never smoked tobacco and those who smoke water-pipe have 5.6 
folds higher risk( AOR =5.667;95%CI;1.222-26.280;P=0.03) to suffer from cervical  
lesions than those who don‘t smoke water-pipe. Water pipe smoking is prevalent nowadays 
in Palestine. This habit was and is still very popular among women in Ramallah 
Governorate. However, additional future studies are necessary to clear up this relationship.  
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In this study, the results showed a significant association between water-pipe smoking   
and acquiring cervical inflammatory lesions( AOR=3.889; 95%CI: 1.422-10.636; p=0.01) 
and infection (AOR=5.372; 95%CI:1.476-19.554; p=0.01), so that those smoking water-
pipe  have 3.8 folds increase in risk of having inflammatory cervical lesion and  5.3 folds 
increase in risk  of infection than those not smoking water-pipe. Moreover, this study 
showed a significant association between smoking cigarettes and developing precancerous 
lesions(AOR=0.125;95%;CI;0.032-1.238;P= 0.003). 
 
 
Multiple previous studies in many countries have had reported a significant association 
between tobacco smoking behavior and risk of having cervical lesions . For example, in a 
large prospective cohort study made by Esther and colleagues, a strong positive association 
between tobacco smoking and risk for precancerous and cancerous cervical lesions was 
reported,  taking into account HPV infection exposure  and they also found that the 
strongest association was with smoking duration and inversely associated with quitting ( 
Esther et al.,2014). 
 
On the other hand , Aline and colleagues documented in their study  a significant 
association between heavy smoking,  HPV infested and risk of precancerous and cancerous 
cervical lesion (OR= 3.2;95%CI;1.7-4.3) , high risk was found even after adjusting for 
HPV infection.( OR=3.2;95%CI;2.6-4) (Aline et al.,2009).   
  
However, passive smoking is a public health problem worldwide and nonsmoker women 
who are exposed to secondhand smoke are inhaling many of the same carcinogens 
substances and poisons as smokers, and that increase their risk of developing cervical 
lesions. Moreover, exposure to second hand  smoking occurs in everyday life, at home, 
work, in public transport, restaurants, especially in absence of any regulations that forbid 
smoking in public place, but this study showed no association between second hand 
smoking and precancerous and cancerous cervical lesion  risk was found. 
 
Our results showed no association between smoking waterpipe and precancerous cervical 
lesions despite the fact that water-pipe smoking is  more popular than cigarette smoking  
among female population in Palestine, especially in Ramallah district, and this may be 
explained by the small number of sample. 
 
 
6.7 Pap smear test 
 
Pap smear test in this study, was able to detect 82 abnormal cervical lesion out of the 100 
participant sample, despite the fact that most of the abnormal findings were not pre-cancer 
or  cancer cells, Pap smear test was able to detect inflammatory changes (80.4% of the 
positive Pap smears samples had inflammatory changes ) and infection ( 92.7% of the 
positive pap smears samples had infection)  that if not treated may progress  to 
precancerous cell and eventually to malignancy. 
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Infections was the most common histological finding in the study results , and as we have 
previously discussed that  globally 99.7% of cervical cancer lesions cases have been 
caused by the most common persistent HPV infection in the human reproductive tract. 
Fortunately, the majority of the STIs caused by HPV infection resolve spontaneously, but 
some specific kinds of persistent HVP infection may lead to precancerous and cancerous 
cervical lesions in approximately ten years, so detecting infection as early as possible gives 
the chance for treating STIs and forbid them to progress to precancerous and malignant 
lesions in the future  
 
Pap smear cytology cervical screening method has been able to detect incidence of cervical 
lesions for many years despite the argument that has been surrounding the ability of 
medical and public community to use Pap smear test for screening (Gedefaw et al.,2013). 
 
 Various studies have had pointed out the important role of Pap smear in detecting 
precancerous and cancerous cervical lesions. Sachan and colleagues concluded -in their 
study to evaluate Pap smear screening ability to detect cervical lesions- that Pap smear 
cervical screening test is a simple, useful, cheap and safe tool for detecting precancerous 
and cancerous cervical lesions, 48.84% of the sample had no malignancies and 42.66% had 
infection and inflammation, 2.9% had ASCUS, 5.09% had LSIL and 0.48% had HSIL  
(Sachan et al.,2018). 
 
Patel and collogues in their 2011 study found that 94.5% of the screened population with 
Pap smear had infection and inflammation and 5.5% had premalignant and malignant 
cervical lesions ( Patel et al.,2011). 
  
On another study made in 2012, the researchers concluded that Pap screening test has a 
definite role in detecting precancerous and cancerous cervical lesion , after they used 
Bethesda system to differentiate   cervical lesions obtained by Pap smear test, and found 
that 88% of the samples were infection and inflammation with no premalignant nor 
malignant changes and 3.53% had cervical dysplasia ( Sarma et al., 2012). 
 
Additionally, it was found in  Verma and collogues study that Pap smear screening test is 
highly specific and sensitive procedure to detect precancerous and cancerous lesions of the 
cervix, they reported 32.5% with inflammatory changes, 1% ASCUS, 5.5% LSIL, and 
2.5% HSIL (Verma et al.,2017). 
 
Unfortunately, this study found 7% inadequate sample results that may be due to lack of 
experience in obtaining Pap smear tissue sample, by the physicians who performed the 
procedure, and instead of taking the tissue from the appropriate site in the SC junction - the   
endocervical tissues as instructed by the researcher,  they obtained it from the ectocervical 
tissues or they may have  taken  few inadequate cell for  testing.   
 
Finally, this study showed a significant association between some medical complains of 
the participants and physical findings by the medical doctors (vaginal bleeding and 
discharge)  and the presence of positive Pap smear findings ; infection, inflammation and 
precancerous cells and this is attributed to the fact that these symptoms and signs almost 
always occur with infection .   
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6.8 Conclusion: 
 
This study might be considered the first one in Palestine that aimed to evaluate the 
effectiveness of Pap smear screening tool, in detecting precancerous and cancerous 
cervical lesions and to explore the possible risk factors for cervical lesions. Most results of 
this study were expected and comparable to other international studies results, while some 
others were unexpectedly contradicted with the literature. From this study, we can 
conclude that Pap smear screening tool is highly sensitive and useful method to detect 
precancerous (including inflammation and infection) cervical lesions before they progress 
to malignancies, as well as, detecting malignant changes. On the other hand, the study 
results showed that age at  marriage , age at first pregnancy, high parity, oral 
contraceptives, having  vaginal infection or married to a husband having infection,  
smoking tobacco and  water-pipe are all major risk factors for developing cervical lesions . 
However, additional studies are necessary to confirm these results. 
 
 
  
6.9  Recommendations 
 
6.9.1 Recommendations for policy makers and health care team: 
 
 Activating the national screening program for the early detection of cervical 
lesions, by Pap smear. 
 Evaluate cost-effectiveness of expanding the Cervical lesion screening programs 
 Carrying out more awareness campaigns to  remind people of the harm caused by 
tobacco and water-pipe smoking for human health. As well as,  adapting the anti-
tobacco law legislation so as to control smoking specially in public places  
 Train more health worker on Pap test procedures so as to avoid the inadequate 
sampling 
 More awareness campaigns should be carried out to increase community awareness 
especially females about the harmful effect of  untreated persistent vaginal 
infection, harmful effect of early marriage and early childbirth, as well as high 
parity on the cervix 
 Improve the quality of  already exciting vaginal infection management procedures  
  Evaluate safety versus risk in using oral contraceptives  
 Develop ongoing evaluation program to all screening programs especially Pap 
smear screening programs  
 Train more medical staff on Bethesda procedures and how to read the Pap smear 
slides  
 Produce uniform protocols and guidelines for cervical lesion screening, and 
designate the exact age, when to start the screening.  
 
6.9.2. Recommendations for the Palestinian female : 
 . 
  Living a healthy life: by stop smoking, and never start smoking . Water pipe is 
a bad smoking habit. 
 Do regular Gynecology checkups 
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  Do Pap smear screening test according to the national guidelines  
  Visit your physician whenever you complain of vaginal bleeding or discharge  
 Follow the family planning program 
  
 
6.9.3. Recommendations for the future research: 
 
 Conducting more detailed researches with larger sample size and including 
more health care facilities over a more extended period of time. 
 Considering the most common type of cervical lesion (histopathology) and 
relating it to the risk factors. 
 Focusing on female with no STIs to exclude confounding by HPV infection  
and to explore other risk factors in more details. 
 Perform more comprehensive longitudinal studies,  to study the cause-effect 
relationship between precancerous and cancerous cervical lesion and its 
predictors. This could be useful for decision makers to plan properly for 
cervical lesion managements.  
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 لا  □َؼى       □ ) ْم صٔعك يزضٔط حبنٛب اكضش يٍ صٔعخ :  4
 ---------انطٕل (عى ) :  -                   --------انٕصٌ (كغى ) :  -) 5
سثخ □أػًبل حشح              □ػبيهخ ثبلأعشح            □يٕظفخ يٛذاَٛخ        □يٕظفخ يكزجٛخ      □   انًُٓخ : )  6
 يُضل
 لا أدس٘    □لا ٕٚعذ         □         ػبنٙ□         ٕعػ يز   □           يزذَٙ   □ -يغزٕٖ انذخم  : )   7
 دساعبد ػهٛب□   ثكبنٕسٕٚط            □       صبَٕ٘   □      اثزذائٙ ٔ ألم    □ يغزٕٖ انزحصٛم انؼهًٙ : )   8
 ...................غٛشِ( حذد٘ )  :..□خ    يعبسة ثبدٚ□   يخٛى    □ لشٚخ    □   يذُٚخ  □ يكبٌ انغكٍ : ) 9
 -------------------------------------------------------------------------------------------------------------
 انغضء انضبَٙ : انًؼهٕيبد الاَغبثٛخ
 
 عُخ   41-21     □عُخ     11-9    □عُٕاد  أٔ ألم      8   □انؼًش ػُذ أٔل دٔسح شٓشٚخ : ) 11
 لا أدس٘     □عُخ أٔ أكضش         51   □  
   عُخ 44-53□     عُخ 43-52□      عُخ 42-51-□     عُخ 51 يٍ ألم -□  : انضٔاط ػُذ انؼًش)   11
 أدس٘ لا□        أكضش ٔ عُخ 54□   
      لا أدس٘      □    لا  -   □  َؼى       -   □:  يغزًشحْم انذٔسح انشٓشٚخ ) 21
 لا أدس٘   □غٛش يُزظًخ        □يُزظًخ     □عبثخ َؼى :  )ارا كبَذ الإ31
 410
                   عُخ     44 – 14-   □  عُخ   14ٍ ألم ي -    □) ارا كبَذ الإعبثخ لا ؛   انؼًش ػُذ رٕلف انذٔسح ؛ 41
 لا أدس٘  □      أٔ اكضشعُخ   55  -□    عُخ     45 – 15 -   □          عُخ     94 – 54-□               
 أدس٘ لا□                لا -□            َؼى -□       ؟ انشٓشٚخ انذٔسح لاَمطبع ْشيَٕٛخ ػلاعبد رهمٛذ   ْم  ) 51
 أكضش يٍ ػششح -   □ يشاد         11-5 -   □يشاد          4- 1-    □ لا ٕٚعذ   -    □ػذد انٕلاداد : ) 61
 عُخ13-62  □  عُخ     52 –  12□  عُخ   12 – 61□        أٔ ألمعُخ   51   □ نٗ :دح الأانؼًش ػُذ انٕلا) 71
 لا أدس٘   □ عُخ     54أكضش يٍ  - □ عُخ       54-14□ عُخ     14-63 □           عُخ 53-13 □ 
 لا أدس٘  □     لا    -  □ ى       َؼ -  □؟  رُظٛى الأعشح  ٔعبئمغزخذيزٙ رْم )  81
 غشق أخشٖ □انٕالٙ انزكش٘   □نٕنت ثلاعزٛكٙ        □نٕنت يؼذَٙ       □حجٕة يُغ انحًم      □ا الإعبثخ َؼى ؛ ) ار91
 لا أدس٘ □    5أكضش يٍ  -  □ يشاد    5 -4يٍ   □يشاد    3-1  □ لا ٕٚعذ   -   □ ػذد يشاد الاعٓبض (اٌ ٔعذ) ؟) 12
 لا أدس٘  □لا                 □      َؼى      □) حم حصم نذٚك حًم خبسط انشحى ؟12
 لا أدس٘   □لا            □َؼى            □) ْم لًذ ثؼًم فحص يغحخ ػُك انشحى يٍ لجم ؟22
 لا أدس٘  □يشاد    3أكضش يٍ    □يشاد    3  □يشربٌ     □يشح       □) ارا كبَذ الإعبثخ َؼى ؛ كى يشح لًزٙ ثؼًهّ ؟ 32
   ---------------------------------------------------------------------------------------------------------------
 ٙزبسٚخ انًشظانغضء انضبنش: ان
 أدس٘ لا□            لا□          َؼى□   يٓجهٛخ؟ افشاصاد يٍ رؼبٍَٛ ْم) 42
 -----------------نَّٕ حذد٘ ؛ َؼى الإعبثخ كبَذ ارا) 52
 أدس٘ لا□            لا□         َؼى□ ؟ يٓجهٙ َضٚف يٍ رؼبٍَٛ ْم) 62
 -------------- حذد٘ ، رنك غٛش□       انغًبع ثؼذ□      انذٔساد ثٍٛ□ يزٗ؛ حذد٘ َؼى الإعبثخ كبَذ ارا) 72
 عًبع ٕٚعذ لا□      أدس٘ لا□            لا□          َؼى□  ؟ انغًبع ثؼذ أٜو يٍ رؼبٍَٛ ْم) 82
 َبدسا□        أحٛبَب□         دائًب□    : يزٗ حذد٘ َؼى الإعبثخ كبَذ إرا) 92
 أدس٘ لا□          لا□                 َؼى□   ؟ انجٕل ساسإد فٙ كضشح أٔ أٜو أٔ صؼٕثخ يٍ رؼبٍَٛ ْم) 13
 __________حذد٘   َؼى  الإعبثخ كبَذ إرا) 13
 أدس٘ لا□            لا□            َؼى□   ؟ انحٕض أٔ انجطٍ اعفم فٙ اٜو يٍ رؼبٍَٛ ْم) 23
 -------------- ٔيزٗ؟----------------------- اٍٚ؟ حذد٘ َؼى   الإعبثخ كبَذ إرا) 33
 أدس٘ لا□               لا -□                   َؼى -□  ؟ ٔساصٛخ ايشاض يٍ رؼبَٙ ْم)  43
 .......................................................: ......حذد٘ َؼى انغٕاة كبٌ ارا) 53
 أدس٘ لا□           لا -□              َؼى -□           ؟ يضيُخ أيشاض يٍ رؼبَٙ ْم) 63
 510
 ...............؟ اكزشبفّ رى ػبو ا٘: ................................................  انًشض  حذد٘ َؼى انغٕاة كبٌ ارا -) 73
  أدس٘ لا□                لا□             َؼى□   ؟ ثبلإنزٓبثبد انًٓجهٛخ ثبلإصبثخ  لجم يٍ رى رشخٛصك  ْم) 83
  أدس٘ لا□          لا□       َؼى□   ؟  ثؼبنغّ لًذ ْم ، َؼى الإعبثخ كبَذ ارا) 93
  أدس٘ لا□            لا□        َؼى□      ؟ أػشاظّ يٍ رؼبٍَٛ صنذ يب ْب) 14
 ؟)انًُخفط انجشٔعٛغزٛشٌٔ أ انؼبنٙ الاعزشٔعٍٛ ْشيٌٕ( انٓشيَٕٙ انزٕاصٌ ػذو يٍ رؼبٍَٛ أٔ ػبَٛذ ْم) 14
  أدس٘ لا□            لا□            َؼى□   
  أدس٘ لا  □              لا□          َؼى□    انٓشيَٕبد؟ فٙ انخهم ْزا يؼبنغخ رًذ ْم ؛ َؼى الإعبثخ كبَذ ارا) 24
  أدس٘ لا□           لا□             َؼى□  عشاحٛخ؟ ػًهٛبد أ٘ ثإعشاء لًذ ْم) 34
 ------------------ انؼًهٛخ َٕع حذد٘ ، َؼى الإعبثخ كبَذ ارا) 44
 لا أدس٘   □                 لا-□                       َؼى -□    ؟ انشحى ػُك ثغشغبٌ ٔأصجذ عجك ْم) 54
 : ........................................................... ٘ انؼبوحذد؛    َؼى ذ الإعبثخ كبَ ارا )64
   عُخ 53 – 62 □  عُخ 52 – 61 - □عُخ أٔ ألم  51□  ؟ انًشض رشخٛص ػُذ انؼًش ْٕ يب -) 74
 لا أدس٘    □عُخ    54أكضش يٍ  -□            عُخ54 -63□   
 لا أدس٘  □   غٛش رنك حذد٘________□ عًٛغ يب ركش    □أشؼخ      □ كًٛبٔ٘  □ عشاحٙ    □ ط؛)  َٕع انؼلا84
 لا أدس٘    □             لا -□                       َؼى -   □ ؟ ثؼًم فحص ػُك انشحى  لًزٙ ْم ٛصكخرش لجم) 94
    ....................................                 : ............؟ ثزنك لًذ يشح كى.  َؼى الاعبثخ كبَذ ارا- ) 15
 لا أدس٘      □       لا    □َؼى                   □) ْم رؼبٍَٛ يٍ أ٘ َٕع يٍ إَٔاع  يشض انغشغبٌ ؟ 15 
 ---------------------------) إرا كبٌ انغٕاة َؼى ، حذد٘ يب ْٕ : 25
 -------------------------------------------------------------------------------------------------------------
 : ربسٚخ انؼبئهخ انشاثغانغضء 
  أدس٘ لا□        لا□         َؼى□   ؟  ٚؼبَٙ أ٘ يٍ أفشاد انؼبئهخ يٍ ايشاض يضيُخْم ) 35
 ......................: .....................................٘ارا كبٌ َؼى ,  حذد) 45
 أدس٘ لا□        لا□         َؼى□   ؟ أصٛت أ٘ يٍ أفشاد انؼبئهخ ثبنغشغبٌْم ) 55
 ----------------------،  َٕع انغشغبٌ ---------------ارا كبَذ الإعبثخ َؼى ؛  حذد٘ صهخ انمشاثخ   ) 65
 أدس٘ لا□        لا□         َؼى□   ) ْم أصٛت انضٔط ثبلأيشاض انًُمٕنخ  عُغٛب ؟ 75
 أدس٘ لا□        لا□         َؼى□   ) ْم ٚؼبَٙ أ٘ أحذ يٍ أفشاد الأعشح يٍ ألأيشاض انزُبعهٛخ أٔ انجٕنٛخ؟85
 انغضء انخبيظ  : عٕدح انحٛبح ٔ انجٛئخ
 610
 يعبسة ٔ خٛبو               -   □شمخ فٙ ثُبٚخ                - □             ممثٛذ يغز -  □ كٍ:يكبٌ انغ -) 95
 -□          كغبساد ٔ يحبعش  -□ يكجبد َفبٚبد        -□   يُطمخ صُبػٛخ        -   □ ْم ٕٚعذ ثبنمشة يٍ يُضنك: -) 16
لا   □  أثشاط ارصبلاد خهٕٛٚخ            -□    خطٕغ كٓشثبء ظغػ ػبنٙ        -□صكُبد ػغكشٚخ             -□    يغزٕغُخ        
 أدس٘ 
 يؼشظخ نزذخٍٛ يٍ لجم شخص اخش   □   يذخُخ عبثمخ           □ لا       □    َؼى    -□؟  خْم أَزٙ يذخُ) 16
 عٛغبسح    12 – 11   □  11الم يٍ     □عبػخ؟ 42فٙ  ارا كبٌ انغٕاة َؼى , يب ْٕ ػذد انغغبئش) 26
        لا أدس٘  □عٛغبسح      12أكضش يٍ □   
 لا أدس٘    □ عُٕاد        11أكضش يٍ  □عُٕاد     11-6  □عُٕاد        5-1  □ألم يٍ عُخ         □يذح انزذخٍٛ : ) 36
 
 لا أدس٘    □       لا   -   □ َؼى                          -    □الأسعٛهخ؟  ذخُٙ ْم ر) 46
     اعجٕػٛب يشاد 3-2□     اعجٕػٛب يشاد 6-4□   ٕٚيٛب-□  ،أدخٍ الأسعٛهخ َؼى انغٕاة كبٌ ارا  ) 56 
 .لا أدس٘      □   ثبنشٓش يشاد 3-1□         ثبلأعجٕع يشح□     
 لا أدس٘    □ عُٕاد    11 يٍ أكضش□     عُٕاد 11-6□   عُٕاد 5-1□        عُخ يٍ ألم□   : ألأسعٛهخ   رذخٍٛ يذح) 66
 لا أدس٘   □           لا     -□                 َؼى            -   □ٍٛ انكحٕل ؟ ششثْم ر) 76
 لا                  -     □َؼى                            - □انشٚبظخ ؟  ٍْم رًبسعٛ) 86 
 يذح انشٚبظخ انزٙ رًبسعُٛٓب ثبلأٚبو :) 96
   يشاد ثبنشٓش 3-1   □عجٕع      يشح ثبلأ    □يشاد اعجٕػٛب       3-2□     اعجٕػٛب يشاد 6-4 □ٕٚيٛب           -  □
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ANNEX 2:  Medical form to be filled by the Gynecologist 
Questionnaire No: -----------------------    Date: _____________                                             
the corrected answer with √) of (Please fill the box                         
A) SYMPTOMS  B) SIGNS  
1- No symptoms                           □  1. No significant clinical 
abnormalities                         □          
2- Vaginal bleeding                       □ 2. Vaginal bleeding                     □ 
3- Vaginal discharge                     □ 3. Vaginal discharge                   □    
4- Menorrhagia                              □ 4. Erosions                                   □  
5- Contact bleeding                       □ 5. Ulcers                                       □ 
6- Blood spots or light bleeding 
between periods                        □ 
6. External polyps                       □ 
7- Dysuria                                         □ 7. Ecto-cervical polyps               □ 
8- Bleeding after menopause        □ 8. Endo-cervical polyps              □ 
9- Post coital bleeding                    □ 9. Well defined mass                  □ 
10- Pelvic pain                                    □ 10. Warts (external genitalia)     □ 
11- Lower abdominal pain                □ 11. Vaginal bleeding after PV      □    
12- Pain during sexual intercourse  □ 12. Metaplasia                               □ 
13- Vaginal mass                                 □ 13. Leukoplakia                              □ 
14- For follow up                                 □    14. Parametrial or pelvic metastasis  
□ 
                                               
 15. Bleeding from mass erosion   □ 
 16. Ectopy  □                                       
 
Gynecologist Signature :      
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Annex 3: Lab result form  
 
Patient Name:  Refereeing center:  
D.O.B \ Age: Years Receiving date: 11\11\2018 
Case No.  Reporting date: 00\00\2018 
 
 
History:L.M.P:  
Cell Descriptions:  
Superficial cells:          
  
 
 Intermediate cells:    
          
 Para basal 
&metaplasia cells: 
 
Basal cells:  Endocervical cells:    Endometrial cells:  
Granulocytes:      
Diagnosis: 
 
Mild inflammation  CIN I, II  Fresh blood  
Moderate 
inflammation 
 CIN III  Old blood  
Severe inflammation  Cervical cancer  Within normal 
limits 
 
Atrophic smear  Candida 
 
   
Atypical squamous 
cells 
 Unsatisfactory    
Atypical Glandular 
cells 
 Inadequate    
 
 
019 
Annex 4 :The letter from Al-Quds University  to MOH.  
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Annex 5 : The letter from Al-Quds University  to Al-Zakat Committee: 
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Annex 6: The letter from Al-Quds University  to the Gynecologist: 
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Annex 7: Letter of approval from PHC in MOH  
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 ثغى الله انشحًٍ انشحٛى
 كهٛخ انصحخ انؼبيخ –عبيؼخ انمذط 
 ثحش ػهًٙ \ًَٕرط يٕافمخ فٙ دساعخ 
  " انغشثٛخ انعفخ إَبس ثٍٛ انشحى ػُك إصبثبد ػٍ انكشف انخطٕسح فٙ ٔػٕايمػُك انشحى  يغحخ اخزجبس دٔس رمٛٛىػُٕاٌ انذساعخ: " 
 , غبنجخ يبعغزٛش صحخ ػبيخ َبَغٙ فلاػ  د.انجبحضخ انشئٛغٛخ:
 1245657950 عٕال :           moc.liamg@87f52n.rdانجشٚذ الانكزشَٔٙ:
 اٌشحُ اٌخٟ حص١ب ػٕك لأِشاض الأخشٜٚا اٌضشطبْ أِشاض  ػٓ اٌّبىش اٌىشف فٟ اٌشحُ ػٕك ِضحت فحص فؼبٌ١ت حذ٠ذح أْذاف انذساعخ:
 .اٌفٍضط١ٕ١بث الإٔبد فٟ اٌشحُ بأِشاض ػٕك  اٌّشحبطت اٌّحخٍّت اٌخطش ػٛاًِ ٌٚخحذ٠ذ
  إٌضبء أِشاض اٌز٠ٓ ٠شاجؼْٛ ػ١بداث )صٕت 55-50(اٌفٍضط١ٕ١بث  إٌضبء جّ١غانفئخ انًغزٓذفخ: 
 .إْ ِشبسوخه طٛػ١ت حّبِب دْٚ اٌخزاَ،  ٚحُ اخخ١بسن وأحذ ِشاجؼبث اٌؼ١بدة فمط نًبرا رى اخزٛبس٘:
بخؼبئت اصخب١بْ ِخؼٍك بّٛضٛع اٌذساصت ٚ ِٓ رُ اػبدحٗ ٌٍببحزت , ٚ فٟ حبٌت ٚجٛد  ١ٓبؼذ الشاس اٌّشبسوت اٌطٛػ١ت صخمِٛكخ: أنٛخ انًشبس
 صؼٛببث فٟ فُٙ أٚ حؼبئت جزء ِٕٗ ٠شجٝ اٌشجٛع ٌٍببحزت ٌٍّضبػذة.
 فحص فؼبٌ١تحضبّ٘ٓ فٟ فبئذة ػظ١ّت ٚ ٟ٘ ححذ٠ذ  ٓلا حٛجذ أٞ ِخبطش فٟ اٌّشبسوت ٚ بّشبسوخىانًخبغش ٔ انفٕائذ انُبرغخ ػٍ انًشبسكخ: 
 فٟ ِٕبطمٕب اٌفٍضط١ٕ١ت ٌىٟ حضًٙ ِخببؼخٗ ٚ ػلاجٗ ٚ اٌحذ ِٓ أخشبسٖ. اٌّبىشػٓ آفبث ػٕك اٌشحُ اٌىشف فٟ اٌشحُ ػٕك ِضحت
خببغ اٌجبٔب الأخلالٟ ٚ أْ ٘زا اٌبحذ ٠خُ ححج اششاف ٌجٕت ٍ٘ضٕىٟ اٌّحٍ١ت لاخلاق اٌبحذ اٌؼٍّٟ بجبِؼت اٌمذس ٚ اٌخٟ حانخصٕصٛخ: 
٠حب اٌٝ صبحبٙب اٌخصٛص١ت اٌؼبٌ١ت فٟ اٌخؼبطٟ ِغ اٌّؼط١بث اٌٛاسدة فٟ الاصخب١بْ ح١ذ ٠خُ حشِ١ز ٘زٖ اٌّؼط١بث ٚ جذٌٚخٙب دْٚ الاشبسة حٍّ١حب ٚ لا حصش
 أٚ ِب ٠ذي ػٍ١ٗ ِٓ لش٠ب أٚ بؼ١ذ.
 ت ػذَ الإصخّشاس فٟ أٞ ٚلج سوالاصخّشاس فٟ اٌّشبسوت طٛػٟ ٚ ٠حك ٌٍّشبالأعزًشاس فٙ انًشبسكخ: 
 الاطلاع ػٍٝ ٔخبئج اٌبحذ ببلاشبسة اٌٝ رٌه فٟ الاصخب١بْ.ت ٠حك ٌٍّشبسوالأغلاع ػهٗ َزبئظ انجحش: 
٠حك ٌٍببحز١ٓ اصخخذاَ ٘زٖ اٌّؼط١بث اٌٛاسدة فٟ الاصخب١بْ لأبحبد أخشٜ فٟ جبِؼت اٌمذس ِب ٌُ ٠طٍب اٌّشبسن ػىش اعزخذاو انًؼطٛبد: 
 رٌه.
مٛذ فكشح كبفٛخ ػٍ يٕظٕع انجحش ٔ لبيذ انجبحضخ ثبلاعبثخ ػهٗ كم اعزفغبسارٙ انًزٕلؼخ ٔ نٛظ نذ٘ يضٚذ يٍ الأعئهخ ٔ ثزٕلٛؼٙ نمذ ره
 ْزا ألش ػهٗ يٕافمزٙ انطٕػٛخ فٙ ْزا انجحش.
 .........................................الأعى :.....................................................................سلى انٓبرف ..........
 ............انجشٚذ الاكزشَٔٙ:........................................................... انزبسٚخ:........................................
